



Finnish Cancer Registry

Institute for Statistical and
Epidemiological Cancer Research



2006/2007

Cancer in Finland 2006 and 2007

Cancer Statistics of the National Institute
for Health and Welfare (THL)

- ▶ **Incidence** page 10
- ▶ **Mortality** page 44
- ▶ **Prevalence** page 66
- ▶ **Survival** page 70
- ▶ **Screening** page 72
- ▶ **Publications** page 78
- ▶ **Predicted numbers of cancers in 2010**
(back cover)

Finnish Cancer Registry
– Institute for Statistical and
Epidemiological Cancer Research

Cancer in Finland 2006 and 2007

**Cancer Statistics of the National Institute
for Health and Welfare (THL)**



Cancer Society of Finland
Publication No. 76
Helsinki 2009
ISSN 0585-9603



Finnish Cancer Registry

Institute for Statistical and
Epidemiological Cancer Research

Pieni Roobertinkatu 9
FI-00130 Helsinki
Finland

Phone: +358 9 135 331
Fax: +358 9 135 5378
www.cancerregistry.fi

E-mail to staff members:
firstname.surname@cancer.fi

Staff (November 2009)

- ◆ Ahti Anttila, PhD, Research Director of the Mass Screening Registry
 - ◆ Tadeusz Dyba, ScD, Scientist
 - ◆ Håkan Forsman, MSc (Eng.), IT Analyst
 - ◆ Matti Hakama, ScD, Research Professor (emer.)
 - ◆ Timo Hakulinen, ScD, Director of the Finnish Cancer Registry
 - ◆ Kaija Halonen, Research Assistant
 - ◆ Minna Heikkilä, Research Secretary
 - ◆ Sanni Helander, MNsc, Research Assistant
 - ◆ Sirpa Hjort, Clerk
 - ◆ Tiina Karhunen, Research Nurse
 - ◆ Arja Kitunen, MSc, Chief of Data Processing
 - ◆ Tuija Korri, Clerk
 - ◆ Laura Kotaniemi-Talonen, MD, Scientist
 - ◆ Sanna Kuivalainen, Research Nurse
 - ◆ Marjut Kutvonen, Clerk
 - ◆ Pentti Kyyrönen, Statistician
 - ◆ Hilikka Laasanen, IT Analyst
 - ◆ Maarit Leinonen, MD, Scientist
 - ◆ Stefan Lönnberg, MD, Scientist
 - ◆ Tapio Luostarinen, MSc, Scientist
 - ◆ Liisa Määttänen, PhD, Scientist
 - ◆ Laura-Maria Madanat-Harjuoja, MD, Scientist
 - ◆ Nea Malila, MD, PhD, Director of the Mass Screening Registry
 - ◆ Tuula Mattila, Secretary, Administrative Assistant
 - ◆ Minna Merikivi, Research Secretary
 - ◆ Susanna Mustonen, Research Secretary
 - ◆ Jussi Orpana, IT System Specialist
 - ◆ Irma Ovaska, MNsc, Actuary
 - ◆ Toni Patama, MSc, Scientist
 - ◆ Anni Pehkonen, Clerk
 - ◆ Tea Piipponen, Clerk
 - ◆ Arun Pokhrel, PhD, Scientist
 - ◆ Eero Pukkala, PhD, Director of Statistics
 - ◆ Liisa Rita, Research Secretary
 - ◆ Risto Sankila, MD, PhD, Chief Medical Officer
 - ◆ Karri Seppä, MSc, Scientist
 - ◆ Päivi Styrman, Secretary
 - ◆ Riku Sydänmaa, PC-Support
 - ◆ Asta Taskinen, MNsc, Scientist
 - ◆ Helena Viljanen, Research Secretary
 - ◆ Anni Virtanen, MD, Scientist
 - ◆ Marja-Liisa Weckman, Office Assistant
-
- ◆ Cancer Registry
 - ◆ Mass Screening Registry

Recommended reference:

Finnish Cancer Registry. Cancer in Finland 2006 and 2007. Cancer Society of Finland Publication No. 76, Helsinki 2009.

Preface

This booklet contains the official cancer statistics of the National Institute for Health and Welfare (THL) produced by the Finnish Cancer Registry – Institute for Statistical and Epidemiological Cancer Research.

In this issue, mainly focusing on the years 2006 and 2007, the theme of the short introductory texts preceding each section (see the page numbers on the right) is a **prediction for the future**. In the incidence, mortality and prevalence sections, we have predicted the trends of rates up to 2020. The predicted rates have been further multiplied by the predicted population counts to give the future numbers of cases. Based on experience in cancer registration in Finland since 1953, we are confident that most of the predictions will hold. There is, however, one major exception. In prostate cancer, exceptionally irregular incidence trends have been observed in recent years related to the frequency of PSA testing. After a very rapid increase before 2005, there has been an even sharper decrease. This decrease in the incidence is expected to level off (as has been seen in the U.S.A.), but we do not know when that will happen. The uncertainty has a crucial effect on incidence predictions, and as a consequence, on the predicted number of prevalent prostate cancer patients.

As a large proportion of PSA-detected prostate cancers are non-fatal, the future estimates of survival may seem to be artificially high. Finally, PSA testing appears to have some effect on prostate cancer mortality. The ongoing screening trials will shed light on the benefits and harms of PSA-based organised screening that is under consideration for a public health programme in the future. The future prospects of population-based cancer screening activities are discussed on pages 72-73.

We are grateful to Finnish physicians and hospital and laboratory personnel for submitting the notifications on new cancer cases. The high-quality registry data are the basis for the production of reliable national cancer statistics and the active epidemiological research performed in Finland and in international collaborations. Planning of the national electronic patient data system has progressed, and hopefully within some years, cancer data collection from the electronic hospital records will be a reality. Meanwhile, we encourage all health care professionals to continue sending the cancer notifications in a timely manner.

Helsinki, November 2009

Eero Pukkala
Director of Statistics
Finnish Cancer Registry

The colours in the page margins distinguish the type of information given on the pages:

Cancer incidence	page 10
Cancer mortality	page 44
Cancer prevalence	page 66
Cancer patient survival	page 70
Cancer screening statistics	page 72

Contents

Introduction.....	6
Population of Finland.....	8
Mean population 2006 and 2007, by sex and age – Table 1.....	8
Mean population in 2003-2007, by sex and region – Table 2.....	9
Cancer incidence, by primary site.....	10
Time trends 1961-2007	
Mean annual numbers of new cases, males – Table 3.....	12
Mean annual numbers of new cases, females – Table 4.....	13
Age-adjusted incidence rates per 100,000 males – Table 5.....	14
Age-adjusted incidence rates per 100,000 females – Table 6.....	15
By age, 2006	
Numbers of cases, males – Table 7.....	16
Numbers of cases, females- Table 8.....	18
Rates per 100,000, males – Table 9.....	20
Rates per 100,000, females – Table 10.....	22
By age, 2007	
Number of cases, males – Table 11.....	24
Number of cases, females – Table 12.....	26
Rates per 100,000, males – Table 13.....	28
Rates per 100,000, females – Table 14.....	30
By health care district, 2003-2007	
Average annual numbers of cases, males – Table 15.....	32
Average annual numbers of cases, females – Table 16.....	34
Age-adjusted incidence rates per 100,000 males – Table 17.....	36
Age-adjusted incidence rates per 100,000 females – Table 18.....	38
Method of confirmation of the diagnosis, 2007	
Percentages, males – Table 19.....	40
Percentages, females – Table 20.....	41
Special tables, 2007	
Subsite distribution of cancers of the skin – Table 21.....	42
Cell type distribution of leukaemia – Table 22.....	42
Site of origin of Non-Hodgkin lymphoma – Table 23.....	43

Cancer mortality, by primary site	44
Time trends 1961-2007	
Mean annual numbers of deaths, males – Table 24	46
Mean annual numbers of deaths, females – Table 25	47
Age-adjusted mortality rates per 100,000 males – Table 26	48
Age-adjusted mortality rates per 100,000 females – Table 27	49
By age, 2007	
Number of cases, males – Table 28	50
Number of cases, females – Table 29	52
Rates per 100,000, males – Table 30	54
Rates per 100,000, females – Table 31	56
By health care district, 2003-2007	
Average annual number of deaths, males – Table 32	58
Average annual number of deaths, females – Table 33	60
Age-adjusted mortality rates per 100,000 males – Table 34	62
Age-adjusted mortality rates per 100,000 females – Table 35	64
Cancer prevalence, by primary site	66
Numbers of prevalent cases 1 January 2008, by time since diagnosis	
Males – Table 36	68
Females – Table 37	69
Cancer survival, by primary site and sex	70
One-year and 5-year relative survival ratios and cause-specific death probabilities	
Patients followed up in 2005-2007 and predictions for patients to be followed up in 2011-2013 – Table 38	71
Cancer screening programmes	72
Cervical cancer screening 2006 and 2007	
Coverage and attendance – Table 39	74
Findings – Table 40	75
Breast cancer screening 2006 and 2007	
Coverage and attendance – Table 41	76
Findings – Table 42	76
Colorectal cancer screening 2007	
Coverage, attendance and findings, males – Table 43	77
Coverage, attendance and findings, females – Table 44	77
Recent publications	78
Most common cancers 2007 and predicted numbers of cases 2010	Back cover

Introduction

Cancer Registry

The cancer statistics of the National Institute for Health and Welfare (Terveyden ja hyvinvoinnin laitos, THL) are produced by the Finnish Cancer Registry – Institute for Statistical and Epidemiological Cancer Research (FCR). FCR was founded in 1952 by the Cancer Society of Finland in collaboration with the National Board of Health. FCR is maintained by the Cancer Society of Finland. The functions of FCR include collection, quality control and refinement of cancer data for production of cancer statistics and for scientific research.

This report constitutes the statistics of cancer burden in Finland in 2006 and 2007. The statistics are updated several times a year, and most recent tabulations are available on the homepage of FCR at www.cancerregistry.fi.

Hospitals, practising physicians and pathological and haematological laboratories are requested to report all cancer cases that come to their attention to FCR. In addition, information on all death certificates in which cancer is mentioned are transferred from the files of Statistics Finland to FCR each year. In 2003-2007, the cancer diagnoses were based on microscopic verification in 93% of the cases. For 2.1% of the cases, the registration was based only on a death certificate (DCO). FCR requests additional data from hospitals if the diagnosis is based only on a death certificate.

FCR started using the International Classification of Diseases for

Oncology, Third Edition (ICD-O-3) in 2008. The classification translated into the Finnish language by the FCR is available at http://www.cancerregistry.fi/rekisterointi/image_14.pdf. Cancers diagnosed since 2007 are directly coded with ICD-O-3 codes. Cancers diagnosed from 1953 to 2006 were in those days coded with ICD-7 and MOT-NAC codes, and these old code combinations have been converted into ICD-O-3 codes.

For this report, the 10th revision of the International Statistical Classification of Diseases (ICD-10, WHO, 1992) has been used for the entire reporting period by converting the ICD-O-3 codes into ICD-10 codes. Neoplasms of uncertain malignancy (borderline tumours of the ovary) and some other entities are reported separately below the main tables. To understand the complicated situation with trends in non-invasive lesions of the cervix uteri, see the graph on page 7. The cancer entity “Non-invasive neoplasms of the cervix uteri” replaces the previous more narrow category “Carcinoma in situ of the cervix uteri” in this publication.

World standard population is used for age adjustment to allow international comparisons. In the 1950s, the age structure of the Finnish population was similar to that of the World standard population (see graph on page 8), giving considerable weight to the youngest age categories, but only 1% weight to ages 80+. In 2007, the largest age category in Finland was 55-59 years, and more than 4% of the popu-

lation were at least 80 years old. Therefore, the numerical values of the rates adjusted to the world standard population are far from the actual crude rates in 2007. The age-standardised rate for overall cancer incidence in 2007 among males was 282 per 100,000, while the crude rate was 507. The respective rates among females were 242 and 482.

Due to the small annual number of cases in many of the healthcare districts, the tabulations for the 22 health care districts of Finland refer to the 5-year period of 2003 to 2007 (Tables 15-18 and 32-35). Since the national Population Register is not 100% complete with respect to place of residence, a small number of cases (0.6%) are only included in the figures for the whole country.

In the tables, magnitude nil is indicated by a dash (–) while “0” or “0.0” refer to a magnitude greater than nil but less than half of the unit employed. For instance, the average annual number of cases is marked with a dash if there are no cases, but with zero if there are 1-2 cases during the 5-year period.

On request, the Finnish Cancer Registry can produce tabular material on the occurrence of cancer in Finland by variables other than those used in this publication. Starting from 2007, the ICD-O-3 codes enable tabulations and data provision by contemporary morphological types that are much more detailed than the old MOT-NAC histological groups. See the list of the variables available in the database http://www.cancerregistry.fi/eng/registration/index_5.doc.

According to the law, identifiable data can only be used for research purposes. Researchers who wish to obtain individual-level data from the FCR must apply for permission from the National Institute for Health and Welfare. FCR follows strict procedures to ensure absolute confidentiality and protection of the data.

Mass Screening Registry


The Mass Screening Registry is a part of the Finnish Cancer Registry. The screening laboratories involved in the organised programme are requested to record the screening data and report it regularly to the Mass Screening Registry. Registration of cancer screening processes is

based on the same legal basis as the general cancer registration. Sources of information for the mass screening registry may be different from those for the general cancer registry, however. For example, the histologically confirmed diagnosis of pre-cancers or cancers originate usually from the first diagnostic episode originating from the screening test, whereas the cancer registry codes are based on information of all diagnostic episodes notified for the case.

The registration of the organised cancer screening programmes includes individual-level information on the invitations, screening visits and tests, referrals for further examinations, histologically confirmed findings, and on primary treatment. Tables 39-44 contain information on the nationwide cancer screening programmes aimed at prevention of cervical cancer by cytological screening, prevention of deaths from breast cancer by early detection through mammography, and prevention of deaths from colorectal cancer through a faecal occult blood test. More detailed tables (e.g., by area) and instructions on the registration of screening are available at:

<http://www.cancer.fi/joukkotarkastusrekisteri/english/statistics>.

► Trends in non-invasive neoplasms of the cervix uteri



With the launch of nationwide PAP smear screening for cervical cancer, the incidence of squamous cell carcinomas in situ increased rapidly in the mid-1960s. The registration of dysplasia gravis lesions was started in 1988, but there was clear under-registration in the early 1990s. In the late 1990s, pathologists started using the term "cervical intraepithelial neoplasia, grade III" (CIN III) that includes a spectrum of cellular changes from severe dysplasia to carcinoma in situ. Due to the above issues, the overall trend in non-invasive lesions is impossible to comprehend until the late 1990s when the figures have been stabilised and are likely to reflect a real incidence of these lesions.


Population of Finland

▶ **TABLE I. Mean population of Finland in 2006 and 2007, by sex and age (in thousands).**

Age group	2006		2007	
	Males	Females	Males	Females
All ages	2578.0	2688.2	2590.3	2698.5
0-4	146.4	140.2	148.0	141.8
5-9	148.8	142.5	147.1	140.7
10-14	166.2	159.9	163.2	157.1
15-19	165.1	158.0	167.8	160.8
20-24	170.3	162.7	168.6	161.0
25-29	169.3	161.8	170.4	162.5
30-34	160.3	152.0	164.3	155.5
35-39	174.1	168.0	168.3	162.0
40-44	191.4	185.5	190.3	184.5
45-49	190.2	187.0	189.0	185.9
50-54	196.5	196.1	194.9	194.9
55-59	206.1	207.4	202.8	204.1
60-64	149.4	156.1	162.4	169.1
65-69	117.4	133.4	120.4	135.8
70-74	91.2	114.7	92.4	115.3
75-79	71.9	109.7	73.4	109.7
80-84	41.1	84.4	43.4	85.6
85-	22.3	68.8	23.8	72.3

Statistics Finland: FINREGION.

▶ **Age distribution of Finnish population in 1953, 1980 and 2007, and the World Standard Population.**




▶ **TABLE 2. Mean population of Finland in 2003-2007, by sex, health control region, and health care district (in thousands).**

Health care district	Males	Females
Finland	2568.4	2680.1
Helsinki region	846.4	904.2
1 Uusimaa	432.1	447.5
2 Helsinki	261.8	299.8
8 Kymenlaakso	88.9	91.8
9 Etelä-Karjala	63.6	65.1
Turku region	347.9	367.5
3 Varsinais-Suomi	221.7	236.7
4 Satakunta	113.0	117.3
22 Åland	13.2	13.5
Tampere region	588.5	612.9
5 Kanta-Häme	82.0	86.3
6 Pirkanmaa	225.7	236.4
7 Päijät-Häme	101.6	108.6
15 Etelä-Pohjanmaa	98.6	100.3
16 Vaasa	80.5	81.3
Kuopio region	421.7	434.0
10 Etelä-Savo	53.7	55.7
11 Itä-Savo	26.4	27.7
12 Pohjois-Karjala	85.9	86.8
13 Pohjois-Savo	123.3	127.2
14 Keski-Suomi	132.5	136.5
Oulu region	363.9	361.5
17 Keski-Pohjanmaa	38.3	39.1
18 Pohjois-Pohjanmaa	191.3	188.9
19 Kainuu	40.9	40.9
20 Länsi-Pohja	33.3	33.2
21 Lappi	60.0	59.4

Statistics Finland: FINREGION.

▶ **The health care districts of Finland.**

The gray lines illustrate the municipality borders in 2009..



Pohjakaartaneuvosto © Maanmittauslaitos lipano 391 /MPL/09

A quarter more new cancer cases in 2020

It is possible to make predictions on future numbers of new cases and cancer incidence by using different approaches. The simplest ones, based on the continuation of existing trends¹ in cancer incidence rates by sex, site and age, have been applied here. The prediction base was the most recent available 10-year period 1998-2007, with two exceptions. In prostate cancer, the recent trends are strongly affected by PSA testing, and therefore, the prediction was based on the rates recorded for 2007 only. In breast cancer, due to mammographic screening, only the years 2004-2007 were used as the prediction base due to the stability of the screening patterns. With the other sites, there may be changes in diagnostics and other factors unduly affecting the predictions. Thus, it is good to be cautious when interpreting the predicted figures. The prediction for all sites combined has been made by adding up the site-specific predictions and by making use of a residual category "other sites" as an additional site.

Population forecasts produced by Statistics Finland have been combined with the incidence rate predictions in order to derive the predictions for the numbers of new cases in 2020. The number of new cases in 2020 is predicted to be about 17,700 in males and about 16,100 in females, which means a 29% increase for males and a 24% increase for females compared with the average annual numbers of

cases in 2005-2007 (see table on page 11). These changes are almost entirely due to population aging in Finland. The age-adjusted incidence is not predicted to change much, a decrease of 7% in males and an increase of 3% in females.

Of the individual sites, more than 60% of the increases in numbers of cancer cases among males are expected in cancers of the skin (both melanoma and non-melanoma) and colon. Population aging plays a large role here; the corresponding changes in the age-adjusted incidence are much more modest. The largest relative decreases in the numbers are predicted for cancers of the stomach and kidney. Here, population aging is to a large extent compensating the much larger decreases predicted for the age-adjusted incidence rates.

The total predicted increase in annual new numbers of cases for males is almost 4000 cases. Prostate cancer is expected to be responsible of almost 30% of this increase, even when in this prediction no changes in the age-specific incidence rates were assumed between 2007 and 2020. Non-melanoma skin cancer is predicted to have the second largest absolute increase in numbers.

In females, the largest relative increase (more than 60%) is predicted for melanoma of the skin. A decrease is predicted for cancer of the stomach. Population aging in females has an analogous role to that in males. In total, the annual number of cancer cases in females

in 2020 is predicted to increase by 3150 cases. Breast cancer is responsible for one-third of this increase.

Some of the trends in the age-adjusted incidence correspond to known changes in risk factor patterns. The past changes in smoking habits in both sexes are consistent with the different future patterns of lung cancer predicted by sex. Potential changes in diagnostic activity and sheer randomness must also be taken into account when interpreting the predictions.



Prostate cancer is a particularly difficult subject for prediction. The future may bring changes in PSA testing and mass-screening that cannot be foreseen at the present moment. The past development in the USA has shown rather constant age-specific incidence rates for roughly ten years or more after the peak created by increased use of PSA diagnostics². It may well be that the incidence of prostate cancer in Finland will decrease from the rate observed in 2007, which is assumed to be the constant level of future incidence. If that happens, the future numbers and rates of prostate cancer will be lower than those predicted here.

Marked increases in the overall annual numbers are predicted. The forthcoming demographic changes in the population will cause an increasing and challenging cancer burden for the health care system to wrestle with.

¹ Dyba, T. and Hakulinen, T.: *Comparison of different approaches to incidence prediction based on simple interpolation techniques*. Stat. Med. 2000; 19:1741-1752. For STATA macros, cf. <http://www.cancerregistry.fi/eng/general/JID84.html>.

² Welch, H.G. and Albertsen, P.S.: *Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005*. J. Natl Cancer Inst. 2009; 101:1325-1329.

► Annual numbers of cases of selected cancers in Finland in 1953-2007, and prediction until 2020, by sex.



► Mean annual numbers of cases and age-adjusted (world) incidence rates as observed in 2005-2007 and predicted for 2020, by site

Site	Males			Age-adjusted rate/100,000		
	2005-7	2020	Change	2005-7	2020	Change
Prostate	4724	5872	+24 %	99.8	85.8	-14 %
Lung	1583	1550	-2 %	32.7	22.3	-32 %
Colon	736	1190	+62 %	15.8	18.4	+17 %
Bladder	633	715	+13 %	13.0	9.9	-24 %
Non-Hodgkin lymphoma	550	774	+41 %	12.7	13.5	+6 %
Rectum	543	790	+46 %	11.7	12.3	+5 %
Skin, non-melanoma	521	1038	+99 %	10.2	12.5	+23 %
Skin, melanoma	458	806	+76 %	10.9	14.7	+35 %
Pancreas	444	698	+57 %	9.5	10.7	+13 %
Kidney	421	385	-9 %	9.3	6.4	-31 %
Stomach	389	312	-20 %	8.3	4.6	-45 %
Nervous system	387	493	+27 %	11.2	13.3	+19 %
Leukaemia	315	432	+37 %	8.5	10.2	+20 %
Other sites	2024	2604	+29 %	48.9	47.7	-2 %
All sites	13728	17659	+29 %	302.5	282.3	-7 %

Site	Females			Age-adjusted rate/100,000		
	2005-7	2020	Change	2005-7	2020	Change
Breast	4090	5119	+25 %	87.9	90.2	+3 %
Colon	798	979	+23 %	12.6	13.1	+4 %
Corpus uteri	790	1015	+29 %	14.7	13.6	-8 %
Lung	653	908	+39 %	10.9	12.7	+17 %
Nervous system	551	749	+36 %	13.3	16.2	+22 %
Skin, non-melanoma	524	718	+37 %	5.8	5.5	-5 %
Non-Hodgkin lymphoma	519	655	+26 %	9.4	10.1	+7 %
Pancreas	501	770	+54 %	7.1	8.3	+17 %
Ovary	443	495	+12 %	8.8	8.6	-2 %
Rectum	434	549	+27 %	7.5	9.2	+23 %
Skin, melanoma	422	703	+67 %	9.5	13.0	+37 %
Kidney	353	414	+17 %	5.9	5.6	-5 %
Stomach	299	240	-20 %	5.0	3.6	-28 %
Thyroid	261	266	+2 %	6.9	7.0	+1 %
Leukaemia	246	241	-2 %	5.8	4.5	-22 %
Bladder	205	211	+3 %	2.9	2.4	-17 %
Other sites	1814	2020	+11 %	29.9	28.5	-5 %
All sites	12903	16052	+24 %	243.9	252.1	+3 %

▶ **TABLE 3. Mean annual numbers of new cancer cases in 1961-2007, by primary site and period, MALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	5018	5728	6308	7119	7732	8214	9379	10983	12935	13794	13121
Mouth, pharynx	C00-14	223	207	218	233	240	240	246	271	275	310	285
Lip	C00	150	133	136	133	131	125	100	93	68	55	50
Tongue	C01-02	16	16	17	24	27	30	38	48	55	65	65
Mouth, other	C03-06	18	15	17	20	24	29	37	49	57	86	57
Salivary glands	C07-08	13	13	13	19	22	17	26	26	28	30	32
Pharynx	C09-14	26	29	35	37	37	39	45	55	66	74	81
Digestive organs	C15-26	1642	1654	1672	1788	1920	1953	2058	2213	2492	2720	2740
Oesophagus	C15	130	114	101	99	99	108	116	122	154	165	161
Stomach	C16	936	832	743	685	631	558	490	445	407	396	371
Small intestine	C17	9	12	15	21	25	31	31	39	45	38	54
Colon	C18	136	165	202	254	344	396	481	563	668	732	743
Rectum, rectosigmoid, anus	C19-21	141	169	217	270	297	330	391	431	499	548	555
Liver	C22	34	49	79	91	117	123	135	157	190	276	255
Gallbladder, bile ducts	C23-24	24	33	41	56	74	72	77	82	85	81	107
Pancreas	C25	168	221	243	272	298	309	320	359	415	448	455
Other digestive organs	C26	65	59	31	39	35	25	16	15	29	36	39
Respiratory organs	C30-39	1664	1962	2083	2213	2156	1914	1860	1765	1747	1742	1680
Nose, sinuses	C30-31	23	24	16	18	15	17	18	19	20	23	33
Larynx, epiglottis	C32	147	161	137	123	125	112	101	108	101	112	117
Lung, trachea	C33-34	1474	1766	1917	2064	2004	1770	1728	1630	1613	1588	1511
Mediastinum, pleura	C38	18	11	11	6	9	12	10	4	11	16	13
Bone	C40-41	35	32	29	31	27	21	22	23	18	24	20
Melanoma of the skin	C43	48	66	95	121	171	239	259	311	379	501	457
Skin, non-melanoma	C44	97	91	102	132	163	221	293	364	452	506	557
Mesothelioma	C45	2	5	7	16	24	31	39	53	60	67	79
Kaposi sarcoma	C46	0	1	2	4	6	12	12	11	7	12	8
Autonomic nervous system	C47	6	7	7	9	10	8	13	9	11	6	3
Soft tissues	C48-49	33	39	43	45	56	60	60	76	79	94	93
Breast	C50	5	5	5	6	6	10	13	12	16	21	16
Male genital organs	C60-63	365	523	735	963	1166	1399	2052	3182	4613	4775	4351
Prostate	C61	334	483	682	908	1104	1322	1960	3073	4483	4640	4183
Testis	C62	20	26	39	41	49	62	72	88	105	104	129
Other male genital	C60,C63	11	14	14	15	14	15	19	21	24	31	39
Urinary organs	C64-68	228	338	427	565	675	839	963	1034	1041	1103	987
Kidney	C64-65	88	136	169	217	267	350	394	437	425	452	399
Bladder, ureter, urethra	C66-68	140	203	258	348	408	488	569	597	616	651	588
Eye	C69	16	20	19	24	20	24	30	33	24	22	20
Brain, central nervous system	C70-72	119	146	155	194	233	266	300	331	370	390	372
Thyroid gland	C73	20	26	40	43	48	51	70	79	83	79	90
Other endocrine glands	C74-75	5	11	9	14	16	14	12	12	10	17	18
Ill-defined or unknown	C76,C80	150	157	167	137	146	179	243	274	268	268	285
Lymphoid and haematopoietic tissue	C81-96	359	437	493	582	648	732	835	930	989	1137	1060
Hodgkin lymphoma	C81	58	69	70	76	71	64	72	74	75	85	68
Non-Hodgkin lymphoma	C82-85,C96	94	126	141	187	220	296	376	441	477	558	535
Nodal non-Hodgkin lymphoma		64	85	105	134	151	204	254	298	301	322	236
Multiple myeloma	C90	39	56	72	87	95	125	121	136	143	164	130
Leukaemia	C91-95	169	186	208	229	258	243	258	270	287	326	316
Acute leukaemia		80	74	90	98	110	104	111	117	117	132	132
Not included above												
Basal cell carcinoma of the skin		321	454	633	843	1168	1492	1742	2132	2546	3073	3139
PUNLMP and ca in situ of the bladder		1	1	0	2	5	5	11	11	23	71	132
Polycythaemia vera ¹				16	23	21	24	22	14	20	23	16

¹ Registered since 1969.

▶ **TABLE 4. Mean annual numbers of new cancer cases in 1961-2007, by primary site and period, FEMALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	4775	5289	5973	6947	8025	9194	10223	11431	12279	13069	12988
Mouth, pharynx	C00-14	82	76	87	113	115	134	160	165	185	213	194
Lip	C00	13	15	15	25	26	39	36	46	31	36	25
Tongue	C01-02	17	16	18	22	25	26	37	37	51	49	56
Mouth, other	C03-06	15	14	15	22	22	30	41	39	48	66	52
Salivary glands	C07-08	17	14	18	22	20	22	26	23	31	28	37
Pharynx	C09-14	19	17	21	23	22	17	19	20	24	34	24
Digestive organs	C15-26	1636	1657	1804	2033	2265	2325	2310	2368	2442	2562	2523
Oesophagus	C15	153	135	126	119	121	106	89	90	80	82	71
Stomach	C16	743	644	586	577	576	517	438	378	323	332	291
Small intestine	C17	14	14	18	20	25	31	32	35	40	41	49
Colon	C18	218	256	339	423	511	586	656	712	772	786	824
Rectum, rectosigmoid, anus	C19-21	180	211	244	296	313	338	368	406	425	436	438
Liver	C22	26	37	64	84	99	112	109	109	117	164	151
Gallbladder, bile ducts	C23-24	56	88	132	180	209	207	188	188	160	152	148
Pancreas	C25	156	183	247	275	343	387	398	412	474	517	495
Other digestive organs	C26	90	88	48	58	68	42	31	38	51	52	56
Respiratory organs	C30-39	166	185	227	311	363	406	476	566	646	692	721
Nose, sinuses	C30-31	20	19	11	16	16	12	15	15	19	8	18
Larynx, epiglottis	C32	10	11	9	11	13	11	11	15	10	18	14
Lung, trachea	C33-34	128	151	201	278	326	374	441	529	607	652	675
Mediastinum, pleura	C38	7	2	4	4	5	7	5	5	7	11	11
Bone	C40-41	29	24	20	22	19	19	17	18	17	12	12
Melanoma of the skin	C43	55	85	119	148	211	250	258	308	363	435	447
Skin, non-melanoma	C44	93	90	104	127	202	277	345	437	453	564	529
Mesothelioma	C45	3	4	4	10	12	17	16	22	18	21	21
Kaposi sarcoma	C46	0	1	2	4	3	7	7	9	7	8	8
Autonomic nervous system	C47	6	6	9	8	7	9	13	10	7	2	2
Soft tissues	C48-49	38	41	48	48	55	63	73	71	91	104	81
Breast	C50	808	1006	1283	1533	1864	2429	2822	3374	3845	4084	4140
Female genital organs	C51-58	1023	1083	1044	1091	1119	1191	1328	1463	1536	1586	1543
Cervix uteri	C53	405	390	282	210	190	148	153	163	155	162	144
Corpus uteri	C54	253	300	357	430	448	521	597	698	739	798	787
Uterus, other	C55	35	33	23	22	13	13	17	15	10	7	10
Ovary	C56	259	280	303	342	373	410	456	446	480	471	420
Other female genital	C51-52,C57	68	77	77	84	91	98	103	138	150	148	182
Placenta	C58	3	3	2	4	4	1	2	2	2	-	-
Urinary organs	C64-68	145	179	240	292	359	447	523	523	552	573	532
Kidney	C64-65	97	115	146	173	231	282	325	326	343	375	339
Bladder, ureter, urethra	C66-68	48	65	94	119	128	165	198	197	208	198	193
Eye	C69	21	25	20	28	21	28	29	27	28	24	23
Brain, central nervous system	C70-72	127	148	190	254	318	358	392	454	531	572	561
Thyroid gland	C73	63	84	121	162	190	206	250	271	258	267	282
Other endocrine glands	C74-75	5	6	6	9	11	12	12	17	12	9	15
Ill-defined or unknown	C76,C80	164	198	194	191	218	273	348	396	364	344	395
Lymphoid and haematopoietic tissue	C81-96	310	393	450	563	672	744	846	932	923	997	959
Hodgkin lymphoma	C81	34	47	54	55	55	53	54	63	57	54	58
Non-Hodgkin lymphoma	C82-85,C96	81	97	124	173	239	320	402	448	474	534	515
Nodal non-Hodgkin lymphoma		51	67	90	119	164	221	275	305	309	298	219
Multiple myeloma	C90	43	69	85	113	138	142	147	169	145	147	130
Leukaemia	C91-95	152	180	187	221	238	225	236	246	240	256	246
Acute leukaemia		75	78	83	95	111	107	115	116	123	110	119
Not included above												
Carcinoma in situ of the breast	D05	3	3	5	9	14	49	92	146	281	330	333
Cervix uteri, non-invasive neoplasms		132	295	223	166	174	297	429	759	800	794	857
Borderline tumour of the ovary	D39	14	29	39	53	61	76	99	115	122	129	137
Basal cell carcinoma of the skin		425	637	895	1201	1681	2093	2370	2692	3133	3726	3651
PUNLMP and ca in situ of the bladder		-	0	0	1	1	1	2	2	7	16	36
Polycythaemia vera ¹				23	36	33	36	33	29	22	24	27

¹ Registered since 1969.

Incidence

► **TABLE 5. Age-adjusted¹ incidence rates of cancer per 100,000 person-years in 1961-2007, by primary site and period. MALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	244.1	256.9	260.7	269.5	268.4	262.6	273.6	290.1	305.9	304.0	281.9
Mouth, pharynx	C00-14	10.7	9.2	9.0	8.8	8.4	7.7	7.4	7.3	6.8	7.2	6.6
Lip	C00	7.1	5.9	5.7	4.9	4.5	4.0	2.9	2.4	1.5	1.1	1.1
Tongue	C01-02	0.8	0.7	0.7	0.9	1.0	1.0	1.2	1.3	1.4	1.5	1.6
Mouth, other	C03-06	0.9	0.7	0.7	0.8	0.8	1.0	1.1	1.3	1.4	2.0	1.3
Salivary glands	C07-08	0.6	0.6	0.5	0.7	0.8	0.6	0.8	0.7	0.8	0.7	0.8
Pharynx	C09-14	1.2	1.3	1.4	1.4	1.3	1.3	1.4	1.5	1.6	1.8	1.8
Digestive organs	C15-26	81.7	75.1	69.4	67.4	65.9	61.5	59.0	57.5	57.6	58.5	56.8
Oesophagus	C15	6.6	5.2	4.2	3.7	3.4	3.4	3.4	3.2	3.6	3.7	3.4
Stomach	C16	46.1	37.5	30.7	25.7	21.6	17.5	13.9	11.4	9.3	8.4	7.8
Small intestine	C17	0.4	0.5	0.6	0.8	0.9	1.0	0.9	1.1	1.1	0.9	1.2
Colon	C18	6.7	7.7	8.4	9.7	11.9	12.5	13.9	14.6	15.4	15.7	15.4
Rectum, rectosigmoid, anus	C19-21	7.1	7.8	9.0	10.2	10.1	10.4	11.1	11.4	11.6	11.8	11.6
Liver	C22	1.6	2.1	3.3	3.5	4.0	3.9	3.9	4.1	4.5	6.0	5.1
Gallbladder, bile ducts	C23-24	1.2	1.5	1.8	2.1	2.5	2.3	2.1	2.1	1.9	1.7	2.1
Pancreas	C25	8.2	9.9	10.0	10.2	10.2	9.8	9.2	9.3	9.6	9.7	9.3
Other digestive organs	C26	3.6	3.0	1.5	1.6	1.2	0.8	0.4	0.4	0.7	0.7	0.8
Respiratory organs	C30-39	78.5	85.3	83.7	82.5	74.4	61.3	54.0	45.6	39.3	36.2	34.0
Nose, sinuses	C30-31	1.1	1.1	0.7	0.7	0.5	0.6	0.5	0.5	0.5	0.6	0.7
Larynx, epiglottis	C32	6.8	6.9	5.5	4.6	4.4	3.7	3.0	2.9	2.4	2.6	2.5
Lung, trachea	C33-34	69.6	76.8	77.0	76.9	69.1	56.6	50.0	41.9	36.2	32.6	30.3
Mediastinum, pleura	C38	0.9	0.5	0.5	0.2	0.3	0.4	0.3	0.1	0.2	0.4	0.3
Bone	C40-41	1.6	1.3	1.2	1.3	1.1	0.8	0.9	0.8	0.6	0.7	0.7
Melanoma of the skin	C43	2.3	2.9	4.0	4.7	6.1	8.0	7.9	8.7	9.6	12.0	10.6
Skin, non-melanoma	C44	5.1	4.4	4.4	5.1	5.7	6.8	8.0	8.9	9.8	9.9	10.4
Mesothelioma	C45	0.1	0.2	0.3	0.6	0.8	1.0	1.2	1.4	1.4	1.4	1.7
Kaposi sarcoma	C46	0.0	0.1	0.1	0.1	0.2	0.4	0.4	0.3	0.2	0.2	0.2
Autonomic nervous system	C47	0.3	0.4	0.4	0.5	0.6	0.5	0.6	0.5	0.6	0.3	0.1
Soft tissues	C48-49	1.6	1.7	1.8	1.8	2.1	2.1	1.9	2.3	2.2	2.7	2.6
Breast	C50	0.2	0.2	0.2	0.2	0.2	0.3	0.4	0.3	0.4	0.5	0.4
Male genital organs	C60-63	19.3	24.9	31.1	35.8	38.6	42.1	56.8	81.5	106.4	102.6	91.3
Prostate	C61	17.8	23.0	28.9	33.7	36.3	39.4	53.5	77.5	101.7	97.8	85.6
Testis	C62	0.9	1.2	1.6	1.6	1.8	2.2	2.8	3.4	4.1	4.1	4.8
Other male genital	C60,C63	0.6	0.7	0.6	0.6	0.5	0.5	0.6	0.6	0.6	0.7	0.9
Urinary organs	C64-68	11.1	15.2	17.8	21.6	23.3	26.8	28.0	27.0	24.0	23.5	20.4
Kidney	C64-65	4.1	6.1	7.1	8.4	9.5	11.6	11.9	11.9	10.3	10.1	8.8
Bladder, ureter, urethra	C66-68	6.9	9.1	10.8	13.2	13.7	15.2	16.1	15.1	13.8	13.4	11.6
Eye	C69	0.8	0.9	0.9	1.0	0.8	0.9	1.0	1.0	0.6	0.5	0.6
Brain, central nervous system	C70-72	5.4	6.5	6.7	7.9	8.9	9.7	10.2	10.5	11.0	11.3	10.7
Thyroid gland	C73	1.0	1.1	1.6	1.6	1.7	1.7	2.2	2.3	2.3	2.2	2.4
Other endocrine glands	C74-75	0.2	0.5	0.4	0.5	0.6	0.5	0.4	0.4	0.3	0.5	0.6
Ill-defined or unknown	C76,C80	7.3	7.2	6.9	5.2	5.1	5.7	6.9	6.9	6.1	5.6	6.2
Lymphoid and haematopoietic tissue	C81-96	17.0	19.6	20.8	22.9	23.7	24.9	26.5	27.0	26.7	28.2	25.6
Hodgkin lymphoma	C81	2.6	2.9	2.8	3.0	2.7	2.2	2.6	2.7	2.8	2.8	2.4
Non-Hodgkin lymphoma	C82-85,C96	4.4	5.6	5.9	7.3	7.9	9.9	11.6	12.2	12.2	12.7	12.0
Nodal non-Hodgkin lymphoma		3.0	3.7	4.4	5.3	5.4	6.8	7.9	8.3	7.6	7.3	5.2
Multiple myeloma	C90	1.8	2.4	2.9	3.3	3.3	3.9	3.5	3.5	3.2	3.5	2.7
Leukaemia	C91-95	8.1	8.6	9.1	9.3	9.8	8.7	8.6	8.3	8.4	9.0	8.4
Acute leukaemia		3.8	3.5	4.2	4.3	4.6	4.2	4.3	4.3	4.2	4.7	4.4
Not included above												
Basal cell carcinoma of the skin		15.5	20.6	26.2	31.9	40.5	47.3	50.1	54.9	58.2	64.5	63.4
PUNLMP and ca in situ of the bladder		0.1	0.0	0.0	0.1	0.2	0.1	0.3	0.3	0.5	1.4	2.6
Polycythaemia vera ²				0.6	0.9	0.7	0.7	0.6	0.4	0.5	0.5	0.3

¹ Adjusted for age to the "world standard population".

² Registered since 1969.

▶ **TABLE 6. Age-adjusted¹ incidence rates of cancer per 100,000 person-years in 1961-2007, by primary site and period. FEMALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	166.0	170.2	175.8	185.0	194.9	211.6	224.2	237.7	242.7	247.6	241.2
Mouth, pharynx	C00-14	2.8	2.4	2.5	2.9	2.5	2.7	3.3	3.2	3.4	3.9	3.6
Lip	C00	0.4	0.4	0.4	0.6	0.5	0.7	0.6	0.6	0.4	0.5	0.3
Tongue	C01-02	0.6	0.5	0.5	0.6	0.5	0.5	0.8	0.8	1.0	0.9	1.0
Mouth, other	C03-06	0.5	0.4	0.4	0.5	0.5	0.6	0.8	0.8	0.9	1.0	0.8
Salivary glands	C07-08	0.6	0.5	0.6	0.6	0.5	0.6	0.6	0.5	0.7	0.7	0.8
Pharynx	C09-14	0.7	0.5	0.6	0.6	0.5	0.4	0.4	0.4	0.5	0.9	0.6
Digestive organs	C15-26	53.9	49.4	47.9	46.9	46.0	43.8	41.0	39.7	39.2	39.3	37.0
Oesophagus	C15	5.0	3.9	3.2	2.6	2.3	1.8	1.4	1.3	1.1	1.2	1.0
Stomach	C16	24.3	19.1	15.4	13.4	11.8	9.7	7.8	6.3	5.1	5.4	4.6
Small intestine	C17	0.5	0.4	0.5	0.5	0.6	0.7	0.6	0.7	0.8	0.9	0.9
Colon	C18	7.3	7.9	9.3	10.1	10.7	11.5	12.1	12.4	12.9	12.5	12.4
Rectum, rectosigmoid, anus	C19-21	5.9	6.3	6.6	7.0	6.6	6.6	6.8	7.4	7.3	7.3	7.1
Liver	C22	0.9	1.1	1.7	1.9	2.0	2.1	1.9	1.7	1.8	2.2	2.0
Gallbladder, bile ducts	C23-24	1.8	2.6	3.4	4.0	4.1	3.7	3.3	2.8	2.4	2.0	2.0
Pancreas	C25	5.2	5.4	6.5	6.2	6.8	7.1	6.6	6.6	7.2	7.2	6.6
Other digestive organs	C26	2.9	2.6	1.2	1.2	1.1	0.6	0.4	0.4	0.6	0.6	0.6
Respiratory organs	C30-39	5.6	5.7	6.4	7.9	8.4	8.7	9.5	10.5	11.1	11.8	11.7
Nose, sinuses	C30-31	0.7	0.6	0.3	0.4	0.4	0.2	0.3	0.3	0.4	0.2	0.2
Larynx, epiglottis	C32	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.3	0.2	0.4	0.3
Lung, trachea	C33-34	4.3	4.7	5.7	7.1	7.6	8.0	8.7	9.8	10.4	11.0	11.0
Mediastinum, pleura	C38	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Bone	C40-41	1.1	0.9	0.8	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.3
Melanoma of the skin	C43	2.0	2.9	3.9	4.6	6.0	6.7	6.5	7.4	8.1	9.4	9.4
Skin, non-melanoma	C44	3.2	2.8	2.9	2.9	3.8	4.5	4.9	5.8	5.5	6.3	5.7
Mesothelioma	C45	0.1	0.1	0.1	0.3	0.3	0.4	0.3	0.5	0.3	0.4	0.3
Kaposi sarcoma	C46	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Autonomic nervous system	C47	0.3	0.3	0.5	0.4	0.3	0.4	0.6	0.6	0.5	0.2	0.1
Soft tissues	C48-49	1.4	1.5	1.6	1.4	1.6	1.8	1.8	1.7	1.9	2.2	1.7
Breast	C50	28.8	33.5	39.9	44.6	50.6	63.3	70.3	79.0	85.6	86.9	87.5
Female genital organs	C51-58	36.6	36.2	31.9	30.4	28.9	28.5	30.7	32.2	31.2	30.4	29.2
Cervix uteri	C53	14.8	13.7	8.9	6.0	4.9	3.6	3.7	4.2	3.9	4.0	3.7
Corpus uteri	C54	8.8	9.6	10.7	11.9	11.5	12.4	13.7	15.1	14.5	14.8	14.2
Uterus, other	C55	1.2	1.1	0.8	0.6	0.3	0.3	0.3	0.2	0.2	0.1	0.1
Ovary	C56	9.2	9.3	9.4	9.6	10.0	10.2	10.9	10.1	10.1	9.2	8.4
Other female genital	C51-52,C57	2.3	2.4	2.1	2.1	2.0	1.9	2.0	2.5	2.5	2.4	2.9
Placenta	C58	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	-	-
Urinary organs	C64-68	4.9	5.7	6.9	7.4	7.9	9.4	10.4	9.5	9.1	9.2	7.9
Kidney	C64-65	3.3	3.7	4.4	4.6	5.4	6.4	6.9	6.3	6.1	6.5	5.4
Bladder, ureter, urethra	C66-68	1.6	2.0	2.5	2.8	2.6	3.0	3.5	3.2	3.0	2.7	2.5
Eye	C69	0.8	0.9	0.6	0.9	0.6	0.8	0.8	0.7	0.7	0.6	0.5
Brain, central nervous system	C70-72	5.0	5.6	6.8	8.3	9.7	10.6	11.0	11.9	13.3	14.0	13.4
Thyroid gland	C73	2.3	2.9	3.9	5.0	5.7	6.1	7.2	7.6	7.1	7.2	7.5
Other endocrine glands	C74-75	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.5	0.3	0.2	0.7
Ill-defined or unknown	C76,C80	5.4	5.9	5.2	4.5	4.3	4.8	5.6	5.9	5.2	4.9	5.5
Lymphoid and haematopoietic tissue	C81-96	11.5	13.4	13.7	15.5	16.9	17.8	19.4	20.3	19.4	20.0	19.0
Hodgkin lymphoma	C81	1.3	1.7	1.8	1.7	1.7	1.7	1.9	2.3	2.3	2.0	2.2
Non-Hodgkin lymphoma	C82-85,C96	2.9	3.1	3.7	4.5	5.7	7.3	8.6	9.0	8.9	9.6	9.4
Nodal non-Hodgkin lymphoma		1.8	2.2	2.7	3.2	4.0	5.1	6.1	6.2	5.9	5.6	4.1
Multiple myeloma	C90	1.5	2.1	2.3	2.6	2.8	2.8	2.7	2.9	2.3	2.2	2.0
Leukaemia	C91-95	5.8	6.4	6.0	6.5	6.6	6.0	6.1	6.0	5.9	6.1	5.3
Acute leukaemia		3.1	3.2	3.0	3.4	3.8	3.6	3.8	3.7	3.8	3.4	3.3
Not included above												
Carcinoma in situ of the breast	D05	0.1	0.1	0.2	0.4	0.5	1.5	2.7	3.7	6.7	7.5	7.7
Cervix uteri, non-invasive neoplasms		5.3	11.9	8.7	6.0	6.0	10.4	15.4	28.6	31.5	31.1	33.5
Borderline tumour of the ovary	D39	0.5	1.0	1.3	1.7	1.9	2.2	2.8	3.2	3.4	3.5	3.5
Basal cell carcinoma of the skin		14.3	19.4	24.6	29.4	37.0	41.9	45.6	48.5	52.5	58.9	57.6
PUNLMP and ca in situ of the bladder		-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.6
Polycythaemia vera ²				0.6	0.9	0.8	0.7	0.7	0.4	0.3	0.3	0.3

¹ Adjusted for age to the "world standard population".

² Registered since 1969.

Incidence

▶ **TABLE 7. Numbers of new cancer cases in 2006, by primary site and age. MALES.**

Primary site	ICD-10 code							
		0-4	5-9	10-14	15-19	20-24	25-29	30-34
All sites	C00-96	45	23	24	35	44	98	102
Mouth, pharynx	C00-14	-	-	-	1	1	4	3
Lip	C00	-	-	-	-	-	1	-
Tongue	C01-02	-	-	-	-	1	-	2
Mouth, other	C03-06	-	-	-	-	-	1	-
Salivary glands	C07-08	-	-	-	-	-	2	1
Pharynx	C09-14	-	-	-	1	-	-	-
Digestive organs	C15-26	3	1	1	3	7	1	8
Oesophagus	C15	-	-	-	-	-	-	-
Stomach	C16	-	-	-	-	-	-	1
Small intestine	C17	-	-	-	-	1	-	-
Colon	C18	-	1	-	3	4	1	7
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	1	-	-
Liver	C22	3	-	-	-	1	-	-
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	-
Pancreas	C25	-	-	1	-	-	-	-
Other digestive organs	C26	-	-	-	-	-	-	-
Respiratory organs	C30-39	-	1	-	1	-	3	2
Nose, sinuses	C30-31	-	-	-	-	-	-	1
Larynx, epiglottis	C32	-	-	-	-	-	1	1
Lung, trachea	C33-34	-	1	-	-	-	1	-
Mediastinum, pleura	C38	-	-	-	1	-	1	-
Bone	C40-41	-	1	-	2	-	-	3
Melanoma of the skin	C43	-	-	1	-	1	6	14
Skin, non-melanoma	C44	-	-	-	1	-	2	-
Mesothelioma	C45	-	-	-	-	-	-	-
Kaposi sarcoma	C46	-	-	-	-	-	-	-
Autonomic nervous system	C47	3	-	-	-	-	-	1
Soft tissues	C48-49	3	-	-	1	3	7	5
Breast	C50	-	-	-	-	-	-	1
Male genital organs	C60-63	2	-	-	5	18	23	17
Prostate	C61	-	-	-	-	-	1	-
Testis	C62	2	-	-	5	18	22	16
Other male genital	C60,C63	-	-	-	-	-	-	1
Urinary organs	C64-68	4	2	-	-	1	2	7
Kidney	C64-65	4	2	-	-	1	1	5
Bladder, ureter, urethra	C66-68	-	-	-	-	-	1	2
Eye	C69	1	-	-	-	-	-	-
Brain, central nervous system	C70-72	7	7	4	9	5	19	19
Thyroid gland	C73	-	-	-	1	1	7	3
Other endocrine glands	C74-75	1	-	-	-	-	-	-
Ill-defined or unknown	C76,C80	-	1	-	1	1	-	2
Lymphoid and haematopoietic tissue	C81-96	21	10	18	10	6	24	17
Hodgkin lymphoma	C81	-	-	4	5	3	12	8
Non-Hodgkin lymphoma	C82-85,C96	1	2	5	-	3	8	6
Nodal non-Hodgkin lymphoma		-	1	2	-	2	3	1
Multiple myeloma	C90	-	-	-	-	-	1	1
Leukaemia	C91-95	20	8	9	5	-	3	2
Acute leukaemia		18	8	9	4	-	2	1
Not included above								
Basal cell carcinoma of the skin		-	-	-	-	1	4	5
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-
Polycythaemia vera		-	-	-	-	-	-	-

Age group												All ages
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
118	198	353	663	1458	1872	2057	2174	2211	1421	898	13794	
4	5	15	30	43	59	44	32	32	21	16	310	
-	-	1	-	2	9	5	11	12	6	8	55	
2	2	6	7	7	5	10	6	11	3	3	65	
1	3	3	11	15	18	12	10	4	4	4	86	
1	-	2	2	4	6	4	-	3	4	1	30	
-	-	3	10	15	21	13	5	2	4	-	74	
13	36	78	136	282	394	394	434	448	278	203	2720	
1	2	4	18	29	29	26	27	16	11	2	165	
1	9	12	20	48	57	47	57	77	32	35	396	
-	-	3	5	3	8	7	3	5	1	2	38	
7	11	16	28	57	109	92	124	126	95	51	732	
1	7	14	27	68	80	91	94	85	47	33	548	
1	3	9	15	24	31	43	36	53	31	26	276	
-	-	2	2	6	8	17	16	12	7	11	81	
1	4	18	21	45	72	67	73	66	44	36	448	
1	-	-	-	2	-	4	4	8	10	7	36	
9	15	31	78	176	228	272	282	319	216	109	1742	
3	-	2	1	4	1	4	2	-	3	2	23	
-	4	2	7	18	22	25	15	9	6	2	112	
6	9	27	70	154	204	241	260	307	204	104	1588	
-	-	-	-	-	-	2	5	3	3	1	16	
2	-	-	3	2	4	4	-	2	1	-	24	
17	20	37	34	69	64	69	59	61	23	26	501	
5	5	6	10	15	36	42	85	108	100	91	506	
-	-	2	1	7	7	12	14	10	8	6	67	
1	1	-	-	1	-	1	1	-	4	3	12	
-	-	-	-	2	-	-	-	-	-	-	6	
2	2	7	7	6	10	11	12	8	6	4	94	
1	-	1	1	2	2	4	3	3	2	1	21	
15	20	64	180	511	753	824	849	780	458	256	4775	
1	10	57	170	504	745	821	846	777	453	255	4640	
14	8	6	5	3	1	1	1	1	1	-	104	
-	2	1	5	4	7	2	2	2	4	1	31	
7	17	29	57	122	126	153	178	173	144	81	1103	
6	13	13	26	71	54	63	62	61	53	17	452	
1	4	16	31	51	72	90	116	112	91	64	651	
-	-	1	3	5	2	2	4	2	2	-	22	
15	31	27	41	50	32	40	24	24	21	15	390	
3	7	4	5	12	9	11	5	9	-	2	79	
1	2	1	1	1	1	3	3	3	-	-	17	
-	3	10	7	22	34	32	37	52	40	26	268	
23	34	40	69	130	111	139	152	177	97	59	1137	
5	6	6	5	11	5	6	4	3	1	1	85	
8	17	23	40	71	56	75	80	91	47	25	558	
6	10	15	25	35	36	40	53	55	25	13	322	
3	3	2	8	20	19	23	24	25	19	16	164	
7	8	9	16	27	30	34	44	57	30	17	326	
3	4	4	4	5	8	7	16	22	10	7	132	
31	57	95	148	295	325	460	480	528	391	253	3073	
1	2	-	6	7	6	10	11	19	7	2	71	
-	-	2	1	3	3	4	2	3	4	1	23	

► **TABLE 8. Numbers of new cancer cases in 2006, by primary site and age. FEMALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	28	20	27	44	53	84	114	
Mouth, pharynx	C00-14	-	1	2	-	-	3	3	
Lip	C00	-	-	-	-	-	-	-	
Tongue	C01-02	-	-	-	-	-	-	2	
Mouth, other	C03-06	-	-	-	-	-	1	-	
Salivary glands	C07-08	-	1	2	-	-	-	-	
Pharynx	C09-14	-	-	-	-	-	2	1	
Digestive organs	C15-26	-	-	2	4	6	3	5	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	1	1	
Small intestine	C17	-	-	-	1	-	-	1	
Colon	C18	-	-	1	3	4	1	2	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	2	-	1	
Liver	C22	-	-	1	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	1	-	
Pancreas	C25	-	-	-	-	-	-	-	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	1	-	-	1	1	2	1	
Nose, sinuses	C30-31	-	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	-	-	
Lung, trachea	C33-34	1	-	-	1	1	2	-	
Mediastinum, pleura	C38	-	-	-	-	-	-	-	
Bone	C40-41	3	-	-	1	1	1	1	
Melanoma of the skin	C43	-	-	-	4	6	6	11	
Skin, non-melanoma	C44	-	-	1	2	-	2	1	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	2	-	-	-	-	-	-	
Soft tissues	C48-49	2	-	1	1	2	-	1	
Breast	C50	-	-	-	-	3	14	25	
Female genital organs	C51-58	-	1	1	-	11	12	18	
Cervix uteri	C53	-	-	-	-	4	6	12	
Corpus uteri	C54	-	-	-	-	-	-	1	
Uterus, other	C55	-	-	-	-	-	-	-	
Ovary	C56	-	1	1	-	7	6	5	
Other female genital	C51-52,C57	-	-	-	-	-	-	-	
Placenta	C58	-	-	-	-	-	-	-	
Urinary organs	C64-68	6	-	-	-	-	-	1	
Kidney	C64-65	6	-	-	-	-	-	1	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	-	-	
Eye	C69	1	-	-	1	1	-	1	
Brain, central nervous system	C70-72	4	8	6	13	8	12	19	
Thyroid gland	C73	-	-	-	3	6	11	15	
Other endocrine glands	C74-75	-	-	1	-	-	1	-	
Ill-defined or unknown	C76,C80	-	1	-	-	-	-	3	
Lymphoid and haematopoietic tissue	C81-96	9	9	13	14	8	17	9	
Hodgkin lymphoma	C81	-	-	3	8	6	8	4	
Non-Hodgkin lymphoma	C82-85,C96	-	1	3	1	-	8	4	
Nodal non-Hodgkin lymphoma		-	-	3	1	-	5	1	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	9	8	7	5	2	1	1	
Acute leukaemia		9	7	7	5	-	1	1	
Not included above									
Carcinoma in situ of the breast	D05	-	-	-	-	-	1	-	
Cervix uteri, non-invasive neoplasms		-	-	-	17	105	143	175	
Borderline tumour of the ovary	D39	-	-	-	3	1	8	9	
Basal cell carcinoma of the skin		-	-	1	-	5	8	16	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	

Age group												All ages
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
236	410	718	1094	1469	1460	1442	1384	1595	1446	1445	13069	
4	6	7	16	25	15	29	20	36	22	24	213	
-	-	-	2	2	3	3	3	9	8	6	36	
1	1	4	2	7	-	10	6	7	5	4	49	
-	2	-	5	6	6	6	6	15	8	11	66	
-	2	1	3	4	1	5	3	5	-	1	28	
3	1	2	4	6	5	5	2	-	1	2	34	
19	46	55	121	191	252	274	317	411	402	454	2562	
-	1	-	3	3	12	10	8	13	18	14	82	
4	13	8	21	32	28	35	42	52	44	51	332	
1	1	3	5	8	4	4	5	5	1	2	41	
7	15	18	43	59	87	76	98	117	127	128	786	
3	12	12	23	49	47	57	58	51	63	58	436	
1	-	3	5	7	13	14	23	29	31	37	164	
1	1	1	2	9	15	12	16	30	28	36	152	
2	3	10	18	23	45	60	63	108	85	100	517	
-	-	-	1	1	1	6	4	6	5	28	52	
4	10	17	40	86	77	90	103	100	94	65	692	
1	1	-	1	-	1	1	1	2	-	-	8	
2	-	2	1	4	2	1	2	2	1	1	18	
1	9	15	37	80	73	88	98	95	92	59	652	
-	-	-	-	1	1	-	2	1	1	5	11	
1	-	-	2	-	-	-	-	2	-	-	12	
22	28	40	35	43	33	45	42	37	43	40	435	
3	-	7	13	8	22	34	44	103	126	198	564	
-	-	1	-	2	4	4	1	4	2	3	21	
-	-	-	-	-	-	1	-	-	4	3	8	
-	-	-	-	-	-	-	-	-	-	-	2	
1	8	6	8	7	14	8	11	16	12	6	104	
79	186	393	561	643	536	496	336	322	264	226	4084	
35	34	66	124	186	227	190	200	212	161	108	1586	
20	13	10	17	16	8	6	8	18	13	11	162	
5	14	21	60	91	147	112	124	110	76	37	798	
-	-	-	-	-	-	-	-	1	-	6	7	
8	6	26	38	61	57	59	55	57	51	33	471	
2	1	9	9	18	15	13	13	26	21	21	148	
-	-	-	-	-	-	-	-	-	-	-	0	
5	5	13	26	59	59	55	80	100	81	83	573	
5	5	11	22	44	39	32	53	70	41	46	375	
-	-	2	4	15	20	23	27	30	40	37	198	
1	1	2	1	2	1	4	2	5	1	-	24	
22	32	41	44	65	66	60	49	47	42	34	572	
27	31	24	25	37	22	18	16	8	18	6	267	
-	-	-	-	1	1	2	1	-	1	1	9	
1	3	5	14	25	27	33	43	48	53	88	344	
12	20	41	64	89	104	99	119	144	120	106	997	
2	-	2	3	3	5	-	4	5	-	1	54	
4	9	27	38	53	54	61	68	92	59	52	534	
1	5	19	23	32	36	34	37	48	30	23	298	
1	4	2	2	14	15	18	23	18	32	18	147	
5	7	10	21	18	29	20	24	27	28	34	256	
2	3	3	9	7	8	7	10	10	11	10	110	
4	19	30	71	72	46	33	21	17	11	5	330	
133	80	61	27	18	10	5	9	5	3	3	794	
6	8	15	12	23	13	13	9	1	4	4	129	
35	78	116	197	302	325	403	513	583	544	600	3726	
-	-	-	-	2	-	3	4	2	3	2	16	
-	-	-	2	3	1	2	1	5	6	4	24	

Incidence

▶ **TABLE 9. Age-specific and age-adjusted incidence rates of cancer in 2006 per 100,000, by primary site. MALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	30.7	15.5	14.4	21.2	25.8	57.9	63.6	
Mouth, pharynx	C00-14	-	-	-	0.6	0.6	2.4	1.9	
Lip	C00	-	-	-	-	-	0.6	-	
Tongue	C01-02	-	-	-	-	0.6	-	1.2	
Mouth, other	C03-06	-	-	-	-	-	0.6	-	
Salivary glands	C07-08	-	-	-	-	-	1.2	0.6	
Pharynx	C09-14	-	-	-	0.6	-	-	-	
Digestive organs	C15-26	2.0	0.7	0.6	1.8	4.1	0.6	5.0	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	-	0.6	
Small intestine	C17	-	-	-	-	0.6	-	-	
Colon	C18	-	0.7	-	1.8	2.3	0.6	4.4	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	0.6	-	-	
Liver	C22	2.0	-	-	-	0.6	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	-	
Pancreas	C25	-	-	0.6	-	-	-	-	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	-	0.7	-	0.6	-	1.8	1.2	
Nose, sinuses	C30-31	-	-	-	-	-	-	0.6	
Larynx, epiglottis	C32	-	-	-	-	-	0.6	0.6	
Lung, trachea	C33-34	-	0.7	-	-	-	0.6	-	
Mediastinum, pleura	C38	-	-	-	0.6	-	0.6	-	
Bone	C40-41	-	0.7	-	1.2	-	-	1.9	
Melanoma of the skin	C43	-	-	0.6	-	0.6	3.5	8.7	
Skin, non-melanoma	C44	-	-	-	0.6	-	1.2	-	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	2.0	-	-	-	-	-	0.6	
Soft tissues	C48-49	2.0	-	-	0.6	1.8	4.1	3.1	
Breast	C50	-	-	-	-	-	-	0.6	
Male genital organs	C60-63	1.4	-	-	3.0	10.6	13.6	10.6	
Prostate	C61	-	-	-	-	-	0.6	-	
Testis	C62	1.4	-	-	3.0	10.6	13.0	10.0	
Other male genital	C60,C63	-	-	-	-	-	-	0.6	
Urinary organs	C64-68	2.7	1.3	-	-	0.6	1.2	4.4	
Kidney	C64-65	2.7	1.3	-	-	0.6	0.6	3.1	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	0.6	1.2	
Eye	C69	0.7	-	-	-	-	-	-	
Brain, central nervous system	C70-72	4.8	4.7	2.4	5.5	2.9	11.2	11.9	
Thyroid gland	C73	-	-	-	0.6	0.6	4.1	1.9	
Other endocrine glands	C74-75	0.7	-	-	-	-	-	-	
Ill-defined or unknown	C76,C80	-	0.7	-	0.6	0.6	-	1.2	
Lymphoid and haematopoietic tissue	C81-96	14.3	6.7	10.8	6.1	3.5	14.2	10.6	
Hodgkin lymphoma	C81	-	-	2.4	3.0	1.8	7.1	5.0	
Non-Hodgkin lymphoma	C82-85,C96	0.7	1.3	3.0	-	1.8	4.7	3.7	
Nodal non-Hodgkin lymphoma		-	0.7	1.2	-	1.2	1.8	0.6	
Multiple myeloma	C90	-	-	-	-	-	0.6	0.6	
Leukaemia	C91-95	13.7	5.4	5.4	3.0	-	1.8	1.2	
Acute leukaemia		12.3	5.4	5.4	2.4	-	1.2	0.6	
Not included above									
Basal cell carcinoma of the skin		-	-	-	-	0.6	2.4	3.1	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	

¹ Adjusted for age to the "world standard population".

Age group												All ages ¹
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
67.8	103.5	185.6	337.3	707.3	1253.3	1752.0	2384.6	3074.9	3453.7	4018.6	304.0	
2.3	2.6	7.9	15.3	20.9	39.5	37.5	35.1	44.5	51.0	71.6	7.2	
-	-	0.5	-	1.0	6.0	4.3	12.1	16.7	14.6	35.8	1.1	
1.1	1.0	3.2	3.6	3.4	3.3	8.5	6.6	15.3	7.3	13.4	1.5	
0.6	1.6	1.6	5.6	7.3	12.1	10.2	11.0	5.6	9.7	17.9	2.0	
0.6	-	1.1	1.0	1.9	4.0	3.4	-	4.2	9.7	4.5	0.7	
-	-	1.6	5.1	7.3	14.1	11.1	5.5	2.8	9.7	-	1.8	
7.5	18.8	41.0	69.2	136.8	263.8	335.6	476.0	623.0	675.7	908.4	58.5	
0.6	1.0	2.1	9.2	14.1	19.4	22.1	29.6	22.3	26.7	9.0	3.7	
0.6	4.7	6.3	10.2	23.3	38.2	40.0	62.5	107.1	77.8	156.6	8.4	
-	-	1.6	2.5	1.5	5.4	6.0	3.3	7.0	2.4	9.0	0.9	
4.0	5.7	8.4	14.2	27.7	73.0	78.4	136.0	175.2	230.9	228.2	15.7	
0.6	3.7	7.4	13.7	33.0	53.6	77.5	103.1	118.2	114.2	147.7	11.8	
0.6	1.6	4.7	7.6	11.6	20.8	36.6	39.5	73.7	75.3	116.4	6.0	
-	-	1.1	1.0	2.9	5.4	14.5	17.5	16.7	17.0	49.2	1.7	
0.6	2.1	9.5	10.7	21.8	48.2	57.1	80.1	91.8	106.9	161.1	9.7	
0.6	-	-	-	1.0	-	3.4	4.4	11.1	24.3	31.3	0.7	
5.2	7.8	16.3	39.7	85.4	152.6	231.7	309.3	443.6	525.0	487.8	36.2	
1.7	-	1.1	0.5	1.9	0.7	3.4	2.2	-	7.3	9.0	0.6	
-	2.1	1.1	3.6	8.7	14.7	21.3	16.5	12.5	14.6	9.0	2.6	
3.4	4.7	14.2	35.6	74.7	136.6	205.3	285.2	427.0	495.8	465.4	32.6	
-	-	-	-	-	-	1.7	5.5	4.2	7.3	4.5	0.4	
1.1	-	-	1.5	1.0	2.7	3.4	-	2.8	2.4	-	0.7	
9.8	10.5	19.5	17.3	33.5	42.8	58.8	64.7	84.8	55.9	116.4	12.0	
2.9	2.6	3.2	5.1	7.3	24.1	35.8	93.2	150.2	243.0	407.2	9.9	
-	-	1.1	0.5	3.4	4.7	10.2	15.4	13.9	19.4	26.9	1.4	
0.6	0.5	-	-	0.5	-	0.9	1.1	-	9.7	13.4	0.2	
-	-	-	-	1.0	-	-	-	-	-	-	0.3	
1.1	1.0	3.7	3.6	2.9	6.7	9.4	13.2	11.1	14.6	17.9	2.7	
0.6	-	0.5	0.5	1.0	1.3	3.4	3.3	4.2	4.9	4.5	0.5	
8.6	10.5	33.7	91.6	247.9	504.1	701.8	931.2	1084.8	1113.2	1145.6	102.6	
0.6	5.2	30.0	86.5	244.5	498.8	699.2	928.0	1080.6	1101.0	1141.1	97.8	
8.0	4.2	3.2	2.5	1.5	0.7	0.9	1.1	1.4	2.4	-	4.1	
-	1.0	0.5	2.5	1.9	4.7	1.7	2.2	2.8	9.7	4.5	0.7	
4.0	8.9	15.2	29.0	59.2	84.4	130.3	195.2	240.6	350.0	362.5	23.5	
3.4	6.8	6.8	13.2	34.4	36.2	53.7	68.0	84.8	128.8	76.1	10.1	
0.6	2.1	8.4	15.8	24.7	48.2	76.7	127.2	155.8	221.2	286.4	13.4	
-	-	0.5	1.5	2.4	1.3	1.7	4.4	2.8	4.9	-	0.5	
8.6	16.2	14.2	20.9	24.3	21.4	34.1	26.3	33.4	51.0	67.1	11.3	
1.7	3.7	2.1	2.5	5.8	6.0	9.4	5.5	12.5	-	9.0	2.2	
0.6	1.0	0.5	0.5	0.5	0.7	2.6	3.3	4.2	-	-	0.5	
-	1.6	5.3	3.6	10.7	22.8	27.3	40.6	72.3	97.2	116.4	5.6	
13.2	17.8	21.0	35.1	63.1	74.3	118.4	166.7	246.2	235.8	264.0	28.2	
2.9	3.1	3.2	2.5	5.3	3.3	5.1	4.4	4.2	2.4	4.5	2.8	
4.6	8.9	12.1	20.4	34.4	37.5	63.9	87.7	126.6	114.2	111.9	12.7	
3.4	5.2	7.9	12.7	17.0	24.1	34.1	58.1	76.5	60.8	58.2	7.3	
1.7	1.6	1.1	4.1	9.7	12.7	19.6	26.3	34.8	46.2	71.6	3.5	
4.0	4.2	4.7	8.1	13.1	20.1	29.0	48.3	79.3	72.9	76.1	9.0	
1.7	2.1	2.1	2.0	2.4	5.4	6.0	17.5	30.6	24.3	31.3	4.7	
17.8	29.8	50.0	75.3	143.1	217.6	391.8	526.5	734.3	950.3	1132.2	64.5	
0.6	1.0	-	3.1	3.4	4.0	8.5	12.1	26.4	17.0	9.0	1.4	
-	-	1.1	0.5	1.5	2.0	3.4	2.2	4.2	9.7	4.5	0.5	

▶ **TABLE 10. Age-specific and age-adjusted incidence rates of cancer in 2006 per 100,000, by primary site. FEMALES.**

Primary site	ICD-10 code	Age group (years)							
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
All sites	C00-96	20.0	14.0	16.9	27.8	32.6	51.9	75.0	100.0
Mouth, pharynx	C00-14	-	0.7	1.3	-	-	1.9	2.0	-
Lip	C00	-	-	-	-	-	-	-	-
Tongue	C01-02	-	-	-	-	-	-	1.3	-
Mouth, other	C03-06	-	-	-	-	-	0.6	-	-
Salivary glands	C07-08	-	0.7	1.3	-	-	-	-	-
Pharynx	C09-14	-	-	-	-	-	1.2	0.7	-
Digestive organs	C15-26	-	-	1.3	2.5	3.7	1.9	3.3	-
Oesophagus	C15	-	-	-	-	-	-	-	-
Stomach	C16	-	-	-	-	-	0.6	0.7	-
Small intestine	C17	-	-	-	0.6	-	-	0.7	-
Colon	C18	-	-	0.6	1.9	2.5	0.6	1.3	-
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	1.2	-	0.7	-
Liver	C22	-	-	0.6	-	-	-	-	-
Gallbladder, bile ducts	C23-24	-	-	-	-	-	0.6	-	-
Pancreas	C25	-	-	-	-	-	-	-	-
Other digestive organs	C26	-	-	-	-	-	-	-	-
Respiratory organs	C30-39	0.7	-	-	0.6	0.6	1.2	0.7	-
Nose, sinuses	C30-31	-	-	-	-	-	-	-	-
Larynx, epiglottis	C32	-	-	-	-	-	-	-	-
Lung, trachea	C33-34	0.7	-	-	0.6	0.6	1.2	-	-
Mediastinum, pleura	C38	-	-	-	-	-	-	-	-
Bone	C40-41	2.1	-	-	0.6	0.6	0.6	0.7	-
Melanoma of the skin	C43	-	-	-	2.5	3.7	3.7	7.2	-
Skin, non-melanoma	C44	-	-	0.6	1.3	-	1.2	0.7	-
Mesothelioma	C45	-	-	-	-	-	-	-	-
Kaposi sarcoma	C46	-	-	-	-	-	-	-	-
Autonomic nervous system	C47	1.4	-	-	-	-	-	-	-
Soft tissues	C48-49	1.4	-	0.6	0.6	1.2	-	0.7	-
Breast	C50	-	-	-	-	1.8	8.7	16.4	-
Female genital organs	C51-58	-	0.7	0.6	-	6.8	7.4	11.8	-
Cervix uteri	C53	-	-	-	-	2.5	3.7	7.9	-
Corpus uteri	C54	-	-	-	-	-	-	0.7	-
Uterus, other	C55	-	-	-	-	-	-	-	-
Ovary	C56	-	0.7	0.6	-	4.3	3.7	3.3	-
Other female genital	C51-52,C57	-	-	-	-	-	-	-	-
Placenta	C58	-	-	-	-	-	-	-	-
Urinary organs	C64-68	4.3	-	-	-	-	-	0.7	-
Kidney	C64-65	4.3	-	-	-	-	-	0.7	-
Bladder, ureter, urethra	C66-68	-	-	-	-	-	-	-	-
Eye	C69	0.7	-	-	0.6	0.6	-	0.7	-
Brain, central nervous system	C70-72	2.9	5.6	3.8	8.2	4.9	7.4	12.5	-
Thyroid gland	C73	-	-	-	1.9	3.7	6.8	9.9	-
Other endocrine glands	C74-75	-	-	0.6	-	-	0.6	-	-
Ill-defined or unknown	C76,C80	-	0.7	-	-	-	-	2.0	-
Lymphoid and haematopoietic tissue	C81-96	6.4	6.3	8.1	8.9	4.9	10.5	5.9	-
Hodgkin lymphoma	C81	-	-	1.9	5.1	3.7	4.9	2.6	-
Non-Hodgkin lymphoma	C82-85,C96	-	0.7	1.9	0.6	-	4.9	2.6	-
Nodal non-Hodgkin lymphoma		-	-	1.9	0.6	-	3.1	0.7	-
Multiple myeloma	C90	-	-	-	-	-	-	-	-
Leukaemia	C91-95	6.4	5.6	4.4	3.2	1.2	0.6	0.7	-
Acute leukaemia		6.4	4.9	4.4	3.2	-	0.6	0.7	-
Not included above									
Carcinoma in situ of the breast	D05	-	-	-	-	-	0.6	-	-
Cervix uteri, non-invasive neoplasms		-	-	-	10.8	64.5	88.4	115.1	-
Borderline tumour of the ovary	D39	-	-	-	1.9	0.6	4.9	5.9	-
Basal cell carcinoma of the skin		-	-	0.6	-	3.1	4.9	10.5	-
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	-
Polycythaemia vera		-	-	-	-	-	-	-	-

¹ Adjusted for age to the "world standard population".

Age group												All ages ¹
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
140.5	221.0	383.9	557.9	708.4	935.1	1081.3	1206.9	1454.0	1713.0	2099.7	247.6	
2.4	3.2	3.7	8.2	12.1	9.6	21.7	17.4	32.8	26.1	34.9	3.9	
-	-	-	1.0	1.0	1.9	2.2	2.6	8.2	9.5	8.7	0.5	
0.6	0.5	2.1	1.0	3.4	-	7.5	5.2	6.4	5.9	5.8	0.9	
-	1.1	-	2.5	2.9	3.8	4.5	5.2	13.7	9.5	16.0	1.0	
-	1.1	0.5	1.5	1.9	0.6	3.7	2.6	4.6	-	1.5	0.7	
1.8	0.5	1.1	2.0	2.9	3.2	3.7	1.7	-	1.2	2.9	0.9	
11.3	24.8	29.4	61.7	92.1	161.4	205.5	276.4	374.7	476.2	659.7	39.3	
-	0.5	-	1.5	1.4	7.7	7.5	7.0	11.9	21.3	20.3	1.2	
2.4	7.0	4.3	10.7	15.4	17.9	26.2	36.6	47.4	52.1	74.1	5.4	
0.6	0.5	1.6	2.5	3.9	2.6	3.0	4.4	4.6	1.2	2.9	0.9	
4.2	8.1	9.6	21.9	28.5	55.7	57.0	85.5	106.7	150.4	186.0	12.5	
1.8	6.5	6.4	11.7	23.6	30.1	42.7	50.6	46.5	74.6	84.3	7.3	
0.6	-	1.6	2.5	3.4	8.3	10.5	20.1	26.4	36.7	53.8	2.2	
0.6	0.5	0.5	1.0	4.3	9.6	9.0	14.0	27.3	33.2	52.3	2.0	
1.2	1.6	5.3	9.2	11.1	28.8	45.0	54.9	98.5	100.7	145.3	7.2	
-	-	-	0.5	0.5	0.6	4.5	3.5	5.5	5.9	40.7	0.6	
2.4	5.4	9.1	20.4	41.5	49.3	67.5	89.8	91.2	111.4	94.4	11.8	
0.6	0.5	-	0.5	-	0.6	0.7	0.9	1.8	-	-	0.2	
1.2	-	1.1	0.5	1.9	1.3	0.7	1.7	1.8	1.2	1.5	0.4	
0.6	4.9	8.0	18.9	38.6	46.8	66.0	85.5	86.6	109.0	85.7	11.0	
-	-	-	-	0.5	0.6	-	1.7	0.9	1.2	7.3	0.1	
0.6	-	-	1.0	-	-	-	-	1.8	-	-	0.6	
13.1	15.1	21.4	17.8	20.7	21.1	33.7	36.6	33.7	50.9	58.1	9.4	
1.8	-	3.7	6.6	3.9	14.1	25.5	38.4	93.9	149.3	287.7	6.3	
-	-	0.5	-	1.0	2.6	3.0	0.9	3.6	2.4	4.4	0.4	
-	-	-	-	-	-	0.7	-	-	4.7	4.4	0.1	
-	-	-	-	-	-	-	-	-	-	-	0.2	
0.6	4.3	3.2	4.1	3.4	9.0	6.0	9.6	14.6	14.2	8.7	2.2	
47.0	100.3	210.1	286.1	310.1	343.3	371.9	293.0	293.5	312.7	328.4	86.9	
20.8	18.3	35.3	63.2	89.7	145.4	142.5	174.4	193.3	190.7	156.9	30.4	
11.9	7.0	5.3	8.7	7.7	5.1	4.5	7.0	16.4	15.4	16.0	4.0	
3.0	7.5	11.2	30.6	43.9	94.1	84.0	108.1	100.3	90.0	53.8	14.8	
-	-	-	-	-	-	-	-	0.9	-	8.7	0.1	
4.8	3.2	13.9	19.4	29.4	36.5	44.2	48.0	52.0	60.4	48.0	9.2	
1.2	0.5	4.8	4.6	8.7	9.6	9.7	11.3	23.7	24.9	30.5	2.4	
-	-	-	-	-	-	-	-	-	-	-	0.0	
3.0	2.7	7.0	13.3	28.5	37.8	41.2	69.8	91.2	96.0	120.6	9.2	
3.0	2.7	5.9	11.2	21.2	25.0	24.0	46.2	63.8	48.6	66.8	6.5	
-	-	1.1	2.0	7.2	12.8	17.2	23.5	27.3	47.4	53.8	2.7	
0.6	0.5	1.1	0.5	1.0	0.6	3.0	1.7	4.6	1.2	-	0.6	
13.1	17.2	21.9	22.4	31.3	42.3	45.0	42.7	42.8	49.8	49.4	14.0	
16.1	16.7	12.8	12.7	17.8	14.1	13.5	14.0	7.3	21.3	8.7	7.2	
-	-	-	-	0.5	0.6	1.5	0.9	-	1.2	1.5	0.2	
0.6	1.6	2.7	7.1	12.1	17.3	24.7	37.5	43.8	62.8	127.9	4.9	
7.1	10.8	21.9	32.6	42.9	66.6	74.2	103.8	131.3	142.2	154.0	20.0	
1.2	-	1.1	1.5	1.4	3.2	-	3.5	4.6	-	1.5	2.0	
2.4	4.9	14.4	19.4	25.6	34.6	45.7	59.3	83.9	69.9	75.6	9.6	
0.6	2.7	10.2	11.7	15.4	23.1	25.5	32.3	43.8	35.5	33.4	5.6	
0.6	2.2	1.1	1.0	6.8	9.6	13.5	20.1	16.4	37.9	26.2	2.2	
3.0	3.8	5.3	10.7	8.7	18.6	15.0	20.9	24.6	33.2	49.4	6.1	
1.2	1.6	1.6	4.6	3.4	5.1	5.2	8.7	9.1	13.0	14.5	3.4	
2.4	10.2	16.0	36.2	34.7	29.5	24.7	18.3	15.5	13.0	7.3	7.5	
79.2	43.1	32.6	13.8	8.7	6.4	3.7	7.8	4.6	3.6	4.4	31.1	
3.6	4.3	8.0	6.1	11.1	8.3	9.7	7.8	0.9	4.7	5.8	3.5	
20.8	42.0	62.0	100.5	145.6	208.1	302.2	447.3	531.5	644.4	871.8	58.9	
-	-	-	-	1.0	-	2.2	3.5	1.8	3.6	2.9	0.2	
-	-	-	1.0	1.4	0.6	1.5	0.9	4.6	7.1	5.8	0.3	

Incidence

► **TABLE 11. Numbers of new cancer cases in 2007, by primary site and age. MALES.**

Primary site	ICD-10 code							
		0-4	5-9	10-14	15-19	20-24	25-29	30-34
All sites	C00-96	32	23	23	40	49	78	95
Mouth, pharynx	C00-14	-	-	1	-	-	2	7
Lip	C00	-	-	-	-	-	-	2
Tongue	C01-02	-	-	-	-	-	1	3
Mouth, other	C03-06	-	-	-	-	-	-	1
Salivary glands	C07-08	-	-	1	-	-	1	1
Pharynx	C09-14	-	-	-	-	-	-	-
Digestive organs	C15-26	-	-	-	3	3	3	4
Oesophagus	C15	-	-	-	-	-	-	-
Stomach	C16	-	-	-	-	1	2	-
Small intestine	C17	-	-	-	-	-	1	-
Colon	C18	-	-	-	3	1	-	4
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	1	-	-
Liver	C22	-	-	-	-	-	-	-
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	-
Pancreas	C25	-	-	-	-	-	-	-
Other digestive organs	C26	-	-	-	-	-	-	-
Respiratory organs	C30-39	-	-	-	-	1	1	4
Nose, sinuses	C30-31	-	-	-	-	-	-	-
Larynx, epiglottis	C32	-	-	-	-	-	1	-
Lung, trachea	C33-34	-	-	-	-	1	-	4
Mediastinum, pleura	C38	-	-	-	-	-	-	-
Bone	C40-41	-	-	3	-	2	1	-
Melanoma of the skin	C43	-	-	-	-	1	5	11
Skin, non-melanoma	C44	-	1	-	-	1	3	1
Mesothelioma	C45	-	-	-	-	-	-	-
Kaposi sarcoma	C46	-	-	-	-	-	-	-
Autonomic nervous system	C47	-	-	-	-	-	-	-
Soft tissues	C48-49	3	1	1	2	2	3	2
Breast	C50	-	-	-	-	-	-	-
Male genital organs	C60-63	1	-	-	4	18	20	29
Prostate	C61	-	-	-	-	-	-	-
Testis	C62	1	-	-	4	18	19	29
Other male genital	C60,C63	-	-	-	-	-	1	-
Urinary organs	C64-68	3	-	-	-	2	1	3
Kidney	C64-65	3	-	-	-	-	1	3
Bladder, ureter, urethra	C66-68	-	-	-	-	2	-	-
Eye	C69	3	-	-	-	-	-	-
Brain, central nervous system	C70-72	7	7	7	7	7	17	12
Thyroid gland	C73	-	1	-	2	-	5	5
Other endocrine glands	C74-75	2	-	-	1	-	-	1
Ill-defined or unknown	C76,C80	1	2	1	1	2	3	1
Lymphoid and haematopoietic tissue	C81-96	12	11	10	20	10	14	15
Hodgkin lymphoma	C81	1	-	2	7	8	4	6
Non-Hodgkin lymphoma	C82-85,C96	-	2	2	1	1	6	7
Nodal non-Hodgkin lymphoma		-	1	-	1	-	2	5
Multiple myeloma	C90	-	-	-	-	-	-	-
Leukaemia	C91-95	11	9	6	12	1	4	2
Acute leukaemia		11	7	6	11	-	3	1
Not included above								
Basal cell carcinoma of the skin		-	-	-	-	3	5	14
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	1
Polycythaemia vera		-	-	-	-	-	-	-

Age group												All ages
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
119	180	325	676	1323	1868	2007	2007	2072	1356	848	13121	
5	5	22	28	50	43	42	32	25	13	10	285	
1	-	1	2	2	2	10	12	8	5	5	50	
2	3	6	7	13	9	9	6	2	3	1	65	
1	1	3	7	8	11	8	8	5	2	2	57	
1	1	4	3	7	4	4	1	3	1	-	32	
-	-	8	9	20	17	11	5	7	2	2	81	
15	33	68	154	276	400	419	426	431	312	193	2740	
-	3	5	11	14	33	27	21	25	15	7	161	
3	4	13	24	36	50	47	68	52	40	31	371	
1	1	3	5	6	7	10	5	8	2	5	54	
5	9	17	47	62	85	121	129	114	93	53	743	
5	8	15	24	60	100	88	79	99	50	26	555	
-	2	4	11	26	37	47	28	38	40	22	255	
-	2	1	4	11	15	13	14	26	9	12	107	
1	4	9	25	54	69	65	75	67	59	27	455	
-	-	1	3	7	4	1	7	2	4	10	39	
5	14	20	83	172	256	270	260	314	191	89	1680	
-	3	3	2	7	2	5	4	4	2	1	33	
1	1	3	11	21	24	15	14	13	8	5	117	
4	8	14	69	143	228	246	241	296	178	79	1511	
-	1	-	1	1	1	3	-	-	2	4	13	
2	-	4	-	1	2	1	1	1	1	1	20	
15	21	28	38	64	56	61	54	48	28	27	457	
-	-	8	13	16	34	48	77	126	107	122	557	
-	-	-	2	11	19	21	12	7	4	3	79	
2	-	-	-	-	-	1	-	3	-	2	8	
-	-	-	1	2	-	-	-	-	-	-	3	
-	4	8	6	12	14	12	4	8	6	5	93	
1	-	1	-	4	2	2	3	3	-	-	16	
25	16	43	175	421	681	798	776	718	397	229	4351	
-	3	38	167	412	668	791	768	717	392	227	4183	
24	13	3	4	5	5	-	1	-	3	-	129	
1	-	2	4	4	8	7	7	1	2	2	39	
7	17	23	54	102	128	137	148	155	128	79	987	
3	13	14	38	55	62	52	59	39	43	14	399	
4	4	9	16	47	66	85	89	116	85	65	588	
-	4	-	-	2	3	1	3	3	1	-	20	
16	20	30	33	43	50	31	31	27	19	8	372	
3	6	12	5	13	9	3	12	9	2	3	90	
-	2	3	-	1	1	2	1	2	1	1	18	
1	6	8	16	28	38	41	42	36	40	18	285	
22	32	47	68	105	132	117	125	156	106	58	1060	
3	7	2	8	5	5	5	1	2	2	-	68	
12	17	29	37	61	70	68	68	75	57	22	535	
5	7	14	16	31	38	25	17	38	24	12	236	
1	-	5	10	13	17	20	10	29	11	14	130	
6	8	11	13	25	39	23	43	48	34	21	316	
5	3	4	6	8	6	8	15	25	11	2	132	
27	39	102	124	267	356	422	492	570	440	278	3139	
-	2	2	3	12	20	21	14	29	14	14	132	
-	-	-	2	6	-	-	3	3	-	2	16	

► **TABLE 12. Numbers of new cancer cases in 2007, by primary site and age. FEMALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	25	11	27	29	63	81	120	
Mouth, pharynx	C00-14	-	-	-	-	1	1	2	
Lip	C00	-	-	-	-	1	-	-	
Tongue	C01-02	-	-	-	-	-	-	1	
Mouth, other	C03-06	-	-	-	-	-	-	-	
Salivary glands	C07-08	-	-	-	-	-	1	1	
Pharynx	C09-14	-	-	-	-	-	-	-	
Digestive organs	C15-26	-	-	1	4	10	4	11	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	2	1	
Small intestine	C17	-	-	-	-	1	-	-	
Colon	C18	-	-	-	4	4	1	6	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	2	1	1	
Liver	C22	-	-	1	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	1	
Pancreas	C25	-	-	-	-	3	-	2	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	-	-	-	-	1	-	2	
Nose, sinuses	C30-31	-	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	-	1	
Lung, trachea	C33-34	-	-	-	-	1	-	1	
Mediastinum, pleura	C38	-	-	-	-	-	-	-	
Bone	C40-41	-	-	1	-	-	1	-	
Melanoma of the skin	C43	-	-	-	1	7	10	13	
Skin, non-melanoma	C44	-	-	-	-	-	-	-	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	-	-	-	1	-	-	-	
Soft tissues	C48-49	1	-	1	1	-	4	1	
Breast	C50	-	-	-	-	4	6	25	
Female genital organs	C51-58	-	-	3	-	6	11	24	
Cervix uteri	C53	-	-	-	-	2	9	19	
Corpus uteri	C54	-	-	-	-	-	2	-	
Uterus, other	C55	-	-	-	-	-	-	-	
Ovary	C56	-	-	3	-	4	-	5	
Other female genital	C51-52,C57	-	-	-	-	-	-	-	
Placenta	C58	-	-	-	-	-	-	-	
Urinary organs	C64-68	1	-	1	-	1	1	-	
Kidney	C64-65	1	-	1	-	1	-	-	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	1	-	
Eye	C69	1	-	-	-	-	1	-	
Brain, central nervous system	C70-72	5	4	11	9	10	16	14	
Thyroid gland	C73	-	-	-	-	7	10	19	
Other endocrine glands	C74-75	5	1	-	-	-	-	-	
Ill-defined or unknown	C76,C80	1	-	-	-	-	2	1	
Lymphoid and haematopoietic tissue	C81-96	11	6	9	13	16	14	8	
Hodgkin lymphoma	C81	-	-	2	9	9	8	4	
Non-Hodgkin lymphoma	C82-85,C96	-	1	5	1	2	4	2	
Nodal non-Hodgkin lymphoma		-	-	1	1	1	2	1	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	11	5	2	3	5	2	2	
Acute leukaemia		11	5	2	2	3	2	2	
Not included above									
Carcinoma in situ of the breast	D05	-	-	-	-	-	1	3	
Cervix uteri, non-invasive neoplasms		-	-	-	13	91	186	171	
Borderline tumour of the ovary	D39	-	-	1	1	3	6	4	
Basal cell carcinoma of the skin		-	-	-	2	3	10	15	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	

Age group												All ages
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
200	416	701	1061	1432	1527	1418	1395	1542	1413	1527	12988	
3	7	10	15	23	26	22	16	28	19	21	194	
-	-	-	-	2	-	2	4	6	6	4	25	
-	3	1	5	9	8	9	3	9	3	5	56	
1	-	2	3	6	10	1	5	7	8	9	52	
1	2	2	5	2	6	5	3	5	2	2	37	
1	2	5	2	4	2	5	1	1	-	1	24	
11	36	59	113	191	220	249	312	398	444	460	2523	
-	-	1	2	8	8	5	10	8	12	17	71	
3	9	8	19	25	29	27	32	35	48	53	291	
1	2	3	2	5	4	6	6	6	7	6	49	
3	15	25	35	56	77	79	98	140	161	120	824	
3	8	9	32	48	44	45	66	57	54	68	438	
-	1	3	4	9	11	15	16	28	31	32	151	
-	-	-	8	7	13	16	15	29	21	38	148	
1	-	10	10	30	33	53	65	90	99	99	495	
-	1	-	1	3	1	3	4	5	11	27	56	
4	4	20	35	91	96	84	103	113	87	81	721	
-	-	1	1	-	-	2	3	2	3	6	18	
-	-	-	1	4	2	2	1	-	3	-	14	
2	3	18	33	86	94	79	97	109	79	73	675	
2	1	1	-	1	-	-	2	2	-	2	11	
1	-	3	-	1	2	-	2	-	1	-	12	
17	23	33	35	44	40	40	61	40	36	47	447	
3	3	2	9	13	22	33	50	81	107	206	529	
-	-	-	-	-	3	1	5	4	7	1	21	
-	-	-	-	-	-	-	-	-	2	6	8	
1	-	-	-	-	-	-	-	-	-	-	2	
-	4	7	6	5	6	7	12	12	8	6	81	
78	195	388	550	645	603	507	362	317	242	218	4140	
19	45	61	99	196	227	205	204	189	131	123	1543	
9	15	10	6	15	8	12	7	9	6	17	144	
2	6	27	49	104	135	117	123	111	65	46	787	
-	-	-	1	-	-	-	2	1	4	2	10	
6	19	17	34	57	62	57	54	40	31	31	420	
2	5	7	9	20	22	19	18	28	25	27	182	
-	-	-	-	-	-	-	-	-	-	-	0	
3	9	10	22	31	48	65	70	103	76	91	532	
2	9	8	17	23	37	37	46	73	44	40	339	
1	-	2	5	8	11	28	24	30	32	51	193	
1	1	1	1	3	4	1	3	2	3	1	23	
16	24	38	55	72	58	55	45	47	46	36	561	
21	35	30	39	22	29	19	10	17	14	10	282	
-	1	2	-	2	-	-	1	-	2	1	15	
2	3	7	24	19	35	35	40	55	76	95	395	
20	26	30	58	74	108	95	99	136	112	124	959	
6	5	1	1	-	4	2	-	2	3	2	58	
10	13	15	42	49	57	68	62	77	53	54	515	
5	8	5	25	17	26	28	28	33	24	14	219	
-	1	4	6	10	22	10	15	22	17	23	130	
4	7	10	8	15	23	15	22	33	37	42	246	
3	5	4	6	5	12	5	7	15	16	14	119	
4	11	31	64	51	68	52	22	14	5	7	333	
151	96	62	30	27	14	2	4	4	5	1	857	
12	8	13	18	19	14	8	9	12	6	3	137	
35	85	131	174	265	360	428	468	557	548	570	3651	
1	-	1	-	5	5	6	6	4	5	3	36	
1	-	-	1	-	2	2	3	5	3	10	27	

Incidence

▶ **TABLE 13. Age-specific and age-adjusted incidence rates of cancer in 2007 per 100,000, by primary site. MALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	21.6	15.6	14.1	23.8	29.1	45.8	57.8	
Mouth, pharynx	C00-14	-	-	0.6	-	-	1.2	4.3	
Lip	C00	-	-	-	-	-	-	1.2	
Tongue	C01-02	-	-	-	-	-	0.6	1.8	
Mouth, other	C03-06	-	-	-	-	-	-	0.6	
Salivary glands	C07-08	-	-	0.6	-	-	0.6	0.6	
Pharynx	C09-14	-	-	-	-	-	-	-	
Digestive organs	C15-26	-	-	-	1.8	1.8	1.8	2.4	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	0.6	1.2	-	
Small intestine	C17	-	-	-	-	-	0.6	-	
Colon	C18	-	-	-	1.8	0.6	-	2.4	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	0.6	-	-	
Liver	C22	-	-	-	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	-	
Pancreas	C25	-	-	-	-	-	-	-	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	-	-	-	-	0.6	0.6	2.4	
Nose, sinuses	C30-31	-	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	0.6	-	
Lung, trachea	C33-34	-	-	-	-	0.6	-	2.4	
Mediastinum, pleura	C38	-	-	-	-	-	-	-	
Bone	C40-41	-	-	1.8	-	1.2	0.6	-	
Melanoma of the skin	C43	-	-	-	-	0.6	2.9	6.7	
Skin, non-melanoma	C44	-	0.7	-	-	0.6	1.8	0.6	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	-	-	-	-	-	-	-	
Soft tissues	C48-49	2.0	0.7	0.6	1.2	1.2	1.8	1.2	
Breast	C50	-	-	-	-	-	-	-	
Male genital organs	C60-63	0.7	-	-	2.4	10.7	11.7	17.7	
Prostate	C61	-	-	-	-	-	-	-	
Testis	C62	0.7	-	-	2.4	10.7	11.2	17.7	
Other male genital	C60,C63	-	-	-	-	-	0.6	-	
Urinary organs	C64-68	2.0	-	-	-	1.2	0.6	1.8	
Kidney	C64-65	2.0	-	-	-	-	0.6	1.8	
Bladder, ureter, urethra	C66-68	-	-	-	-	1.2	-	-	
Eye	C69	2.0	-	-	-	-	-	-	
Brain, central nervous system	C70-72	4.7	4.8	4.3	4.2	4.2	10.0	7.3	
Thyroid gland	C73	-	0.7	-	1.2	-	2.9	3.0	
Other endocrine glands	C74-75	1.4	-	-	0.6	-	-	0.6	
Ill-defined or unknown	C76,C80	0.7	1.4	0.6	0.6	1.2	1.8	0.6	
Lymphoid and haematopoietic tissue	C81-96	8.1	7.5	6.1	11.9	5.9	8.2	9.1	
Hodgkin lymphoma	C81	0.7	-	1.2	4.2	4.7	2.3	3.7	
Non-Hodgkin lymphoma	C82-85,C96	-	1.4	1.2	0.6	0.6	3.5	4.3	
Nodal non-Hodgkin lymphoma		-	0.7	-	0.6	-	1.2	3.0	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	7.4	6.1	3.7	7.2	0.6	2.3	1.2	
Acute leukaemia		7.4	4.8	3.7	6.6	-	1.8	0.6	
Not included above									
Basal cell carcinoma of the skin		-	-	-	-	1.8	2.9	8.5	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	0.6	
Polycythaemia vera		-	-	-	-	-	-	-	

¹ Adjusted for age to the "world standard population".

Age group												All ages ¹
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
70.7	94.6	172.0	346.9	652.3	1150.5	1667.2	2171.8	2821.7	3126.7	3570.1	281.9	
3.0	2.6	11.6	14.4	24.7	26.5	34.9	34.6	34.0	30.0	42.1	6.6	
0.6	-	0.5	1.0	1.0	1.2	8.3	13.0	10.9	11.5	21.0	1.1	
1.2	1.6	3.2	3.6	6.4	5.5	7.5	6.5	2.7	6.9	4.2	1.6	
0.6	0.5	1.6	3.6	3.9	6.8	6.6	8.7	6.8	4.6	8.4	1.3	
0.6	0.5	2.1	1.5	3.5	2.5	3.3	1.1	4.1	2.3	-	0.8	
-	-	4.2	4.6	9.9	10.5	9.1	5.4	9.5	4.6	8.4	1.8	
8.9	17.3	36.0	79.0	136.1	246.4	348.1	461.0	586.9	719.4	812.5	56.8	
-	1.6	2.6	5.6	6.9	20.3	22.4	22.7	34.0	34.6	29.5	3.4	
1.8	2.1	6.9	12.3	17.8	30.8	39.0	73.6	70.8	92.2	130.5	7.8	
0.6	0.5	1.6	2.6	3.0	4.3	8.3	5.4	10.9	4.6	21.0	1.2	
3.0	4.7	9.0	24.1	30.6	52.4	100.5	139.6	155.2	214.4	223.1	15.4	
3.0	4.2	7.9	12.3	29.6	61.6	73.1	85.5	134.8	115.3	109.5	11.6	
-	1.1	2.1	5.6	12.8	22.8	39.0	30.3	51.7	92.2	92.6	5.1	
-	1.1	0.5	2.1	5.4	9.2	10.8	15.1	35.4	20.8	50.5	2.1	
0.6	2.1	4.8	12.8	26.6	42.5	54.0	81.2	91.2	136.0	113.7	9.3	
-	-	0.5	1.5	3.5	2.5	0.8	7.6	2.7	9.2	42.1	0.8	
3.0	7.4	10.6	42.6	84.8	157.7	224.3	281.4	427.6	440.4	374.7	34.0	
-	1.6	1.6	1.0	3.5	1.2	4.2	4.3	5.4	4.6	4.2	0.7	
0.6	0.5	1.6	5.6	10.4	14.8	12.5	15.1	17.7	18.4	21.0	2.5	
2.4	4.2	7.4	35.4	70.5	140.4	204.4	260.8	403.1	410.4	332.6	30.3	
-	0.5	-	0.5	0.5	0.6	2.5	-	-	4.6	16.8	0.3	
1.2	-	2.1	-	0.5	1.2	0.8	1.1	1.4	2.3	4.2	0.7	
8.9	11.0	14.8	19.5	31.6	34.5	50.7	58.4	65.4	64.6	113.7	10.6	
-	-	4.2	6.7	7.9	20.9	39.9	83.3	171.6	246.7	513.6	10.4	
-	-	-	1.0	5.4	11.7	17.4	13.0	9.5	9.2	12.6	1.7	
1.2	-	-	-	-	-	0.8	-	4.1	-	8.4	0.2	
-	-	-	0.5	1.0	-	-	-	-	-	-	0.1	
-	2.1	4.2	3.1	5.9	8.6	10.0	4.3	10.9	13.8	21.0	2.6	
0.6	-	0.5	-	2.0	1.2	1.7	3.2	4.1	-	-	0.4	
14.9	8.4	22.8	89.8	207.6	419.4	662.9	839.7	977.8	915.4	964.1	91.3	
-	1.6	20.1	85.7	203.1	411.4	657.1	831.1	976.4	903.9	955.7	85.6	
14.3	6.8	1.6	2.1	2.5	3.1	-	1.1	-	6.9	-	4.8	
0.6	-	1.1	2.1	2.0	4.9	5.8	7.6	1.4	4.6	8.4	0.9	
4.2	8.9	12.2	27.7	50.3	78.8	113.8	160.2	211.1	295.1	332.6	20.4	
1.8	6.8	7.4	19.5	27.1	38.2	43.2	63.8	53.1	99.2	58.9	8.8	
2.4	2.1	4.8	8.2	23.2	40.7	70.6	96.3	158.0	196.0	273.6	11.6	
-	2.1	-	-	1.0	1.8	0.8	3.2	4.1	2.3	-	0.6	
9.5	10.5	15.9	16.9	21.2	30.8	25.8	33.5	36.8	43.8	33.7	10.7	
1.8	3.2	6.4	2.6	6.4	5.5	2.5	13.0	12.3	4.6	12.6	2.4	
-	1.1	1.6	-	0.5	0.6	1.7	1.1	2.7	2.3	4.2	0.6	
0.6	3.2	4.2	8.2	13.8	23.4	34.1	45.4	49.0	92.2	75.8	6.2	
13.1	16.8	24.9	34.9	51.8	81.3	97.2	135.3	212.4	244.4	244.2	25.6	
1.8	3.7	1.1	4.1	2.5	3.1	4.2	1.1	2.7	4.6	-	2.4	
7.1	8.9	15.3	19.0	30.1	43.1	56.5	73.6	102.1	131.4	92.6	12.0	
3.0	3.7	7.4	8.2	15.3	23.4	20.8	18.4	51.7	55.3	50.5	5.2	
0.6	-	2.6	5.1	6.4	10.5	16.6	10.8	39.5	25.4	58.9	2.7	
3.6	4.2	5.8	6.7	12.3	24.0	19.1	46.5	65.4	78.4	88.4	8.4	
3.0	1.6	2.1	3.1	3.9	3.7	6.6	16.2	34.0	25.4	8.4	4.4	
16.0	20.5	54.0	63.6	131.7	219.3	350.6	532.4	776.2	1014.6	1170.4	63.4	
-	1.1	1.1	1.5	5.9	12.3	17.4	15.1	39.5	32.3	58.9	2.6	
-	-	-	1.0	3.0	-	-	3.2	4.1	-	8.4	0.3	

▶ **TABLE 14. Age-specific and age-adjusted incidence rates of cancer in 2007 per 100,000, by primary site. FEMALES.**

Primary site	ICD-10 code	Age group (years)							
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39
All sites	C00-96	17.6	7.8	17.2	18.0	39.1	49.9	77.2	81.1
Mouth, pharynx	C00-14	-	-	-	-	0.6	0.6	1.3	1.3
Lip	C00	-	-	-	-	0.6	-	-	-
Tongue	C01-02	-	-	-	-	-	-	0.6	-
Mouth, other	C03-06	-	-	-	-	-	-	-	-
Salivary glands	C07-08	-	-	-	-	-	0.6	0.6	-
Pharynx	C09-14	-	-	-	-	-	-	-	-
Digestive organs	C15-26	-	-	0.6	2.5	6.2	2.5	7.1	7.1
Oesophagus	C15	-	-	-	-	-	-	-	-
Stomach	C16	-	-	-	-	-	1.2	0.6	-
Small intestine	C17	-	-	-	-	0.6	-	-	-
Colon	C18	-	-	-	2.5	2.5	0.6	3.9	-
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	1.2	0.6	0.6	-
Liver	C22	-	-	0.6	-	-	-	-	-
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	0.6	-
Pancreas	C25	-	-	-	-	1.9	-	1.3	-
Other digestive organs	C26	-	-	-	-	-	-	-	-
Respiratory organs	C30-39	-	-	-	-	0.6	-	1.3	1.3
Nose, sinuses	C30-31	-	-	-	-	-	-	-	-
Larynx, epiglottis	C32	-	-	-	-	-	-	0.6	-
Lung, trachea	C33-34	-	-	-	-	0.6	-	0.6	-
Mediastinum, pleura	C38	-	-	-	-	-	-	-	-
Bone	C40-41	-	-	0.6	-	-	0.6	-	-
Melanoma of the skin	C43	-	-	-	0.6	4.3	6.2	8.4	8.4
Skin, non-melanoma	C44	-	-	-	-	-	-	-	-
Mesothelioma	C45	-	-	-	-	-	-	-	-
Kaposi sarcoma	C46	-	-	-	-	-	-	-	-
Autonomic nervous system	C47	-	-	-	0.6	-	-	-	-
Soft tissues	C48-49	0.7	-	0.6	0.6	-	2.5	0.6	0.6
Breast	C50	-	-	-	-	2.5	3.7	16.1	16.1
Female genital organs	C51-58	-	-	1.9	-	3.7	6.8	15.4	15.4
Cervix uteri	C53	-	-	-	-	1.2	5.5	12.2	12.2
Corpus uteri	C54	-	-	-	-	-	1.2	-	-
Uterus, other	C55	-	-	-	-	-	-	-	-
Ovary	C56	-	-	1.9	-	2.5	-	3.2	3.2
Other female genital	C51-52,C57	-	-	-	-	-	-	-	-
Placenta	C58	-	-	-	-	-	-	-	-
Urinary organs	C64-68	0.7	-	0.6	-	0.6	0.6	-	-
Kidney	C64-65	0.7	-	0.6	-	0.6	-	-	-
Bladder, ureter, urethra	C66-68	-	-	-	-	-	0.6	-	-
Eye	C69	0.7	-	-	-	-	0.6	-	-
Brain, central nervous system	C70-72	3.5	2.8	7.0	5.6	6.2	9.8	9.0	9.0
Thyroid gland	C73	-	-	-	-	4.3	6.2	12.2	12.2
Other endocrine glands	C74-75	3.5	0.7	-	-	-	-	-	-
Ill-defined or unknown	C76,C80	0.7	-	-	-	-	1.2	0.6	0.6
Lymphoid and haematopoietic tissue	C81-96	7.8	4.3	5.7	8.1	9.9	8.6	5.1	5.1
Hodgkin lymphoma	C81	-	-	1.3	5.6	5.6	4.9	2.6	2.6
Non-Hodgkin lymphoma	C82-85,C96	-	0.7	3.2	0.6	1.2	2.5	1.3	1.3
Nodal non-Hodgkin lymphoma		-	-	0.6	0.6	0.6	1.2	0.6	0.6
Multiple myeloma	C90	-	-	-	-	-	-	-	-
Leukaemia	C91-95	7.8	3.6	1.3	1.9	3.1	1.2	1.3	1.3
Acute leukaemia		7.8	3.6	1.3	1.2	1.9	1.2	1.3	1.3
Not included above									
Carcinoma in situ of the breast	D05	-	-	-	-	-	0.6	1.9	1.9
Cervix uteri, non-invasive neoplasms		-	-	-	8.1	56.5	114.5	110.0	110.0
Borderline tumour of the ovary	D39	-	-	0.6	0.6	1.9	3.7	2.6	2.6
Basal cell carcinoma of the skin		-	-	-	1.2	1.9	6.2	9.6	9.6
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	-
Polycythaemia vera		-	-	-	-	-	-	-	-

¹ Adjusted for age to the "world standard population".


Age group												All ages ¹
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
123.5	225.5	377.1	544.5	701.6	903.1	1044.3	1210.3	1405.5	1650.4	2113.1	241.2	
1.9	3.8	5.4	7.7	11.3	15.4	16.2	13.9	25.5	22.2	29.1	3.6	
-	-	-	-	1.0	-	1.5	3.5	5.5	7.0	5.5	0.3	
-	1.6	0.5	2.6	4.4	4.7	6.6	2.6	8.2	3.5	6.9	1.0	
0.6	-	1.1	1.5	2.9	5.9	0.7	4.3	6.4	9.3	12.5	0.8	
0.6	1.1	1.1	2.6	1.0	3.5	3.7	2.6	4.6	2.3	2.8	0.8	
0.6	1.1	2.7	1.0	2.0	1.2	3.7	0.9	0.9	-	1.4	0.6	
6.8	19.5	31.7	58.0	93.6	130.1	183.4	270.7	362.8	518.6	636.5	37.0	
-	-	0.5	1.0	3.9	4.7	3.7	8.7	7.3	14.0	23.5	1.0	
1.9	4.9	4.3	9.8	12.2	17.2	19.9	27.8	31.9	56.1	73.3	4.6	
0.6	1.1	1.6	1.0	2.4	2.4	4.4	5.2	5.5	8.2	8.3	0.9	
1.9	8.1	13.5	18.0	27.4	45.5	58.2	85.0	127.6	188.0	166.1	12.4	
1.9	4.3	4.8	16.4	23.5	26.0	33.1	57.3	52.0	63.1	94.1	7.1	
-	0.5	1.6	2.1	4.4	6.5	11.0	13.9	25.5	36.2	44.3	2.0	
-	-	-	4.1	3.4	7.7	11.8	13.0	26.4	24.5	52.6	2.0	
0.6	-	5.4	5.1	14.7	19.5	39.0	56.4	82.0	115.6	137.0	6.6	
-	0.5	-	0.5	1.5	0.6	2.2	3.5	4.6	12.8	37.4	0.6	
2.5	2.2	10.8	18.0	44.6	56.8	61.9	89.4	103.0	101.6	112.1	11.7	
-	-	0.5	0.5	-	-	1.5	2.6	1.8	3.5	8.3	0.2	
-	-	-	0.5	2.0	1.2	1.5	0.9	-	3.5	-	0.3	
1.2	1.6	9.7	16.9	42.1	55.6	58.2	84.2	99.4	92.3	101.0	11.0	
1.2	0.5	0.5	-	0.5	-	-	1.7	1.8	-	2.8	0.2	
0.6	-	1.6	-	0.5	1.2	-	1.7	-	1.2	-	0.3	
10.5	12.5	17.8	18.0	21.6	23.7	29.5	52.9	36.5	42.0	65.0	9.4	
1.9	1.6	1.1	4.6	6.4	13.0	24.3	43.4	73.8	125.0	285.1	5.7	
-	-	-	-	-	1.8	0.7	4.3	3.6	8.2	1.4	0.3	
-	-	-	-	-	-	-	-	-	2.3	8.3	0.1	
0.6	-	-	-	-	-	-	-	-	-	-	0.1	
-	2.2	3.8	3.1	2.4	3.5	5.2	10.4	10.9	9.3	8.3	1.7	
48.2	105.7	208.7	282.3	316.0	356.6	373.4	314.1	288.9	282.7	301.7	87.5	
11.7	24.4	32.8	50.8	96.0	134.2	151.0	177.0	172.3	153.0	170.2	29.2	
5.6	8.1	5.4	3.1	7.3	4.7	8.8	6.1	8.2	7.0	23.5	3.7	
1.2	3.3	14.5	25.1	51.0	79.8	86.2	106.7	101.2	75.9	63.7	14.2	
-	-	-	0.5	-	-	-	1.7	0.9	4.7	2.8	0.1	
3.7	10.3	9.1	17.4	27.9	36.7	42.0	46.9	36.5	36.2	42.9	8.4	
1.2	2.7	3.8	4.6	9.8	13.0	14.0	15.6	25.5	29.2	37.4	2.9	
-	-	-	-	-	-	-	-	-	-	-	0.0	
1.9	4.9	5.4	11.3	15.2	28.4	47.9	60.7	93.9	88.8	125.9	7.9	
1.2	4.9	4.3	8.7	11.3	21.9	27.2	39.9	66.5	51.4	55.4	5.4	
0.6	-	1.1	2.6	3.9	6.5	20.6	20.8	27.3	37.4	70.6	2.5	
0.6	0.5	0.5	0.5	1.5	2.4	0.7	2.6	1.8	3.5	1.4	0.5	
9.9	13.0	20.4	28.2	35.3	34.3	40.5	39.0	42.8	53.7	49.8	13.4	
13.0	19.0	16.1	20.0	10.8	17.2	14.0	8.7	15.5	16.4	13.8	7.5	
-	0.5	1.1	-	1.0	-	-	0.9	-	2.3	1.4	0.7	
1.2	1.6	3.8	12.3	9.3	20.7	25.8	34.7	50.1	88.8	131.5	5.5	
12.3	14.1	16.1	29.8	36.3	63.9	70.0	85.9	124.0	130.8	171.6	19.0	
3.7	2.7	0.5	0.5	-	2.4	1.5	-	1.8	3.5	2.8	2.2	
6.2	7.0	8.1	21.6	24.0	33.7	50.1	53.8	70.2	61.9	74.7	9.4	
3.1	4.3	2.7	12.8	8.3	15.4	20.6	24.3	30.1	28.0	19.4	4.1	
-	0.5	2.2	3.1	4.9	13.0	7.4	13.0	20.1	19.9	31.8	2.0	
2.5	3.8	5.4	4.1	7.3	13.6	11.0	19.1	30.1	43.2	58.1	5.3	
1.9	2.7	2.2	3.1	2.4	7.1	3.7	6.1	13.7	18.7	19.4	3.3	
2.5	6.0	16.7	32.8	25.0	40.2	38.3	19.1	12.8	5.8	9.7	7.7	
93.2	52.0	33.4	15.4	13.2	8.3	1.5	3.5	3.6	5.8	1.4	33.5	
7.4	4.3	7.0	9.2	9.3	8.3	5.9	7.8	10.9	7.0	4.2	3.5	
21.6	46.1	70.5	89.3	129.8	212.9	315.2	406.0	507.7	640.1	788.8	57.6	
0.6	-	0.5	-	2.4	3.0	4.4	5.2	3.6	5.8	4.2	0.6	
0.6	-	-	0.5	-	1.2	1.5	2.6	4.6	3.5	13.8	0.3	

Incidence

► **TABLE 15. Mean annual numbers of new cancers in 2003-2007, by primary site and health care district. MALES.**

Primary site	ICD-10 code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	1910	1313	1294	677	492	1301	595	540	339	284	171
Mouth, pharynx	C00-14	41	35	27	13	10	22	10	13	7	5	5
Lip	C00	5	3	6	3	3	4	2	2	2	0	2
Tongue	C01-02	8	7	8	3	1	4	2	3	1	1	1
Mouth, other	C03-06	9	10	6	3	3	3	3	4	1	1	1
Salivary glands	C07-08	4	3	2	1	1	3	2	1	1	0	1
Pharynx	C09-14	15	12	5	2	2	7	3	3	2	2	1
Digestive organs	C15-26	357	252	248	139	91	249	115	119	75	58	38
Oesophagus	C15	21	15	12	7	7	18	6	10	4	2	2
Stomach	C16	47	30	35	26	12	37	15	16	6	13	6
Small intestine	C17	7	6	4	3	2	5	1	2	1	0	1
Colon	C18	99	70	75	37	26	66	30	35	21	17	9
Rectum, rectosigmoid, anus	C19-21	75	46	53	28	19	53	24	26	19	12	8
Liver	C22	32	31	20	9	6	21	14	7	6	3	4
Gallbladder, bile ducts	C23-24	12	6	8	5	4	9	5	3	2	2	1
Pancreas	C25	60	45	38	21	15	35	19	19	15	8	6
Other digestive organs	C26	5	3	3	3	1	4	0	1	1	1	1
Respiratory organs	C30-39	228	170	159	89	70	139	76	69	47	38	23
Nose, sinuses	C30-31	3	2	2	2	1	3	1	1	0	-	0
Larynx, epiglottis	C32	15	13	9	7	4	7	5	5	3	2	1
Lung, trachea	C33-34	209	153	146	79	65	127	70	62	43	35	21
Mediastinum, pleura	C38	1	2	1	0	0	2	1	0	0	1	0
Bone	C40-41	3	1	2	1	1	1	0	1	1	0	-
Melanoma of the skin	C43	80	49	42	19	13	39	21	19	13	9	5
Skin, non-melanoma	C44	63	47	50	29	15	49	18	24	19	3	11
Mesothelioma	C45	14	9	14	2	1	4	2	2	2	0	0
Kaposi sarcoma	C46	1	2	1	0	-	1	0	0	-	-	-
Autonomic nervous system	C47	1	0	1	1	0	1	0	-	-	0	0
Soft tissues	C48-49	14	11	6	3	2	9	3	3	3	3	1
Breast	C50	4	1	1	1	1	1	1	1	1	-	-
Male genital organs	C60-63	680	472	450	244	191	541	227	181	88	103	55
Prostate	C61	653	455	435	238	188	528	222	175	85	101	53
Testis	C62	23	15	11	5	3	9	4	5	3	2	1
Other male genital	C60,C63	4	2	4	1	1	4	1	2	0	-	1
Urinary organs	C64-68	150	87	100	53	38	87	50	44	31	25	11
Kidney	C64-65	60	34	40	20	17	43	20	18	11	12	4
Bladder, ureter, urethra	C66-68	90	54	60	33	21	44	31	26	19	14	7
Eye	C69	1	2	3	1	1	2	1	1	0	0	-
Brain, central nervous system	C70-72	65	38	38	21	10	33	19	14	11	8	4
Thyroid gland	C73	13	10	6	4	3	8	3	2	1	1	1
Other endocrine glands	C74-75	2	1	2	0	0	1	0	0	0	0	-
Ill-defined or unknown	C76,C80	27	29	32	16	9	26	10	9	8	8	2
Lymphoid and haematopoietic tissue	C81-96	164	97	113	43	35	87	36	38	31	22	14
Hodgkin lymphoma	C81	13	7	5	2	3	7	2	3	2	2	1
Non-Hodgkin lymphoma	C82-85,C96	81	54	48	21	17	44	20	17	18	11	7
Nodal non-Hodgkin lymphoma		47	29	33	12	9	22	11	9	10	7	4
Multiple myeloma	C90	21	12	18	6	5	13	5	6	4	2	3
Leukaemia	C91-95	48	24	42	14	11	23	10	13	7	7	4
Acute leukaemia		15	11	16	7	5	8	3	5	2	2	1
Not included above												
Basal cell carcinoma of the skin		463	353	209	96	92	268	126	114	68	67	45
PUNLMP and ca in situ of the bladder		4	3	7	1	1	11	1	3	-	0	0
Polycythaemia vera		7	3	2	-	-	1	0	0	1	1	0

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	430	599	631	643	469	194	790	217	191	295	94	13550
	9	11	13	13	10	4	16	4	4	8	2	283
	3	3	3	5	3	1	5	2	1	1	1	60
	2	2	3	2	2	1	3	1	0	3	0	57
	2	3	2	2	2	1	5	1	1	2	0	64
	1	1	2	2	2	0	1	1	1	1	0	30
	1	2	2	1	2	1	2	-	1	1	0	70
	87	119	137	117	97	42	153	39	30	58	15	2649
	6	8	6	7	4	4	7	2	1	4	1	154
	13	19	23	21	21	6	25	6	4	9	3	395
	2	2	2	2	2	0	3	0	0	1	1	47
	21	32	39	30	28	9	35	8	8	13	4	715
	17	21	27	23	18	8	30	9	4	11	4	534
	9	8	13	7	4	4	15	4	4	8	1	231
	3	4	6	4	2	1	6	2	2	2	0	89
	16	23	21	20	17	9	30	7	6	11	3	447
	1	2	1	2	1	1	1	1	1	1	-	35
	71	91	84	74	55	26	112	37	28	49	8	1753
	1	1	1	1	1	0	1	1	1	-	0	24
	2	6	5	6	2	1	5	3	3	2	0	105
	68	82	78	66	51	24	105	33	25	47	7	1607
	0	1	0	1	0	-	0	-	0	0	0	13
	1	1	1	1	1	1	2	-	-	0	-	19
	10	19	17	16	13	5	22	7	5	5	2	432
	13	20	30	26	17	7	25	7	7	5	4	496
	2	1	3	2	1	1	3	0	1	1	0	66
	-	-	-	1	0	-	1	-	0	-	0	8
	0	1	0	-	0	-	0	-	-	0	-	8
	4	4	4	4	1	1	4	2	1	3	0	85
	1	1	-	0	1	-	1	1	0	-	0	17
	128	194	212	270	180	68	275	74	75	103	42	4873
	124	188	205	265	175	66	264	73	74	100	42	4729
	3	5	5	4	4	1	9	0	0	2	0	116
	1	1	2	1	1	1	2	1	0	1	-	28
	37	54	52	45	37	14	68	18	18	19	7	1055
	14	23	20	17	12	6	29	6	6	8	4	428
	23	31	32	28	25	8	39	12	12	10	4	626
	1	1	1	0	0	-	2	1	0	0	0	19
	12	19	12	13	13	5	22	4	3	6	2	375
	3	3	2	4	3	1	11	2	1	3	0	87
	-	2	0	0	0	-	1	0	0	1	-	12
	12	12	14	13	9	4	14	6	4	5	1	273
	38	48	46	45	30	16	60	16	14	28	8	1039
	3	3	5	4	3	1	5	1	1	1	-	73
	21	25	24	25	15	8	27	8	5	14	4	514
	12	15	11	13	8	4	17	4	3	8	3	292
	6	9	7	4	4	2	9	2	3	4	2	147
	9	11	11	11	8	5	18	5	4	8	2	297
	4	6	5	4	4	2	6	3	2	4	1	119
	117	180	154	51	87	46	174	45	31	38	10	2855
	3	2	0	1	2	4	5	2	1	4	0	59
	1	1	0	1	0	0	1	0	0	1	-	21




Incidence

▶ **TABLE 16. Mean annual numbers of new cancers in 2003-2007, by primary site and health care district. FEMALES.**

Primary site	ICD-10code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	1892	1481	1231	603	443	1152	536	506	339	287	139
Mouth, pharynx	C00-14	29	23	20	11	7	16	10	6	5	2	2
Lip	C00	2	3	3	2	1	3	1	1	0	0	0
Tongue	C01-02	7	6	6	3	2	5	3	2	2	0	0
Mouth, other	C03-06	9	7	6	3	2	4	3	1	2	1	1
Salivary glands	C07-08	7	3	3	1	1	1	1	1	0	1	0
Pharynx	C09-14	3	4	3	1	1	2	2	1	0	0	-
Digestive organs	C15-26	321	253	239	132	92	222	117	111	70	68	32
Oesophagus	C15	7	8	7	6	3	11	3	3	2	1	1
Stomach	C16	37	28	31	19	13	27	14	12	9	11	5
Small intestine	C17	7	6	2	2	1	4	1	1	1	1	1
Colon	C18	100	79	84	40	28	68	37	36	20	22	10
Rectum, rectosigmoid, anus	C19-21	63	48	40	24	17	43	18	20	13	9	5
Liver	C22	22	15	11	7	2	10	9	8	3	3	2
Gallbladder, bile ducts	C23-24	15	11	12	8	8	17	10	7	5	6	1
Pancreas	C25	66	54	45	24	19	38	24	23	15	14	6
Other digestive organs	C26	4	5	6	3	1	5	1	1	2	2	1
Respiratory organs	C30-39	112	107	66	28	24	57	23	25	14	14	7
Nose, sinuses	C30-31	2	2	2	0	-	3	0	0	1	1	-
Larynx, epiglottis	C32	2	1	1	1	1	1	1	0	0	0	-
Lung, trachea	C33-34	105	102	62	26	23	51	22	24	13	12	7
Mediastinum, pleura	C38	1	1	1	1	0	1	-	0	1	0	-
Bone	C40-41	2	2	2	0	1	2	1	-	0	0	0
Melanoma of the skin	C43	74	48	44	18	12	38	21	12	11	10	5
Skin, non-melanoma	C44	61	47	47	23	16	49	20	24	23	5	12
Mesothelioma	C45	3	2	3	1	1	1	1	1	1	-	-
Kaposi sarcoma	C46	0	0	1	0	0	1	-	-	-	0	0
Autonomic nervous system	C47	1	0	1	0	0	1	-	-	-	0	-
Soft tissues	C48-49	14	11	8	5	3	10	3	3	2	1	1
Breast	C50	653	527	377	178	137	370	164	153	97	90	39
Female genital organs	C51-58	221	165	142	80	51	154	64	63	41	43	14
Cervix uteri	C53	25	18	14	8	4	14	6	5	3	4	2
Corpus uteri	C54	101	79	72	47	26	78	31	32	20	24	6
Uterus, other	C55	2	1	0	-	0	0	-	-	0	-	-
Ovary	C56	66	48	41	19	16	47	21	20	14	11	4
Other female genital	C51-52,C57	26	18	14	6	3	14	5	6	4	5	2
Placenta	C58	0	-	-	-	-	-	0	-	0	-	-
Urinary organs	C64-68	72	60	50	27	18	45	26	21	17	11	7
Kidney	C64-65	48	35	33	16	11	29	16	15	10	8	5
Bladder, ureter, urethra	C66-68	24	25	17	11	7	16	10	6	7	3	3
Eye	C69	3	1	3	1	1	2	2	1	1	0	1
Brain, central nervous system	C70-72	97	69	60	25	21	43	22	20	13	9	4
Thyroid gland	C73	43	26	19	11	9	25	10	9	3	3	2
Other endocrine glands	C74-75	3	1	1	1	-	2	0	0	0	-	1
Ill-defined or unknown	C76,C80	53	35	41	18	16	34	14	12	15	9	4
Lymphoid and haematopoietic tissue	C81-96	128	104	108	44	35	82	37	45	25	20	9
Hodgkin lymphoma	C81	7	7	5	2	3	5	2	3	1	2	0
Non-Hodgkin lymphoma	C82-85,C96	71	55	53	21	16	42	21	24	14	10	5
Nodal non-Hodgkin lymphoma		40	34	31	11	10	24	12	13	8	6	3
Multiple myeloma	C90	19	16	19	8	5	13	5	7	3	2	1
Leukaemia	C91-95	31	25	30	13	10	22	8	11	7	6	2
Acute leukaemia		14	10	13	6	5	11	5	4	4	4	1
Not included above												
Carcinoma in situ of the breast	D05	55	51	30	12	8	27	9	5	10	6	5
Cervix uteri, non-invasive neoplasms		175	72	81	25	26	91	30	6	11	9	9
Borderline tumour of the ovary	D39	14	11	11	5	3	12	4	4	3	2	1
Basal cell carcinoma of the skin		532	479	248	114	118	325	172	139	86	90	58
PUNLMP and ca in situ of the bladder		2	2	1	0	0	3	0	-	-	-	-
Polycythaemia vera		5	4	2	1	1	1	0	1	-	2	0

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	383	584	602	523	399	182	709	180	152	236	71	12699
	6	12	12	6	5	4	13	3	2	4	0	200
	1	3	3	1	1	1	4	1	-	1	-	32
	2	3	4	2	1	1	3	1	1	1	-	55
	1	3	2	1	1	1	3	1	1	1	-	54
	1	2	1	1	1	0	3	-	0	1	0	33
	1	2	2	0	1	0	1	-	0	0	-	26
	76	119	135	101	91	38	141	34	28	47	15	2499
	2	3	4	2	4	2	6	1	1	2	1	80
	9	16	19	14	10	5	18	5	4	9	1	316
	1	2	3	2	1	0	3	1	0	0	0	41
	20	37	50	32	30	15	39	11	8	12	5	789
	15	21	19	16	16	6	20	5	2	8	3	432
	5	6	7	6	4	2	8	2	2	2	1	139
	7	9	9	6	5	3	9	1	2	2	0	152
	15	21	22	20	19	5	33	8	7	12	3	496
	2	5	2	3	2	1	4	1	1	1	0	54
	16	22	25	18	20	10	40	12	10	19	4	679
	2	1	1	0	1	0	0	0	-	-	-	16
	0	0	1	-	0	0	0	0	-	-	0	13
	15	20	22	17	19	9	39	11	10	19	4	638
	-	-	1	0	0	0	-	-	0	0	-	9
	0	1	0	1	0	0	2	-	0	0	-	16
	13	16	13	14	10	3	19	6	4	5	4	403
	13	24	32	25	17	9	21	7	5	4	3	494
	0	1	1	-	0	0	0	0	1	1	-	19
	-	-	-	1	1	0	1	-	0	0	-	6
	-	0	0	0	0	-	0	-	-	0	-	5
	2	5	4	4	4	2	6	2	2	2	0	94
	114	175	184	168	119	56	207	52	44	69	20	4002
	56	76	72	66	51	26	87	22	22	32	10	1566
	4	7	8	5	5	3	8	2	2	4	1	154
	28	35	33	39	27	12	44	12	12	14	5	781
	0	0	-	-	1	0	0	-	0	-	-	7
	17	25	22	18	15	8	28	6	5	10	3	469
	7	8	10	5	2	2	7	3	3	4	1	155
	-	0	0	0	-	-	0	-	-	-	-	1
	20	29	29	23	16	5	39	8	7	11	4	550
	13	18	19	14	9	4	25	5	4	7	2	349
	7	11	10	9	7	1	14	3	3	3	3	201
	1	1	1	2	0	0	2	1	-	1	0	26
	15	21	23	24	16	7	27	7	5	11	3	547
	11	15	9	11	5	5	32	7	4	7	0	267
	0	0	0	0	0	0	1	-	0	-	-	11
	9	17	18	15	15	6	18	6	5	6	3	371
	29	48	42	44	29	12	51	14	12	16	4	944
	2	3	2	3	2	1	4	1	1	0	-	57
	15	29	24	23	15	6	24	8	6	10	2	497
	9	16	13	12	11	3	13	5	3	6	1	286
	5	6	5	8	5	1	7	2	2	2	1	142
	8	9	11	10	7	3	16	3	4	3	2	241
	5	5	6	5	4	1	7	2	2	1	1	116
	15	10	15	4	5	4	20	3	2	4	1	304
	31	23	54	31	25	2	51	12	10	13	5	795
	5	12	10	6	4	0	8	2	2	4	1	125
	130	239	192	61	92	47	173	43	38	53	10	3457
	1	1	0	1	0	0	1	0	0	1	0	15
	0	1	1	1	-	-	1	1	0	0	-	24




Incidence

► **TABLE 17.** Age-adjusted¹ cancer incidence rates per 100,000 person-years in 2003-2007, by primary site and health care district. **MALES.**

Primary site	ICD-10 code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	318.7	341.4	322.4	300.5	321.6	336.8	313.7	304.5	270.6	253.2	278.9
Mouth, pharynx	C00-14	6.8	9.6	7.3	5.8	6.9	5.9	5.9	8.8	5.9	5.0	8.5
Lip	C00	0.9	0.8	1.3	1.3	1.9	0.9	1.0	1.4	1.4	0.4	2.6
Tongue	C01-02	1.3	1.8	2.1	1.5	0.9	1.1	1.0	1.8	1.2	1.4	1.1
Mouth, other	C03-06	1.5	2.7	1.8	1.4	1.9	1.0	1.4	2.1	1.0	0.8	2.2
Salivary glands	C07-08	0.7	0.9	0.6	0.6	0.3	1.0	1.1	1.2	0.6	0.5	1.1
Pharynx	C09-14	2.4	3.4	1.5	1.0	2.1	1.9	1.5	2.3	1.6	1.9	1.6
Digestive organs	C15-26	58.0	63.9	59.8	60.8	58.5	62.7	58.6	64.5	59.1	49.0	58.7
Oesophagus	C15	3.4	4.0	3.2	3.5	4.5	4.5	3.2	5.9	3.5	2.2	3.8
Stomach	C16	7.5	7.4	8.2	11.5	7.4	9.5	7.7	8.2	4.9	10.6	9.3
Small intestine	C17	1.1	1.5	1.0	1.3	1.0	1.3	0.8	1.1	0.6	0.2	1.6
Colon	C18	16.2	17.4	17.9	15.7	17.0	16.8	15.2	18.5	17.1	14.6	14.4
Rectum, rectosigmoid, anus	C19-21	12.1	11.9	13.0	12.3	12.4	13.5	12.2	14.5	14.0	9.6	11.7
Liver	C22	5.2	8.0	4.9	3.9	3.7	5.0	7.1	3.8	5.1	3.1	5.8
Gallbladder, bile ducts	C23-24	2.0	1.5	1.8	2.2	2.5	2.3	2.5	1.6	1.4	1.2	1.8
Pancreas	C25	9.6	11.5	9.2	9.4	9.5	8.8	9.8	10.6	11.9	6.7	8.8
Other digestive organs	C26	0.8	0.8	0.7	1.1	0.4	1.0	0.1	0.4	0.7	0.8	1.5
Respiratory organs	C30-39	36.8	42.8	37.3	38.2	43.1	34.0	38.7	36.2	35.2	31.7	34.7
Nose, sinuses	C30-31	0.5	0.6	0.6	0.9	0.6	0.9	0.5	0.4	0.2	-	0.2
Larynx, epiglottis	C32	2.4	3.4	2.3	3.3	2.6	1.7	2.5	3.1	2.9	2.2	2.2
Lung, trachea	C33-34	33.7	38.1	34.0	33.8	39.6	31.0	35.3	32.6	31.6	28.5	32.0
Mediastinum, pleura	C38	0.2	0.5	0.3	0.1	0.3	0.4	0.4	0.1	0.3	0.5	0.4
Bone	C40-41	0.6	0.2	1.0	0.7	1.0	0.5	0.3	0.8	1.0	0.2	-
Melanoma of the skin	C43	13.5	12.8	11.5	9.2	8.9	11.1	12.2	11.7	11.3	8.4	8.7
Skin, non-melanoma	C44	10.3	11.0	10.9	11.0	8.7	11.8	9.1	11.6	13.4	2.9	14.9
Mesothelioma	C45	2.3	2.3	3.4	1.0	0.7	1.0	0.9	1.1	2.0	0.2	0.2
Kaposi sarcoma	C46	0.2	0.5	0.2	0.0	-	0.3	0.2	0.1	-	-	-
Autonomic nervous system	C47	0.3	0.1	0.4	1.1	0.7	0.8	0.4	-	-	0.2	0.2
Soft tissues	C48-49	2.6	2.8	1.9	1.4	1.8	3.0	1.6	2.0	3.2	2.5	3.2
Breast	C50	0.7	0.4	0.4	0.4	0.4	0.3	0.6	0.6	0.9	-	-
Male genital organs	C60-63	112.8	122.9	108.9	105.4	121.1	136.5	115.2	98.6	67.1	88.8	86.9
Prostate	C61	106.9	117.5	103.1	100.0	116.8	131.6	110.3	92.5	62.4	85.7	80.9
Testis	C62	5.1	4.9	4.9	4.8	3.7	4.0	4.3	5.2	4.6	3.1	4.6
Other male genital	C60,C63	0.7	0.5	0.9	0.5	0.7	1.0	0.6	1.0	0.2	-	1.4
Urinary organs	C64-68	24.4	22.5	24.0	23.4	23.9	22.2	26.2	23.4	24.3	23.2	18.0
Kidney	C64-65	9.9	9.2	10.1	9.8	11.0	11.4	10.7	10.5	9.5	12.0	7.1
Bladder, ureter, urethra	C66-68	14.5	13.3	13.9	13.7	12.8	10.8	15.5	12.9	14.9	11.2	10.9
Eye	C69	0.2	0.4	1.1	0.3	1.0	0.9	0.6	0.5	0.5	0.3	-
Brain, central nervous system	C70-72	12.5	11.5	12.7	12.4	9.1	11.2	14.0	11.1	12.4	11.3	9.7
Thyroid gland	C73	2.3	2.6	1.7	2.4	2.9	2.7	2.1	1.6	1.2	0.8	2.8
Other endocrine glands	C74-75	0.3	0.3	0.4	0.1	0.2	0.2	0.2	0.2	0.3	0.4	-
Ill-defined or unknown	C76,C80	4.6	7.3	7.3	5.9	5.7	6.5	5.4	5.2	6.4	7.0	3.6
Lymphoid and haematopoietic tissue	C81-96	29.3	27.5	32.2	20.9	27.0	25.3	21.6	26.5	26.4	21.4	28.7
Hodgkin lymphoma	C81	2.9	2.1	2.1	1.7	3.0	2.7	1.9	2.8	2.9	2.9	1.8
Non-Hodgkin lymphoma	C82-85,C96	14.1	15.0	12.7	10.0	12.0	12.1	10.6	10.2	15.2	10.1	14.9
Nodal non-Hodgkin lymphoma		7.9	7.7	8.8	5.9	6.9	6.1	6.2	5.4	8.3	6.9	9.5
Multiple myeloma	C90	3.4	3.1	4.4	2.4	2.9	2.9	1.9	3.1	3.0	1.7	3.7
Leukaemia	C91-95	8.7	7.1	12.9	6.6	9.2	7.5	7.1	10.3	5.3	6.7	8.1
Acute leukaemia		3.4	3.7	6.5	3.5	5.1	3.7	3.1	5.8	1.5	2.5	4.4
Not included above												
Basal cell carcinoma of the skin		75.7	86.7	48.9	39.7	55.8	66.1	63.3	60.7	53.7	56.7	68.3
PUNLMP and ca in situ of the bladder		0.7	0.8	1.6	0.5	0.7	2.7	0.6	1.2	-	0.4	0.7
Polycythaemia vera		1.1	0.8	0.4	-	-	0.2	0.1	0.1	0.3	0.8	0.2

¹ Adjusted for age to the "world standard population".

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	262.0	258.8	264.8	342.5	296.6	283.5	274.8	261.2	301.5	264.0	363.1	305.6
	6.0	5.2	5.5	7.8	6.8	6.2	5.6	5.4	6.4	7.2	9.9	6.7
	1.4	1.4	1.1	2.5	1.6	1.7	1.6	1.9	2.1	0.8	3.3	1.3
	1.4	0.8	1.2	1.2	1.1	1.4	1.1	1.8	0.9	2.8	2.3	1.4
	1.1	1.5	0.9	1.7	1.4	0.9	1.7	1.0	1.1	2.1	1.3	1.6
	1.3	0.5	1.1	1.7	1.2	0.9	0.3	0.7	1.2	0.6	1.2	0.8
	0.9	0.9	1.0	0.8	1.4	1.4	0.9	-	1.1	1.0	1.8	1.7
	52.4	51.8	55.9	61.0	58.8	57.0	52.4	48.6	46.5	50.8	63.7	58.3
	3.5	3.6	2.5	3.9	2.4	4.8	2.4	2.8	1.3	3.7	2.4	3.5
	7.9	8.0	9.3	10.6	12.6	8.0	8.5	8.3	6.4	7.8	11.3	8.6
	1.3	1.0	0.8	1.5	1.3	0.2	1.1	0.3	0.4	1.3	2.8	1.1
	13.6	14.3	15.9	15.3	16.4	13.3	12.1	10.2	11.6	11.1	15.9	15.8
	10.0	9.0	10.9	12.3	11.4	11.4	10.2	10.3	6.5	9.0	13.8	11.8
	5.2	3.2	5.4	4.2	2.4	5.2	5.3	5.1	6.7	6.1	2.5	5.1
	1.5	1.8	2.2	2.1	1.2	1.3	2.1	1.8	2.9	1.5	1.5	1.9
	9.0	9.9	8.3	10.0	10.6	12.1	10.0	8.5	10.1	9.7	13.5	9.8
	0.3	1.0	0.6	1.0	0.5	0.7	0.6	1.3	0.7	0.7	-	0.7
	38.4	37.9	33.0	36.8	32.3	35.7	36.3	42.3	40.3	41.7	29.6	37.4
	0.8	0.4	0.4	0.6	0.7	0.3	0.4	1.0	1.1	-	0.8	0.6
	1.0	2.8	2.2	3.1	1.0	1.6	1.7	3.6	4.0	1.8	0.8	2.4
	36.4	33.8	30.2	32.7	30.2	33.8	33.9	37.7	34.8	39.6	27.1	34.1
	0.1	0.8	0.2	0.3	0.1	-	0.2	-	0.4	0.2	1.0	0.3
	0.7	0.2	0.6	0.6	1.1	1.3	0.6	-	-	0.6	-	0.6
	7.6	9.1	7.6	9.3	10.5	7.3	8.2	8.3	8.1	5.7	9.9	10.5
	7.4	7.1	11.4	11.2	8.6	9.1	8.3	8.1	10.7	4.1	13.3	10.0
	1.3	0.6	1.2	0.8	0.8	2.5	1.1	0.2	1.2	0.6	0.5	1.5
	-	-	-	0.6	0.1	-	0.2	-	0.5	-	0.9	0.2
	0.4	0.8	0.4	-	0.8	-	0.4	-	-	0.5	-	0.4
	3.5	2.1	2.3	2.6	0.8	2.0	1.6	3.5	3.0	3.3	2.1	2.4
	0.5	0.3	-	0.3	0.4	-	0.2	0.7	0.2	-	1.3	0.4
	74.8	79.6	86.2	141.4	111.0	95.8	93.6	83.5	115.6	88.5	158.0	107.3
	69.3	75.2	81.7	136.0	104.5	92.7	88.5	81.5	113.4	83.2	156.7	102.1
	5.2	4.0	3.7	5.0	5.8	2.1	4.4	1.1	1.4	3.9	1.3	4.5
	0.4	0.3	0.8	0.4	0.7	1.0	0.7	0.9	0.8	1.3	-	0.7
	21.6	22.9	21.3	22.8	22.1	19.6	22.9	20.2	26.5	16.4	26.6	23.1
	9.0	10.5	8.4	9.2	7.4	9.2	10.1	7.7	9.3	8.1	13.1	9.9
	12.6	12.4	12.9	13.5	14.6	10.4	12.8	12.6	17.3	8.3	13.5	13.2
	0.4	0.5	0.6	0.2	0.2	-	0.7	0.8	0.8	0.2	1.1	0.5
	9.9	10.2	7.4	9.1	11.5	10.4	9.9	8.1	7.2	6.7	9.3	11.1
	2.1	1.0	1.3	3.0	2.8	2.6	4.6	2.7	1.7	3.0	2.3	2.4
	-	1.5	0.5	0.1	0.1	-	0.4	0.6	0.8	0.8	-	0.3
	7.0	4.4	5.8	6.9	5.1	3.9	4.8	7.6	5.8	4.6	3.4	6.0
	28.0	23.6	23.8	27.9	22.9	30.0	22.8	20.6	26.4	29.2	31.3	26.5
	3.4	2.1	3.4	4.0	3.0	3.2	2.3	2.4	4.2	1.5	-	2.6
	14.2	11.6	10.9	14.1	11.1	12.5	9.8	10.4	8.4	13.0	18.0	12.4
	8.4	6.9	5.4	7.6	5.7	6.0	6.0	4.8	5.9	8.6	11.3	7.0
	3.5	3.6	2.8	2.0	2.8	2.9	2.9	2.1	4.8	3.9	7.3	3.2
	6.8	6.2	6.8	7.4	6.0	11.5	7.5	5.7	9.0	10.2	5.5	8.2
	4.0	4.0	4.4	3.7	3.8	7.3	3.1	3.7	5.7	6.6	2.4	4.1
	68.1	73.1	62.7	25.6	53.7	61.1	57.6	52.7	46.3	33.5	37.1	61.5
	1.4	0.7	0.1	0.6	1.5	6.0	1.8	2.4	1.0	4.0	2.0	1.3
	0.4	0.3	0.2	0.2	0.3	0.3	0.3	0.5	0.4	0.9	-	0.5




Incidence

► **TABLE 18.** Age-adjusted¹ cancer incidence rates per 100,000 person-years in 2003-2007, by primary site and health care district. **FEMALES.**

Primary site	ICD-10 code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	262.3	268.2	255.8	232.3	253.6	248.8	238.8	251.2	235.6	236.4	202.6
Mouth, pharynx	C00-14	4.0	3.8	4.3	3.6	3.8	3.2	4.4	3.0	3.8	2.3	2.4
Lip	C00	0.2	0.2	0.3	0.5	0.4	0.3	0.3	0.4	0.1	0.2	0.2
Tongue	C01-02	1.0	1.0	1.3	1.0	1.1	1.0	1.4	1.0	2.0	0.1	0.8
Mouth, other	C03-06	1.2	1.1	1.2	0.9	0.8	0.8	1.2	0.4	1.4	0.9	0.7
Salivary glands	C07-08	1.1	0.7	0.8	0.6	0.8	0.3	0.7	0.6	0.2	1.0	0.6
Pharynx	C09-14	0.5	0.8	0.7	0.5	0.8	0.8	0.8	0.6	0.2	0.2	-
Digestive organs	C15-26	39.3	39.2	39.4	40.0	40.9	39.0	41.1	43.3	36.8	40.4	37.8
Oesophagus	C15	0.7	1.3	1.1	1.5	1.1	1.9	1.1	0.8	0.8	0.3	0.8
Stomach	C16	4.4	4.7	4.9	5.6	6.0	5.1	4.4	4.8	4.0	6.4	6.1
Small intestine	C17	1.0	1.0	0.5	0.6	0.3	0.8	0.9	0.7	0.6	0.4	1.2
Colon	C18	12.8	11.8	14.2	12.0	13.7	12.0	13.4	14.5	11.6	13.4	16.4
Rectum, rectosigmoid, anus	C19-21	7.9	8.2	7.1	8.0	8.7	8.0	6.7	7.9	7.5	5.9	5.2
Liver	C22	2.6	2.5	1.8	2.1	1.2	1.7	3.2	3.2	1.4	1.4	1.2
Gallbladder, bile ducts	C23-24	1.7	1.5	1.8	2.2	2.8	2.8	3.3	2.7	2.9	2.8	0.7
Pancreas	C25	7.7	7.4	7.3	7.2	6.7	6.1	7.8	8.3	7.2	8.8	5.1
Other digestive organs	C26	0.4	0.6	0.7	0.8	0.4	0.6	0.4	0.3	0.7	1.0	1.1
Respiratory organs	C30-39	13.9	16.1	11.4	10.1	11.5	11.3	8.8	10.1	8.5	9.8	9.0
Nose, sinuses	C30-31	0.3	0.2	0.3	0.2	-	0.6	0.1	0.2	0.3	0.7	-
Larynx, epiglottis	C32	0.3	0.3	0.2	0.4	0.2	0.3	0.2	0.0	0.3	0.4	-
Lung, trachea	C33-34	13.2	15.3	10.7	9.4	11.2	10.2	8.4	9.7	7.6	8.4	9.0
Mediastinum, pleura	C38	0.2	0.2	0.1	0.1	0.2	0.2	-	0.1	0.2	0.1	-
Bone	C40-41	0.4	0.9	0.6	0.6	0.6	0.4	0.9	-	0.2	0.5	0.5
Melanoma of the skin	C43	11.1	9.9	11.0	7.4	7.3	9.2	11.1	7.5	8.9	11.4	6.9
Skin, non-melanoma	C44	6.4	5.3	5.7	5.1	5.3	6.7	5.0	6.5	8.5	2.1	9.2
Mesothelioma	C45	0.4	0.3	0.6	0.1	0.2	0.1	0.3	0.5	0.5	-	-
Kaposi sarcoma	C46	0.0	0.1	0.1	0.1	0.1	0.1	-	-	-	0.1	0.1
Autonomic nervous system	C47	0.5	0.4	0.2	0.4	0.2	0.6	-	-	-	0.5	-
Soft tissues	C48-49	2.2	2.1	1.6	2.0	2.0	2.2	1.2	1.2	1.9	0.9	1.6
Breast	C50	95.3	105.5	91.8	80.3	90.7	89.5	81.9	87.7	78.7	85.8	73.6
Female genital organs	C51-58	30.9	30.3	30.6	31.1	27.0	34.1	29.5	30.7	31.0	35.6	21.9
Cervix uteri	C53	4.2	4.1	4.0	4.5	2.7	4.3	3.6	3.8	4.4	3.8	3.9
Corpus uteri	C54	13.8	14.0	15.0	17.9	13.8	16.8	13.5	14.0	13.4	18.9	8.0
Uterus, other	C55	0.1	0.1	0.0	-	0.1	0.0	-	-	0.1	-	-
Ovary	C56	9.3	9.4	8.9	6.6	8.7	10.8	10.1	10.5	10.9	10.0	7.5
Other female genital	C51-52,C57	3.4	2.8	2.6	2.2	1.6	2.3	2.1	2.4	1.9	2.8	2.6
Placenta	C58	0.0	-	-	-	-	-	0.2	-	0.5	-	-
Urinary organs	C64-68	8.6	8.9	7.6	9.0	9.2	7.6	10.4	8.4	9.9	7.2	9.2
Kidney	C64-65	5.8	5.8	5.3	6.2	6.2	5.1	7.2	6.2	6.0	5.6	6.1
Bladder, ureter, urethra	C66-68	2.7	3.1	2.3	2.9	3.0	2.5	3.3	2.2	3.8	1.6	3.1
Eye	C69	0.6	0.4	0.5	0.7	1.0	0.4	1.2	0.3	1.3	0.3	0.8
Brain, central nervous system	C70-72	15.8	14.7	15.2	12.7	16.4	11.7	13.0	14.0	13.5	11.3	7.9
Thyroid gland	C73	7.2	6.1	6.0	5.6	8.9	7.9	6.8	6.7	3.3	3.5	3.4
Other endocrine glands	C74-75	0.5	0.4	0.3	0.3	-	0.6	0.3	0.6	0.2	-	3.1
Ill-defined or unknown	C76,C80	6.3	4.6	5.5	5.0	5.8	5.3	5.1	5.2	8.0	4.4	3.3
Lymphoid and haematopoietic tissue	C81-96	18.7	19.2	23.4	18.2	22.7	18.8	17.7	25.4	20.7	20.3	12.0
Hodgkin lymphoma	C81	1.5	1.9	2.2	2.1	4.8	2.4	1.8	3.6	1.7	4.3	2.3
Non-Hodgkin lymphoma	C82-85,C96	9.7	9.3	10.7	7.3	8.4	8.4	8.9	11.6	9.4	7.0	4.7
Nodal non-Hodgkin lymphoma		5.5	5.8	6.3	4.1	5.2	5.0	5.8	6.4	6.1	4.4	2.9
Multiple myeloma	C90	2.2	2.4	3.1	2.6	2.2	2.3	1.6	2.8	1.4	0.9	1.9
Leukaemia	C91-95	5.2	5.5	7.3	6.1	7.3	5.6	5.2	7.3	8.1	8.2	3.1
Acute leukaemia		2.9	3.3	4.2	4.0	5.1	3.7	3.6	3.7	6.5	6.6	1.9
Not included above												
Carcinoma in situ of the breast	D05	8.1	11.1	8.0	5.6	5.9	7.2	5.4	2.9	9.1	5.1	10.0
Cervix uteri, non-invasive neoplasms		38.7	20.9	36.5	25.0	35.0	39.3	31.9	6.8	18.1	19.5	38.7
Borderline tumour of the ovary	D39	2.3	2.6	3.3	2.7	2.1	3.9	2.7	2.7	2.9	3.9	3.8
Basal cell carcinoma of the skin		68.3	75.3	44.2	36.9	52.3	58.4	62.6	57.2	50.0	59.0	67.7
PUNLMP and ca in situ of the bladder		0.3	0.3	0.2	0.1	0.2	0.5	0.1	-	-	-	-
Polycythaemia vera		0.6	0.7	0.2	0.2	0.3	0.2	0.1	0.5	-	1.4	0.4

¹ Adjusted for age to the "world standard population".

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	217.5	221.9	221.2	246.3	238.7	236.2	221.2	210.3	223.8	205.3	259.4	244.1
	2.5	4.3	4.4	2.5	3.3	3.8	3.7	2.0	2.9	3.6	1.0	3.7
	0.4	0.7	0.5	0.4	0.3	0.7	0.9	0.4	-	0.2	-	0.4
	0.6	0.9	1.6	0.8	0.9	1.0	1.0	1.1	0.9	0.8	-	1.1
	0.4	1.0	0.7	0.5	0.6	0.9	0.7	0.5	1.1	1.3	-	0.9
	0.4	0.9	0.6	0.6	0.6	0.8	0.8	-	0.5	1.0	1.0	0.7
	0.6	0.8	1.0	0.2	1.0	0.4	0.3	-	0.4	0.3	-	0.6
	34.0	36.1	39.1	34.8	43.2	39.1	35.9	32.1	32.4	34.4	40.8	38.9
	0.7	1.2	0.8	0.4	1.8	1.2	1.4	1.1	0.8	0.9	1.9	1.1
	4.1	5.2	5.9	5.3	5.3	5.5	4.2	4.8	5.9	6.9	4.6	5.0
	0.5	0.8	1.0	0.8	0.3	0.7	0.9	0.8	0.5	0.2	0.2	0.8
	9.6	11.7	14.9	12.0	14.2	15.8	10.7	11.1	11.2	8.9	14.4	12.7
	8.3	7.1	6.3	6.5	8.1	7.4	5.9	5.1	1.9	6.1	10.4	7.4
	2.2	1.7	2.1	1.3	2.0	1.6	1.9	1.1	2.6	1.3	2.7	2.1
	2.6	2.1	2.2	1.8	2.0	2.5	2.0	0.7	1.7	0.8	1.3	2.1
	5.5	5.7	5.6	6.2	9.0	3.9	8.2	6.9	7.2	8.5	5.2	7.2
	0.5	0.7	0.4	0.7	0.6	0.3	0.6	0.4	0.7	0.7	0.2	0.6
	7.2	7.6	8.2	7.9	11.2	12.2	11.3	12.5	13.2	13.2	14.1	11.3
	0.8	0.5	0.3	0.0	0.4	0.1	0.1	0.2	-	-	-	0.3
	0.1	0.2	0.7	-	0.1	0.5	0.1	0.3	-	-	1.2	0.2
	6.3	6.8	7.1	7.6	10.5	11.4	10.9	12.0	12.8	13.0	12.9	10.6
	-	-	0.1	0.2	0.1	0.2	-	-	0.1	0.2	-	0.1
	0.0	0.9	0.2	0.5	0.0	0.7	0.7	-	1.7	0.7	-	0.5
	8.3	7.2	5.6	6.1	6.3	4.2	6.1	6.3	8.1	4.4	16.8	8.8
	4.3	4.8	6.2	6.5	5.0	6.3	4.4	5.1	4.4	2.0	5.1	5.7
	0.2	0.4	0.4	-	0.1	0.6	0.0	0.3	0.5	0.7	-	0.3
	-	-	-	0.1	0.1	0.1	0.1	-	0.3	0.1	-	0.1
	-	0.6	0.7	0.4	0.6	-	0.2	-	-	0.9	-	0.4
	1.4	2.4	1.5	2.5	2.6	2.2	1.9	3.2	2.7	1.3	2.6	2.0
	73.4	75.5	80.0	95.7	83.1	78.2	71.1	63.3	74.3	67.1	83.9	86.8
	32.2	28.4	27.7	31.9	33.7	37.7	28.3	28.0	32.6	28.7	42.0	30.8
	2.9	2.5	4.0	2.6	4.7	4.9	3.0	3.9	3.5	5.0	6.4	3.9
	16.0	13.4	12.1	17.5	16.5	17.3	13.9	14.3	17.3	12.0	19.1	14.7
	0.0	0.4	-	-	0.3	0.2	0.0	-	0.1	-	-	0.1
	10.1	9.8	8.4	10.0	11.1	12.7	9.6	6.8	7.7	9.3	13.7	9.5
	3.2	2.2	3.1	1.7	1.1	2.6	1.6	3.0	3.9	2.4	2.8	2.5
	-	0.1	0.1	0.2	-	-	0.1	-	-	-	-	0.1
	9.5	9.0	9.3	8.1	7.1	6.5	11.5	8.3	8.3	8.5	13.9	8.8
	6.9	5.8	6.5	5.7	4.3	5.9	8.0	5.7	5.1	6.6	5.7	6.0
	2.6	3.2	2.8	2.4	2.8	0.6	3.5	2.6	3.1	1.9	8.2	2.8
	0.6	0.3	0.4	0.7	0.1	0.5	1.0	1.3	-	0.7	0.2	0.6
	12.9	10.7	12.5	14.3	13.6	9.9	10.1	11.4	9.2	12.2	11.3	13.4
	8.3	9.2	4.1	6.8	4.6	9.7	13.6	12.9	7.2	8.6	2.4	7.2
	0.3	0.2	0.1	0.1	0.3	0.4	0.3	-	0.5	-	-	0.4
	3.3	4.1	4.0	5.0	6.5	5.6	3.8	5.3	4.6	4.0	8.3	5.1
	19.0	20.2	16.9	22.3	17.1	18.5	17.4	18.3	20.9	14.3	17.0	19.4
	1.7	2.8	1.7	3.1	2.1	4.2	2.4	2.6	1.6	0.7	-	2.2
	8.9	10.1	8.5	10.5	7.5	7.7	7.4	8.3	8.1	8.4	7.0	9.1
	6.1	5.8	5.1	5.5	5.6	4.0	4.1	5.0	5.0	4.8	2.2	5.3
	2.2	2.0	1.6	3.1	1.7	1.2	2.0	2.0	2.7	1.3	5.0	2.2
	5.9	5.1	5.1	5.5	5.8	5.1	5.7	5.3	8.5	3.5	5.1	5.8
	4.3	3.5	4.0	3.4	4.4	3.1	2.7	3.8	5.9	2.1	2.6	3.6
	10.6	4.9	6.8	2.3	4.4	6.1	7.5	5.1	5.0	4.3	4.6	7.1
	41.3	21.3	43.1	39.3	33.1	7.0	28.6	33.9	31.6	24.4	33.2	31.3
	4.2	6.8	4.7	4.4	3.3	0.7	3.5	3.7	5.2	5.1	3.0	3.4
	57.6	70.6	56.2	23.3	48.4	49.8	43.4	39.4	42.4	38.5	27.2	56.0
	0.3	0.1	0.1	0.2	0.2	0.2	0.3	0.3	0.3	0.6	1.0	0.2
	0.0	0.3	0.2	0.2	-	-	0.2	0.5	0.2	0.1	-	0.3



Incidence

► **TABLE 19. Distribution of new cancer cases in 2007, by primary site and confirmation of the diagnosis, given as percentages, MALES.**

Primary site	ICD-10 code	No. of cases	Microscopical		Surgery X-ray, etc.	Clinical or death certificate diagnosis
			Histology	Cytology		
All sites	C00-96	13121	90	4	3	3
Mouth, pharynx	C00-14	285	99	-	-	1
Lip	C00	50	100	-	-	-
Tongue	C01-02	65	98	-	-	2
Mouth, other	C03-06	57	100	-	-	-
Salivary glands	C07-08	32	100	-	-	-
Pharynx	C09-14	81	99	-	-	1
Digestive organs	C15-26	2740	86	4	5	5
Oesophagus	C15	161	96	1	2	2
Stomach	C16	371	97	-	1	2
Small intestine	C17	54	98	-	-	2
Colon	C18	743	97	-	1	2
Rectum, rectosigmoid, anus	C19-21	555	98	0	0	2
Liver	C22	255	76	7	12	6
Gallbladder, bile ducts	C23-24	107	61	12	15	12
Pancreas	C25	455	56	13	17	13
Other digestive organs	C26	39	54	5	10	31
Respiratory organs	C30-39	1680	69	16	8	6
Nose, sinuses	C30-31	33	97	-	3	-
Larynx, epiglottis	C32	117	98	-	-	2
Lung, trachea	C33-34	1511	66	18	9	7
Mediastinum, pleura	C38	13	62	23	-	15
Bone	C40-41	20	95	-	5	-
Melanoma of the skin	C43	457	100	-	0	-
Skin, non-melanoma	C44	557	100	-	-	0
Mesothelioma	C45	79	99	1	-	-
Kaposi sarcoma	C46	8	100	-	-	-
Autonomic nervous system	C47	3	100	-	-	-
Soft tissues	C48-49	93	98	-	2	-
Breast	C50	16	100	-	-	-
Male genital organs	C60-63	4351	99	-	0	1
Prostate	C61	4183	99	-	0	1
Testis	C62	129	99	-	-	1
Other male genital	C60,C63	39	100	-	-	-
Urinary organs	C64-68	987	93	2	3	3
Kidney	C64-65	399	88	1	6	4
Bladder, ureter, urethra	C66-68	588	95	3	0	2
Eye	C69	20	35	5	60	-
Brain, central nervous system	C70-72	372	89	-	7	4
Thyroid gland	C73	90	98	1	1	-
Other endocrine glands	C74-75	18	78	11	6	6
Ill-defined or unknown	C76,C80	285	66	12	12	10
Lymphoid and haematopoietic tissue	C81-96	1060	88	4	1	8
Hodgkin lymphoma	C81	68	99	-	1	-
Non-Hodgkin lymphoma	C82-85,C96	535	99	0	0	0
Nodal non-Hodgkin lymphoma		236	99	0	-	0
Multiple myeloma	C90	130	68	9	3	19
Leukaemia	C91-95	316	75	9	1	16
Acute leukaemia		132	72	10	1	17
Not included above						
Basal cell carcinoma of the skin		3139	100	-	-	0
PUNLMP and ca in situ of the bladder		132	100	-	-	-
Polycythaemia vera		16	63	13	-	25

Note for Tables 19 and 20

The following order of preference for confirmation of the diagnosis is used:

1. Histology (including autopsy, and bone marrow and blood smear examination in leukaemias)
2. Cytology
3. Surgery (including endoscopy), autopsy without histology, X-ray and some specified laboratory examinations

► **TABLE 20. Distribution of new cancer cases in 2007, by primary site and confirmation of the diagnosis, given as percentages, FEMALES.**

Primary site	ICD-10 code	No. of cases	Microscopical		Surgery X-ray, etc.	Clinical or death certificate diagnosis
			Histology	Cytology		
All sites	C00-96	12988	90	3	4	4
Mouth, pharynx	C00-14	194	99	-	1	1
Lip	C00	25	100	-	-	-
Tongue	C01-02	56	98	-	2	-
Mouth, other	C03-06	52	100	-	-	-
Salivary glands	C07-08	37	100	-	-	-
Pharynx	C09-14	24	96	-	-	4
Digestive organs	C15-26	2523	80	4	10	7
Oesophagus	C15	71	86	-	4	10
Stomach	C16	291	96	-	2	2
Small intestine	C17	49	94	-	-	6
Colon	C18	824	96	0	2	2
Rectum, rectosigmoid, anus	C19-21	438	97	-	1	2
Liver	C22	151	62	7	21	11
Gallbladder, bile ducts	C23-24	148	58	9	19	14
Pancreas	C25	495	45	13	28	14
Other digestive organs	C26	56	27	9	29	36
Respiratory organs	C30-39	721	63	19	10	8
Nose, sinuses	C30-31	18	89	6	-	6
Larynx, epiglottis	C32	14	100	-	-	-
Lung, trachea	C33-34	675	61	20	10	8
Mediastinum, pleura	C38	11	73	9	18	-
Bone	C40-41	12	100	-	-	-
Melanoma of the skin	C43	447	100	-	-	0
Skin, non-melanoma	C44	529	100	-	-	-
Mesothelioma	C45	21	100	-	-	-
Kaposi sarcoma	C46	8	100	-	-	-
Autonomic nervous system	C47	2	100	-	-	-
Soft tissues	C48-49	81	96	1	1	1
Breast	C50	4140	99	1	0	0
Female genital organs	C51-58	1543	95	1	2	2
Cervix uteri	C53	144	96	3	-	1
Corpus uteri	C54	787	99	0	0	1
Uterus, other	C55	10	50	-	20	30
Ovary	C56	420	91	2	4	3
Other female genital	C51-52,C57	182	89	3	3	4
Placenta	C58	-	-	-	-	-
Urinary organs	C64-68	532	87	2	7	4
Kidney	C64-65	339	86	1	9	3
Bladder, ureter, urethra	C66-68	193	89	4	3	4
Eye	C69	23	52	4	35	9
Brain, central nervous system	C70-72	561	88	-	7	5
Thyroid gland	C73	282	95	4	1	0
Other endocrine glands	C74-75	15	87	-	7	7
Ill-defined or unknown	C76,C80	395	61	11	18	10
Lymphoid and haematopoietic tissue	C81-96	959	86	3	1	10
Hodgkin lymphoma	C81	58	100	-	-	-
Non-Hodgkin lymphoma	C82-85,C96	515	97	0	1	2
Nodal non-Hodgkin lymphoma		219	99	-	-	1
Multiple myeloma	C90	130	67	5	4	24
Leukaemia	C91-95	246	70	7	1	22
Acute leukaemia		119	73	9	-	18
Not included above						
Carcinoma in situ of the breast	D05	333	100	-	0	-
Cervix uteri, non-invasive neoplasms		857	100	0	-	-
Borderline tumour of the ovary	D39	137	99	-	1	-
Basal cell carcinoma of the skin		3651	100	-	-	0
PUNLMP and ca in situ of the bladder		36	97	-	3	-
Polycythaemia vera		27	33	11	-	56

► **TABLE 21. Numbers of skin cancers diagnosed in 2007, by sex and subsite.**

Site	Melanoma		Non-melanoma		Basal cell carcinoma	
	Males	Females	Males	Females	Males	Females
Face	46	70	324	305	1479	1928
Scalp and neck	18	11	39	20	186	247
Trunk	195	98	46	32	499	432
Upper limbs	78	94	45	48	166	118
Lower limbs	42	115	22	46	64	109
Multiple sites	8	4	14	22	175	159
Unspecified	70	55	67	56	570	658
Total	457	447	557	529	3139	3651

► **TABLE 22. Numbers of leukaemias diagnosed in 2007, by cell type and sex.**

ICD-O-3 morphology		Males	Females
M9800/3	Leukaemia, NOS	6	3
M9801/3	Acute leukaemia, NOS	10	15
M9805/3	Acute biphenotypic leukaemia	2	4
M9820/3	Lymphoid leukaemia, NOS	-	4
M9823/3	B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma	127	93
M9826/3	Burkitt cell leukaemia	2	3
M9831/3	T-cell large granular lymphocytic leukaemia	1	1
M9832/3	Prolymphocytic leukaemia, NOS	2	1
M9834/3	Prolymphocytic leukaemia, T-cell type	3	2
M9835/3	Precursor cell lymphoblastic leukaemia, NOS	30	18
M9836/3	Precursor B-cell lymphoblastic leukaemia	5	3
M9837/3	Precursor T-cell lymphoblastic leukaemia	3	1
M9840/3	Acute myeloid leukaemia, M6 type	2	1
M9860/3	Myeloid leukaemia, NOS	6	5
M9861/3	Acute myeloid leukaemia, NOS	61	57
M9863/3	Chronic myeloid leukaemia, NOS	25	9
M9866/3	Acute promyelocytic leukaemia, t(15;17)(q22;q11-12)	3	4
M9867/3	Acute myelomonocytic leukaemia	2	1
M9871/3	Acute myeloid leukaemia with abnormal marrow eosinophils	-	1
M9872/3	Acute myeloid leukaemia, minimal differentiation	-	1
M9873/3	Acute myeloid leukaemia without maturation	1	1
M9874/3	Acute myeloid leukaemia with maturation	-	1
M9891/3	Acute monocytic leukaemia	7	3
M9910/3	Acute megakaryoblastic leukaemia	1	-
M9930/3	Myeloid sarcoma	3	1
M9931/3	Acute panmyelosis with myelofibrosis	3	5
M9940/3	Hairy cell leukaemia	8	3
M9945/3	Chronic myelomonocytic leukaemia, NOS	3	5
Total		316	246

► **TABLE 23.**
Numbers of non-Hodgkin lymphomas
diagnosed in 2007, by site of origin and sex.

Primary site	Males	Females
Tongue	4	1
Mouth, other	3	3
Salivary glands	6	7
Pharynx	18	16
Stomach	23	26
Small intestine	18	16
Colon	8	2
Liver	4	4
Pancreas	-	2
Spleen	11	14
Nose, sinuses	3	7
Lung, trachea	4	5
Mediastinum, pleura	7	5
Bone	3	4
Skin, non-melanoma	37	32
Soft tissues	24	33
Breast	-	2
Ovary	.	2
Other female genital	.	1
Prostate	1	.
Testis	9	.
Other male genital	1	.
Kidney	1	-
Bladder, ureter, urethra	-	1
Eye	6	6
Brain, central nervous system	18	22
Thyroid gland	-	3
Other endocrine glands	1	-
Ill-defined or unknown	89	82
Lymph nodes	236	219
Total	535	515

Cancer mortality rate will decrease by 10-20% by 2020

The future numbers of cancer deaths and the cancer mortality rate in the population have been predicted in the same way as the cancer incidence (see page 10). The changes in mortality are, however, much slower than those in incidence and do not reflect changes in diagnostic activity as strongly as the changes in incidence rates. Thus, no exceptions to the general prediction method have been applied to the mortality predictions of any of the cancer sites. Due attention has been paid that the incidence and mortality predictions will be mutually compatible even when being done independently of each other.

The age-adjusted mortality rate is predicted to decrease by 19% in males and by 11% in females (see table on page 45). The annual number of cancer deaths in 2020 is, however, predicted to increase by 18% in males and by 13% in females compared with the recorded annual numbers of cancer deaths in 2005-2007.

Age-adjusted cancer mortality is predicted to decrease for most cancer sites (see graphs on opposite page), among them the most common cancer sites in males and females, prostate and breast, respectively. Lung cancer shows a decreasing trend in males and an increasing trend in females. In males, the number of lung cancer deaths will remain approximately constant, but in females it will increase and approach the number of breast cancer deaths.

The largest decrease in age-adjusted mortality is predicted for cancers of the stomach and prostate in males and for non-Hodgkin lymphoma, stomach cancer and leukaemia in females. The predicted increase in pancreatic cancer mortality in both genders is worth noticing.

Mortality predictions partly reflect trends in incidence, which may be due to changes in the prevalence of the risk factors, e.g. smoking in lung cancer. Another impor-



tant component is the development of patient survival, which has been favourable in Finland (see page 70). Therefore, the predictions on mortality are not increased in the same way as the respective predictions for cancer incidence (pages 10-11).

The future development may be different from the predictions made due to possible future advances in cancer prevention, early detection or treatment. On the other hand, it is not guaranteed that these improvements will take place at the same rate in the future as in the past.

The observed decrease in cancer mortality in Finland has been the largest in Europe¹. It will be a challenge for the future to keep these favourable trends on-going.

¹Boyle, P., d'Onofrio, A., Maisonneuve, P., Severi, G., Robertson, C., Tubiana, M. and Veronesi, U.: *Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about?* Ann. Oncol. 2003;14:1312-1325.

► Age-adjusted mortality from selected cancers in Finland in 1953-2007, and prediction until 2020, by sex.



► Mean annual number of deaths and age-adjusted (world) mortality rate as observed in 2005-2007 and predicted for 2020, by sex and site

Site	Males			Age-adjusted rate/100,000		
	2005-7	2020	Change	2005-7	2020	Change
Lung	1446	1451	+0 %	29.3	20.1	-31 %
Prostate	794	879	+11 %	14.7	9.9	-33 %
Pancreas	424	675	+59 %	9.0	9.9	+10 %
Colon	303	425	+40 %	6.0	5.7	-5 %
Stomach	293	243	-17 %	6.1	3.4	-44 %
Rectum	235	289	+23 %	4.8	4.1	-15 %
Non-Hodgkin lymphoma	223	253	+14 %	4.6	3.4	-26 %
Kidney	189	196	+4 %	3.9	2.9	-26 %
Nervous system	177	192	+12 %	4.4	3.9	-11 %
Leukaemia	175	196	+12 %	3.9	3.0	-23 %
Bladder	172	234	+36 %	3.4	2.8	-18 %
Other sites	1248	1683	+35 %	26.3	25.3	-4 %
All sites	5679	6716	+18 %	116.4	94.4	-19 %

Site	Females			Age-adjusted rate/100,000		
	2005-7	2020	Change	2005-7	2020	Change
Breast	846	894	+6 %	14.8	11.3	-24 %
Lung	550	783	+42 %	8.5	10.4	+22 %
Pancreas	475	730	+54 %	6.5	7.6	+17 %
Colon	350	358	+2 %	4.7	3.8	-19 %
Ovary	298	365	+23 %	4.8	5.0	+4 %
Stomach	230	200	-13 %	3.6	2.2	-39 %
Non-Hodgkin lymphoma	228	188	-18 %	2.9	1.6	-45 %
Rectum	187	171	-9 %	2.5	1.8	-28 %
Nervous system	186	240	+29 %	3.6	3.6	+0 %
Corpus uteri	152	201	+32 %	2.1	2.0	-5 %
Leukaemia	147	118	-20 %	2.3	1.5	-35 %
Kidney	145	146	+1 %	1.9	1.6	-16 %
Other sites	1349	1432	+6 %	18.2	15.6	-14 %
All sites	5143	5826	+13 %	76.4	68.0	-11 %

► **TABLE 24. Mean annual numbers of cancer deaths in 1961-2007, by primary site and period, MALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	3949	4263	4511	4852	4943	5004	5155	5298	5454	5771	5728
Mouth, pharynx	C00-14	64	64	61	66	64	66	78	85	93	89	85
Lip	C00	22	12	10	9	5	7	7	5	1	4	1
Tongue	C01-02	9	10	10	12	14	14	16	19	24	16	24
Mouth, other	C03-06	10	10	11	9	12	12	15	19	26	20	19
Salivary glands	C07-08	6	8	6	7	8	8	11	12	12	11	8
Pharynx	C09-14	18	24	24	29	25	26	30	29	31	38	33
Digestive organs	C15-26	1464	1428	1381	1421	1441	1432	1442	1459	1569	1730	1799
Oesophagus	C15	123	107	93	89	90	90	106	106	126	112	158
Stomach	C16	860	753	653	580	521	450	384	334	302	314	263
Small intestine	C17	8	7	10	10	14	18	19	19	20	12	27
Colon	C18	98	111	123	157	176	213	229	255	278	304	333
Rectum, rectosigmoid, anus	C19-21	104	114	138	158	173	174	208	207	224	242	228
Liver	C22	31	45	68	81	99	103	113	124	141	221	213
Gallbladder, bile ducts	C23-24	20	27	39	49	64	64	68	71	70	59	94
Pancreas	C25	160	209	228	258	272	296	300	330	380	435	443
Other digestive organs	C26	61	55	29	39	32	25	15	14	27	31	40
Respiratory organs	C30-39	1410	1625	1742	1887	1833	1687	1587	1496	1461	1524	1516
Nose, sinuses	C30-31	17	14	10	10	8	11	10	11	11	7	14
Larynx, epiglottis	C32	70	69	65	58	54	52	35	39	37	37	36
Lung, trachea	C33-34	1305	1530	1655	1813	1761	1614	1532	1441	1402	1470	1452
Mediastinum, pleura	C38	17	11	10	6	8	10	9	3	10	10	12
Bone	C40-41	28	22	18	18	14	12	11	10	10	10	9
Melanoma of the skin	C43	23	38	45	48	58	63	80	76	93	125	110
Skin, non-melanoma	C44	13	12	10	10	9	12	10	12	17	21	20
Mesothelioma	C45	2	4	6	13	20	28	33	48	53	60	71
Kaposi sarcoma	C46	-	0	-	1	0	1	1	1	0	-	1
Autonomic nervous system	C47	5	6	4	6	5	4	5	6	5	7	2
Soft tissues	C48-49	18	22	24	26	29	33	29	37	38	44	42
Breast	C50	2	2	1	2	2	2	3	3	3	5	2
Male genital organs	C60-63	222	253	346	443	494	589	692	779	799	825	806
Prostate	C61	206	239	328	424	479	579	678	767	785	817	793
Testis	C62	10	10	13	14	10	8	6	7	5	4	6
Other male genital	C60,C63	6	4	4	6	4	3	7	5	8	4	7
Urinary organs	C64-68	153	195	224	266	290	309	328	349	359	363	364
Kidney	C64-65	66	84	102	130	148	168	174	196	192	194	201
Bladder, ureter, urethra	C66-68	87	110	121	136	141	141	154	153	168	169	163
Eye	C69	8	9	7	8	5	10	11	10	11	11	11
Brain, central nervous system	C70-72	91	103	106	115	125	137	155	166	176	205	157
Thyroid gland	C73	13	13	15	15	14	15	13	16	16	14	18
Other endocrine glands	C74-75	5	8	7	9	10	9	7	9	6	7	9
Ill-defined or unknown	C76,C80	138	142	155	120	124	159	216	242	228	202	182
Lymphoid and haematopoietic tissue	C81-96	290	318	357	377	408	434	458	496	518	529	524
Hodgkin lymphoma	C81	46	45	41	41	35	26	21	12	12	16	10
Non-Hodgkin lymphoma	C82-85,C96	73	87	101	119	129	161	183	225	231	214	219
Nodal non-Hodgkin lymphoma		50	63	82	92	96	115	137	165	158	134	103
Multiple myeloma	C90	32	41	49	57	67	88	93	91	108	119	113
Leukaemia	C91-95	140	146	166	159	178	158	157	164	162	177	176
Acute leukaemia		72	71	80	82	88	71	75	81	76	87	94
Not included above												
Basal cell carcinoma of the skin		4	4	4	5	4	2	3	1	1	1	1
PUNLMP and ca in situ of the bladder		1	-	-	-	1	1	2	1	1	-	3
Polycythaemia vera ¹				4	7	6	5	8	4	4	9	4

¹ Registered since 1969.

▶ TABLE 25. Mean annual numbers of cancer deaths in 1961-2007, by primary site and period, FEMALES.

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	3242	3382	3603	3956	4329	4693	4839	4946	5046	5107	5203
Mouth, pharynx	C00-14	42	36	39	49	52	45	54	60	57	56	69
Lip	C00	2	1	1	2	2	2	1	2	2	2	1
Tongue	C01-02	11	8	9	13	14	12	16	17	15	19	22
Mouth, other	C03-06	8	7	8	10	12	14	17	19	19	22	26
Salivary glands	C07-08	7	6	5	9	8	6	8	11	10	2	7
Pharynx	C09-14	14	13	15	15	17	11	12	11	11	11	13
Digestive organs	C15-26	1452	1401	1482	1587	1740	1747	1642	1586	1605	1637	1699
Oesophagus	C15	145	124	118	107	109	98	80	80	65	80	77
Stomach	C16	699	590	523	490	480	431	335	276	263	221	224
Small intestine	C17	11	8	11	11	14	20	22	18	18	16	14
Colon	C18	163	171	214	249	291	311	335	338	327	332	353
Rectum, rectosigmoid, anus	C19-21	128	138	158	175	179	198	200	196	202	188	183
Liver	C22	24	34	59	76	89	101	92	97	95	149	135
Gallbladder, bile ducts	C23-24	50	81	117	166	186	185	171	157	145	135	131
Pancreas	C25	149	172	236	261	329	359	380	387	441	464	525
Other digestive organs	C26	83	83	47	53	64	44	28	36	48	52	57
Respiratory organs	C30-39	132	149	177	245	291	342	391	449	529	575	595
Nose, sinuses	C30-31	10	15	8	11	10	8	9	8	11	9	11
Larynx, epiglottis	C32	4	4	3	3	4	6	4	6	4	8	3
Lung, trachea	C33-34	110	126	161	227	270	322	372	430	507	545	568
Mediastinum, pleura	C38	7	3	3	3	4	6	5	3	6	13	10
Bone	C40-41	21	16	13	12	11	10	9	9	6	11	6
Melanoma of the skin	C43	22	38	38	40	45	53	58	56	62	77	69
Skin, non-melanoma	C44	13	11	10	9	10	14	13	16	18	19	18
Mesothelioma	C45	2	3	4	8	10	15	15	19	16	17	26
Kaposi sarcoma	C46	-	0	-	0	0	0	1	1	1	1	-
Autonomic nervous system	C47	4	4	5	4	4	4	4	4	3	6	2
Soft tissues	C48-49	22	20	28	30	29	34	31	34	47	42	48
Breast	C50	394	462	522	564	648	740	769	808	821	857	852
Female genital organs	C51-58	526	531	512	540	503	565	576	573	581	585	586
Cervix uteri	C53	194	178	134	117	103	89	73	68	59	54	44
Corpus uteri	C54	87	92	106	111	109	133	137	141	153	136	168
Uterus, other	C55	26	21	15	16	10	7	11	7	6	5	4
Ovary	C56	173	194	207	250	236	280	299	289	283	313	284
Other female genital	C51-52,C57	45	45	50	46	45	56	55	68	81	77	86
Placenta	C58	2	1	1	0	1	-	1	0	-	-	-
Urinary organs	C64-68	90	108	132	157	176	202	231	210	237	201	218
Kidney	C64-65	58	72	84	99	122	142	149	146	160	129	145
Bladder, ureter, urethra	C66-68	32	36	48	57	54	60	82	64	77	72	73
Eye	C69	9	8	8	9	9	12	10	12	13	8	9
Brain, central nervous system	C70-72	82	84	98	126	134	158	159	178	174	185	194
Thyroid gland	C73	30	37	38	42	44	39	42	30	28	23	34
Other endocrine glands	C74-75	4	5	4	5	8	6	7	7	10	3	10
Ill-defined or unknown	C76,C80	146	174	174	175	193	238	317	350	307	293	276
Lymphoid and haematopoietic tissue	C81-96	249	297	319	354	422	468	511	541	532	511	492
Hodgkin lymphoma	C81	23	30	36	29	23	22	16	13	10	6	9
Non-Hodgkin lymphoma	C82-85,C96	58	69	82	101	133	185	216	243	237	233	219
Nodal non-Hodgkin lymphoma		39	52	64	72	96	134	155	176	167	143	105
Multiple myeloma	C90	34	49	59	77	97	111	117	124	127	132	107
Leukaemia	C91-95	135	150	142	147	168	150	159	158	155	135	153
Acute leukaemia		71	73	75	76	88	74	79	79	83	73	92
Not included above												
Carcinoma in situ of the breast	D05	0	0	-	-	0	0	0	2	3	4	4
Cervix uteri, non-invasive neoplasms		0	-	0	-	0	0	0	-	-	2	2
Borderline tumour of the ovary	D39	3	3	2	3	5	3	5	5	6	5	10
Basal cell carcinoma of the skin		4	5	5	3	3	3	4	3	2	1	2
PUNLMP and ca in situ of the bladder		-	-	-	-	-	0	1	0	0	-	-
Polycythaemia vera ¹				7	11	9	9	13	9	10	1	8

¹ Registered since 1969.

► **TABLE 26.** Age-adjusted¹ cancer mortality rates per 100,000 person-years in 1961-2007, by primary site and period. **MALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	194.1	193.1	187.0	183.9	170.6	157.8	147.2	135.5	122.5	117.4	113.7
Mouth, pharynx	C00-14	3.2	3.0	2.5	2.5	2.2	2.2	2.3	2.3	2.2	2.1	1.9
Lip	C00	1.2	0.6	0.5	0.4	0.2	0.2	0.2	0.1	0.0	0.1	0.0
Tongue	C01-02	0.4	0.5	0.4	0.5	0.5	0.5	0.5	0.5	0.6	0.4	0.6
Mouth, other	C03-06	0.5	0.5	0.4	0.4	0.4	0.4	0.4	0.5	0.6	0.5	0.4
Salivary glands	C07-08	0.3	0.4	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.2
Pharynx	C09-14	0.8	1.1	1.0	1.1	0.9	0.8	0.9	0.8	0.7	0.9	0.7
Digestive organs	C15-26	73.6	65.5	57.7	53.8	49.4	44.8	40.9	37.3	35.5	35.4	36.0
Oesophagus	C15	6.3	4.9	3.9	3.4	3.1	2.8	3.1	2.8	2.9	2.4	3.4
Stomach	C16	42.8	34.2	27.1	21.8	17.8	14.0	10.8	8.5	6.8	6.4	5.3
Small intestine	C17	0.4	0.3	0.4	0.4	0.5	0.6	0.6	0.5	0.5	0.2	0.6
Colon	C18	4.9	5.3	5.2	6.1	6.0	6.6	6.5	6.5	6.1	5.9	6.3
Rectum, rectosigmoid, anus	C19-21	5.4	5.5	5.8	6.1	5.9	5.4	5.9	5.3	5.1	5.0	4.4
Liver	C22	1.5	1.9	2.8	3.1	3.4	3.2	3.2	3.2	3.2	4.6	4.3
Gallbladder, bile ducts	C23-24	1.0	1.2	1.6	1.8	2.2	2.0	1.9	1.8	1.5	1.2	1.9
Pancreas	C25	7.8	9.3	9.4	9.7	9.3	9.4	8.6	8.5	8.7	9.2	9.0
Other digestive organs	C26	3.5	2.8	1.4	1.6	1.1	0.8	0.4	0.3	0.6	0.6	0.8
Respiratory organs	C30-39	67.1	71.2	69.9	69.9	62.7	53.1	45.5	38.0	32.2	30.5	29.9
Nose, sinuses	C30-31	0.8	0.7	0.4	0.4	0.3	0.3	0.3	0.3	0.2	0.1	0.3
Larynx, epiglottis	C32	3.4	3.1	2.6	2.2	1.9	1.6	1.0	1.0	0.8	0.8	0.7
Lung, trachea	C33-34	62.0	66.9	66.4	67.1	60.2	50.8	43.9	36.5	30.8	29.4	28.6
Mediastinum, pleura	C38	0.9	0.5	0.4	0.2	0.3	0.3	0.2	0.1	0.2	0.2	0.2
Bone	C40-41	1.3	0.9	0.7	0.8	0.5	0.5	0.4	0.4	0.3	0.3	0.2
Melanoma of the skin	C43	1.1	1.7	1.9	1.9	2.1	2.1	2.4	2.0	2.2	2.8	2.3
Skin, non-melanoma	C44	0.7	0.6	0.5	0.4	0.3	0.4	0.3	0.3	0.4	0.4	0.4
Mesothelioma	C45	0.1	0.2	0.3	0.5	0.7	0.9	1.0	1.3	1.3	1.3	1.5
Kaposi sarcoma	C46	-	0.0	-	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0
Autonomic nervous system	C47	0.3	0.3	0.2	0.3	0.3	0.2	0.2	0.3	0.2	0.3	0.1
Soft tissues	C48-49	0.9	1.0	1.0	1.0	1.0	1.1	0.9	1.0	1.0	1.0	1.0
Breast	C50	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
Male genital organs	C60-63	12.2	12.8	15.5	17.3	16.8	17.8	18.6	18.8	16.7	15.2	14.3
Prostate	C61	11.4	12.1	14.8	16.5	16.3	17.4	18.1	18.4	16.3	15.1	14.0
Testis	C62	0.5	0.4	0.5	0.5	0.4	0.3	0.2	0.2	0.2	0.1	0.2
Other male genital	C60,C63	0.4	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.1	0.2
Urinary organs	C64-68	7.6	9.0	9.5	10.2	10.0	9.8	9.4	8.8	8.0	7.3	7.0
Kidney	C64-65	3.1	3.8	4.2	5.0	5.2	5.5	5.1	5.1	4.4	4.0	4.0
Bladder, ureter, urethra	C66-68	4.5	5.2	5.3	5.2	4.8	4.3	4.2	3.7	3.6	3.3	3.0
Eye	C69	0.4	0.4	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.2	0.2
Brain, central nervous system	C70-72	4.1	4.5	4.5	4.7	4.5	4.7	5.0	4.7	4.6	5.0	3.9
Thyroid gland	C73	0.7	0.6	0.6	0.6	0.5	0.5	0.4	0.4	0.4	0.3	0.3
Other endocrine glands	C74-75	0.2	0.3	0.3	0.3	0.4	0.3	0.2	0.2	0.2	0.1	0.3
Ill-defined or unknown	C76,C80	6.7	6.5	6.4	4.6	4.3	5.0	6.1	6.1	5.1	4.0	3.6
Lymphoid and haematopoietic tissue	C81-96	13.7	14.5	15.1	14.6	14.6	14.1	13.4	13.2	11.9	11.1	10.6
Hodgkin lymphoma	C81	2.1	1.9	1.7	1.5	1.3	0.8	0.6	0.4	0.3	0.4	0.3
Non-Hodgkin lymphoma	C82-85,C96	3.5	3.9	4.2	4.6	4.5	5.2	5.3	5.9	5.2	4.3	4.3
Nodal non-Hodgkin lymphoma		2.4	2.8	3.4	3.6	3.3	3.7	4.0	4.4	3.6	2.7	2.0
Multiple myeloma	C90	1.5	1.8	2.0	2.2	2.3	2.8	2.6	2.3	2.3	2.4	2.1
Leukaemia	C91-95	6.7	6.8	7.2	6.3	6.6	5.3	4.7	4.5	4.0	3.9	3.8
Acute leukaemia		3.4	3.3	3.6	3.4	3.4	2.5	2.4	2.4	2.1	2.2	2.1
Not included above												
Basal cell carcinoma of the skin		0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0
PUNLMP and ca in situ of the bladder		0.0	-	-	-	0.0	0.0	0.0	0.0	0.0	-	0.1
Polycythaemia vera ²				0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.1

¹ Adjusted for age to the "world standard population".

² Registered since 1969.

▶ **TABLE 27. Age-adjusted¹ cancer mortality rates per 100,000 person-years in 1961-2007, by primary site and period. FEMALES.**

Primary site	ICD-10 code	1961-1965	1966-1970	1971-1975	1976-1980	1981-1985	1986-1990	1991-1995	1996-2000	2001-2005	2006	2007
All sites	C00-96	110.1	104.8	100.3	96.9	93.1	92.1	88.3	83.8	79.1	75.7	75.5
Mouth, pharynx	C00-14	1.4	1.1	1.1	1.2	1.1	0.8	0.9	0.9	0.9	0.8	1.1
Lip	C00	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tongue	C01-02	0.4	0.2	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.3	0.4
Mouth, other	C03-06	0.3	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.2	0.3
Salivary glands	C07-08	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.2	0.2	0.0	0.1
Pharynx	C09-14	0.5	0.4	0.4	0.4	0.4	0.2	0.2	0.2	0.2	0.2	0.3
Digestive organs	C15-26	47.5	41.4	38.6	35.6	34.0	30.4	26.7	23.9	22.8	22.2	22.5
Oesophagus	C15	4.7	3.6	2.9	2.3	2.0	1.6	1.2	1.1	0.8	1.0	1.1
Stomach	C16	22.8	17.4	13.5	11.2	9.5	7.6	5.5	4.3	3.8	3.4	3.3
Small intestine	C17	0.4	0.2	0.3	0.3	0.3	0.4	0.4	0.3	0.3	0.2	0.2
Colon	C18	5.4	5.2	5.7	5.6	5.7	5.3	5.3	5.0	4.5	4.4	4.6
Rectum, rectosigmoid, anus	C19-21	4.1	4.0	4.2	3.9	3.5	3.4	3.3	3.0	2.8	2.5	2.4
Liver	C22	0.8	1.1	1.6	1.8	1.8	1.9	1.6	1.5	1.4	2.1	1.8
Gallbladder, bile ducts	C23-24	1.6	2.4	3.0	3.6	3.6	3.2	2.9	2.3	2.1	1.7	1.7
Pancreas	C25	4.9	5.0	6.1	5.9	6.4	6.4	6.2	6.0	6.5	6.3	6.9
Other digestive organs	C26	2.7	2.5	1.2	1.1	1.1	0.6	0.4	0.4	0.5	0.6	0.6
Respiratory organs	C30-39	4.4	4.5	4.8	6.1	6.4	7.0	7.4	7.8	8.5	8.7	9.4
Nose, sinuses	C30-31	0.3	0.4	0.2	0.3	0.2	0.2	0.1	0.1	0.2	0.2	0.2
Larynx, epiglottis	C32	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
Lung, trachea	C33-34	3.6	3.9	4.4	5.6	6.0	6.6	7.1	7.4	8.2	8.2	9.0
Mediastinum, pleura	C38	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1
Bone	C40-41	0.8	0.6	0.4	0.4	0.3	0.3	0.2	0.2	0.1	0.2	0.2
Melanoma of the skin	C43	0.8	1.2	1.2	1.1	1.1	1.2	1.2	1.1	1.0	1.2	1.1
Skin, non-melanoma	C44	0.5	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2
Mesothelioma	C45	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.4	0.2	0.2	0.3
Kaposi sarcoma	C46	-	0.0	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-
Autonomic nervous system	C47	0.2	0.2	0.3	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.1
Soft tissues	C48-49	0.8	0.7	0.9	0.9	0.7	0.8	0.7	0.7	0.9	0.7	0.8
Breast	C50	13.8	14.9	15.5	15.3	15.7	17.1	16.6	16.3	15.0	15.0	14.4
Female genital organs	C51-58	18.2	16.8	14.5	13.7	11.4	11.5	11.1	10.3	9.5	8.9	8.7
Cervix uteri	C53	6.8	5.8	3.9	3.0	2.3	1.7	1.3	1.3	1.0	1.0	0.7
Corpus uteri	C54	2.9	2.7	2.8	2.6	2.3	2.4	2.4	2.3	2.3	1.9	2.2
Uterus, other	C55	0.9	0.6	0.4	0.4	0.2	0.1	0.2	0.1	0.1	0.0	0.0
Ovary	C56	6.0	6.2	6.0	6.6	5.7	6.2	6.2	5.5	5.0	4.8	4.6
Other female genital	C51-52,C57	1.5	1.4	1.3	1.1	0.9	1.0	0.9	1.1	1.1	1.1	1.2
Placenta	C58	0.1	0.0	0.0	0.0	0.0	-	0.0	0.0	-	-	-
Urinary organs	C64-68	3.0	3.3	3.7	3.7	3.6	3.7	3.7	3.2	3.2	2.6	2.5
Kidney	C64-65	2.0	2.2	2.4	2.4	2.7	2.8	2.6	2.4	2.3	1.8	1.8
Bladder, ureter, urethra	C66-68	1.0	1.1	1.2	1.2	0.9	0.9	1.1	0.8	0.9	0.8	0.7
Eye	C69	0.3	0.2	0.2	0.3	0.2	0.3	0.2	0.2	0.2	0.2	0.1
Brain, central nervous system	C70-72	3.2	3.1	3.4	4.0	3.7	4.3	3.8	3.9	3.6	3.5	3.6
Thyroid gland	C73	1.0	1.1	1.0	0.9	0.8	0.7	0.7	0.4	0.4	0.2	0.4
Other endocrine glands	C74-75	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.3
Ill-defined or unknown	C76,C80	4.9	5.1	4.6	4.0	3.7	4.1	4.9	4.9	4.0	3.7	3.3
Lymphoid and haematopoietic tissue	C81-96	9.2	10.0	9.6	9.0	9.4	9.2	9.3	9.0	8.0	7.0	6.5
Hodgkin lymphoma	C81	0.9	1.0	1.1	0.8	0.6	0.5	0.3	0.3	0.2	0.1	0.2
Non-Hodgkin lymphoma	C82-85,C96	2.1	2.2	2.3	2.4	2.8	3.5	3.8	3.9	3.4	2.8	2.8
Nodal non-Hodgkin lymphoma		1.4	1.7	1.9	1.7	2.1	2.5	2.8	3.0	2.5	1.8	1.4
Multiple myeloma	C90	1.1	1.4	1.5	1.8	1.8	1.9	1.9	1.8	1.8	1.8	1.3
Leukaemia	C91-95	5.1	5.3	4.6	4.1	4.2	3.3	3.3	2.9	2.6	2.3	2.2
Acute leukaemia		2.9	2.9	2.7	2.3	2.5	1.9	1.9	1.7	1.6	1.7	1.6
Not included above												
Carcinoma in situ of the breast	D05	0.0	0.0	-	-	0.0	0.0	0.0	0.0	0.1	0.0	0.1
Cervix uteri, non-invasive neoplasms		0.0	-	0.0	-	0.0	0.0	0.0	-	-	0.0	0.0
Borderline tumour of the ovary	D39	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2
Basal cell carcinoma of the skin		0.2	0.2	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0
PUNLMP and ca in situ of the bladder		-	-	-	-	-	0.0	0.0	0.0	0.0	-	-
Polycythaemia vera ²				0.2	0.2	0.2	0.1	0.2	0.1	0.1	0.0	0.1

¹ Adjusted for age to the "world standard population".

² Registered since 1969.

▶ **TABLE 28. Numbers of cancer deaths in 2007, by primary site and age. MALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	7	2	6	9	10	7	16	
Mouth, pharynx	C00-14	-	-	-	1	-	-	-	
Lip	C00	-	-	-	-	-	-	-	
Tongue	C01-02	-	-	-	1	-	-	-	
Mouth, other	C03-06	-	-	-	-	-	-	-	
Salivary glands	C07-08	-	-	-	-	-	-	-	
Pharynx	C09-14	-	-	-	-	-	-	-	
Digestive organs	C15-26	-	-	2	-	-	1	2	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	-	-	
Small intestine	C17	-	-	1	-	-	1	-	
Colon	C18	-	-	-	-	-	-	1	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	-	-	-	
Liver	C22	-	-	1	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	-	
Pancreas	C25	-	-	-	-	-	-	1	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	1	-	-	-	-	2	2	
Nose, sinuses	C30-31	1	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	-	-	
Lung, trachea	C33-34	-	-	-	-	-	1	2	
Mediastinum, pleura	C38	-	-	-	-	-	1	-	
Bone	C40-41	-	-	-	1	-	-	-	
Melanoma of the skin	C43	-	-	1	-	-	-	1	
Skin, non-melanoma	C44	-	-	-	-	-	-	-	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	-	-	-	-	-	-	-	
Soft tissues	C48-49	1	-	1	1	1	2	1	
Breast	C50	-	-	-	-	-	-	-	
Male genital organs	C60-63	-	-	-	-	1	-	-	
Prostate	C61	-	-	-	-	-	-	-	
Testis	C62	-	-	-	-	1	-	-	
Other male genital	C60,C63	-	-	-	-	-	-	-	
Urinary organs	C64-68	-	-	-	-	-	-	-	
Kidney	C64-65	-	-	-	-	-	-	-	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	-	-	
Eye	C69	-	-	-	-	-	-	-	
Brain, central nervous system	C70-72	1	2	1	3	4	-	5	
Thyroid gland	C73	-	-	-	-	-	-	-	
Other endocrine glands	C74-75	1	-	-	-	-	-	-	
Ill-defined or unknown	C76,C80	-	-	-	-	-	-	1	
Lymphoid and haematopoietic tissue	C81-96	3	-	1	3	4	2	4	
Hodgkin lymphoma	C81	-	-	-	-	-	1	2	
Non-Hodgkin lymphoma	C82-85,C96	-	-	-	-	2	-	1	
Nodal non-Hodgkin lymphoma		-	-	-	-	1	-	1	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	3	-	1	3	2	1	1	
Acute leukaemia		2	-	1	3	2	-	1	
Not included above									
Basal cell carcinoma of the skin		-	-	-	-	-	-	-	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	

Age group												All ages
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
18	48	93	219	440	666	734	865	1080	888	620	5728	
1	1	8	6	10	18	10	9	8	9	4	85	
-	-	-	-	-	-	-	-	-	1	-	1	
-	1	4	1	4	1	4	4	2	2	-	24	
1	-	1	1	1	4	2	4	1	1	3	19	
-	-	2	1	-	-	-	1	3	-	1	8	
-	-	1	3	5	13	4	-	2	5	-	33	
3	17	35	86	156	266	230	263	320	249	169	1799	
-	4	4	15	15	36	18	26	22	11	7	158	
-	3	9	18	20	36	34	32	49	31	31	263	
-	-	1	3	1	6	-	2	5	4	3	27	
2	4	2	9	24	40	38	46	71	62	34	333	
-	2	2	5	26	29	25	37	50	29	23	228	
-	1	3	10	18	32	39	20	33	33	23	213	
-	-	1	1	7	15	11	20	17	12	10	94	
1	3	13	23	40	67	64	72	69	60	30	443	
-	-	-	2	5	5	1	8	4	7	8	40	
3	8	17	57	119	190	247	252	294	224	100	1516	
-	-	1	1	2	1	2	1	2	3	-	14	
-	-	-	5	1	6	6	4	7	4	3	36	
3	8	16	51	116	183	237	246	282	213	94	1452	
-	-	-	-	-	-	2	1	2	3	3	12	
1	-	-	-	1	2	-	2	1	1	-	9	
1	5	4	5	11	15	15	14	15	15	8	110	
-	-	1	-	-	2	2	3	2	5	5	20	
-	-	-	1	11	15	12	19	6	4	3	71	
-	-	-	-	-	-	-	-	1	-	-	1	
1	-	-	1	-	-	-	-	-	-	-	2	
1	-	1	3	6	2	3	4	7	7	1	42	
-	-	-	-	-	-	1	-	-	-	1	2	
1	1	1	4	18	28	66	129	189	183	185	806	
-	-	-	4	16	26	65	127	189	181	185	793	
1	-	1	-	-	1	-	-	-	2	-	6	
-	1	-	-	2	1	1	2	-	-	-	7	
1	3	7	16	36	35	33	52	66	59	56	364	
-	3	6	12	31	19	21	32	33	26	18	201	
1	-	1	4	5	16	12	20	33	33	38	163	
-	-	1	1	-	-	3	1	3	2	-	11	
1	6	8	9	23	25	23	11	17	13	5	157	
-	-	-	2	-	3	-	1	5	4	3	18	
-	1	1	2	1	1	-	-	1	1	-	9	
1	1	2	5	18	14	29	35	23	31	22	182	
3	5	7	21	30	50	60	70	122	81	58	524	
-	-	1	-	-	2	2	-	1	-	1	10	
2	4	2	12	16	25	24	26	47	40	18	219	
1	2	2	5	10	14	8	13	21	17	8	103	
-	-	-	4	8	11	13	15	30	16	16	113	
1	1	4	5	6	11	21	28	43	24	21	176	
1	1	3	4	2	7	8	17	30	9	3	94	
-	-	-	-	-	-	-	-	-	-	1	1	
-	-	-	-	-	-	-	-	1	-	2	3	
-	-	-	1	-	-	-	-	1	2	-	4	

► **TABLE 29. Numbers of cancer deaths in 2007, by primary site and age. FEMALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	2	4	6	6	7	7	19	
Mouth, pharynx	C00-14	-	-	-	-	-	-	-	
Lip	C00	-	-	-	-	-	-	-	
Tongue	C01-02	-	-	-	-	-	-	-	
Mouth, other	C03-06	-	-	-	-	-	-	-	
Salivary glands	C07-08	-	-	-	-	-	-	-	
Pharynx	C09-14	-	-	-	-	-	-	-	
Digestive organs	C15-26	-	-	-	-	1	-	4	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	-	1	
Small intestine	C17	-	-	-	-	-	-	-	
Colon	C18	-	-	-	-	-	-	1	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	1	-	-	
Liver	C22	-	-	-	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	1	
Pancreas	C25	-	-	-	-	-	-	1	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	1	-	-	-	-	-	-	
Nose, sinuses	C30-31	-	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	-	-	
Lung, trachea	C33-34	1	-	-	-	-	-	-	
Mediastinum, pleura	C38	-	-	-	-	-	-	-	
Bone	C40-41	-	-	-	-	1	1	-	
Melanoma of the skin	C43	-	-	-	-	-	-	-	
Skin, non-melanoma	C44	-	-	-	-	-	-	-	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	-	1	-	-	-	-	-	
Soft tissues	C48-49	-	-	1	-	1	-	-	
Breast	C50	-	-	-	-	1	1	5	
Female genital organs	C51-58	-	-	-	-	1	2	3	
Cervix uteri	C53	-	-	-	-	-	1	1	
Corpus uteri	C54	-	-	-	-	-	-	-	
Uterus, other	C55	-	-	-	-	-	-	-	
Ovary	C56	-	-	-	-	1	1	2	
Other female genital	C51-52,C57	-	-	-	-	-	-	-	
Placenta	C58	-	-	-	-	-	-	-	
Urinary organs	C64-68	1	-	-	-	-	-	-	
Kidney	C64-65	1	-	-	-	-	-	-	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	-	-	
Eye	C69	-	-	-	-	-	-	-	
Brain, central nervous system	C70-72	-	1	2	2	-	2	7	
Thyroid gland	C73	-	-	-	-	-	-	-	
Other endocrine glands	C74-75	-	-	1	-	-	-	-	
Ill-defined or unknown	C76,C80	-	1	-	-	-	-	-	
Lymphoid and haematopoietic tissue	C81-96	-	1	2	4	2	1	-	
Hodgkin lymphoma	C81	-	-	-	1	-	1	-	
Non-Hodgkin lymphoma	C82-85,C96	-	-	-	-	-	-	-	
Nodal non-Hodgkin lymphoma		-	-	-	-	-	-	-	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	-	1	2	3	2	-	-	
Acute leukaemia		-	1	2	3	2	-	-	
Not included above									
Carcinoma in situ of the breast	D05	-	-	-	-	-	-	-	
Cervix uteri, non-invasive neoplasms		-	-	-	-	-	-	-	
Borderline tumour of the ovary	D39	-	-	-	-	-	-	-	
Basal cell carcinoma of the skin		-	-	-	-	-	-	-	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	

Age group												All ages
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
24	77	111	220	376	468	536	583	829	908	1020	5203	
1	1	2	2	7	7	8	10	7	9	15	69	
-	-	-	-	-	-	-	-	-	-	1	1	
1	-	1	1	2	4	3	3	2	2	3	22	
-	-	-	1	-	-	1	4	5	6	9	26	
-	1	-	-	-	1	1	2	-	1	1	7	
-	-	1	-	5	2	3	1	-	-	1	13	
6	19	26	50	99	134	172	186	272	323	407	1699	
-	1	-	2	6	11	10	10	7	13	17	77	
2	8	5	5	28	24	16	22	35	34	44	224	
-	-	-	1	1	-	1	1	2	3	5	14	
1	5	7	11	17	28	34	32	44	81	92	353	
2	-	5	7	10	12	19	17	23	31	56	183	
-	2	2	8	4	10	9	18	29	28	25	135	
1	1	-	4	7	10	15	8	25	21	38	131	
-	2	7	11	22	38	64	73	102	102	103	525	
-	-	-	1	4	1	4	5	5	10	27	57	
1	3	13	36	59	79	76	75	98	82	72	595	
-	1	-	-	-	1	4	1	-	-	4	11	
-	-	-	1	-	-	-	1	-	-	1	3	
1	2	13	35	58	78	71	70	95	80	64	568	
-	-	-	-	1	-	-	3	3	-	3	10	
-	-	-	-	-	2	-	-	1	1	-	6	
1	7	2	4	3	8	8	2	9	10	15	69	
-	1	-	-	-	-	1	-	3	5	8	18	
-	-	2	1	-	1	2	3	5	9	3	26	
-	-	-	-	-	-	-	-	-	-	-	0	
-	-	-	-	-	-	-	-	1	-	-	2	
-	2	3	2	5	3	1	7	8	7	8	48	
9	26	40	62	95	93	93	83	121	115	108	852	
2	7	9	21	46	59	70	79	100	98	89	586	
1	2	-	2	2	5	2	3	9	6	10	44	
-	2	1	2	11	15	18	22	36	35	26	168	
-	-	-	-	-	-	-	-	-	3	1	4	
-	3	5	11	28	35	38	46	45	38	31	284	
1	-	3	6	5	4	12	8	10	16	21	86	
-	-	-	-	-	-	-	-	-	-	-	0	
-	-	-	5	9	7	20	25	38	46	67	218	
-	-	-	5	7	6	16	16	28	31	35	145	
-	-	-	-	2	1	4	9	10	15	32	73	
-	-	-	-	-	5	-	-	1	-	3	9	
4	2	2	11	20	26	16	26	23	31	19	194	
-	2	-	-	2	1	3	1	5	8	12	34	
-	-	3	-	3	-	2	-	-	1	-	10	
-	2	1	13	12	16	22	24	43	55	87	276	
-	5	8	13	16	27	42	62	94	108	107	492	
-	-	-	-	1	1	-	2	1	-	2	9	
-	1	4	4	9	12	23	36	40	47	43	219	
-	-	3	2	5	5	12	17	22	26	13	105	
-	1	1	2	2	7	12	11	24	23	24	107	
-	3	3	7	4	7	7	13	28	36	37	153	
-	2	3	6	2	7	5	7	16	18	18	92	
-	-	-	-	-	1	-	1	-	-	2	4	
-	-	-	-	-	-	-	-	-	-	2	2	
-	-	2	1	1	1	3	-	2	-	-	10	
-	-	-	-	-	-	-	-	1	-	1	2	
-	-	-	-	-	-	-	-	-	-	-	0	
-	-	-	-	-	-	1	-	2	2	3	8	

▶ **TABLE 30. Age-specific and age-adjusted mortality rates of cancer in 2007 per 100,000, by primary site, MALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	4.7	1.4	3.7	5.4	5.9	4.1	9.7	
Mouth, pharynx	C00-14	-	-	-	0.6	-	-	-	
Lip	C00	-	-	-	-	-	-	-	
Tongue	C01-02	-	-	-	0.6	-	-	-	
Mouth, other	C03-06	-	-	-	-	-	-	-	
Salivary glands	C07-08	-	-	-	-	-	-	-	
Pharynx	C09-14	-	-	-	-	-	-	-	
Digestive organs	C15-26	-	-	1.2	-	-	0.6	1.2	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	-	-	
Small intestine	C17	-	-	0.6	-	-	0.6	-	
Colon	C18	-	-	-	-	-	-	0.6	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	-	-	-	
Liver	C22	-	-	0.6	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	-	
Pancreas	C25	-	-	-	-	-	-	0.6	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	0.7	-	-	-	-	1.2	1.2	
Nose, sinuses	C30-31	0.7	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	-	-	
Lung, trachea	C33-34	-	-	-	-	-	0.6	1.2	
Mediastinum, pleura	C38	-	-	-	-	-	0.6	-	
Bone	C40-41	-	-	-	0.6	-	-	-	
Melanoma of the skin	C43	-	-	0.6	-	-	-	0.6	
Skin, non-melanoma	C44	-	-	-	-	-	-	-	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	-	-	-	-	-	-	-	
Soft tissues	C48-49	0.7	-	0.6	0.6	0.6	1.2	0.6	
Breast	C50	-	-	-	-	-	-	-	
Male genital organs	C60-63	-	-	-	-	0.6	-	-	
Prostate	C61	-	-	-	-	-	-	-	
Testis	C62	-	-	-	-	0.6	-	-	
Other male genital	C60,C63	-	-	-	-	-	-	-	
Urinary organs	C64-68	-	-	-	-	-	-	-	
Kidney	C64-65	-	-	-	-	-	-	-	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	-	-	
Eye	C69	-	-	-	-	-	-	-	
Brain, central nervous system	C70-72	0.7	1.4	0.6	1.8	2.4	-	3.0	
Thyroid gland	C73	-	-	-	-	-	-	-	
Other endocrine glands	C74-75	0.7	-	-	-	-	-	-	
Ill-defined or unknown	C76,C80	-	-	-	-	-	-	0.6	
Lymphoid and haematopoietic tissue	C81-96	2.0	-	0.6	1.8	2.4	1.2	2.4	
Hodgkin lymphoma	C81	-	-	-	-	-	0.6	1.2	
Non-Hodgkin lymphoma	C82-85,C96	-	-	-	-	1.2	-	0.6	
Nodal non-Hodgkin lymphoma		-	-	-	-	0.6	-	0.6	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	2.0	-	0.6	1.8	1.2	0.6	0.6	
Acute leukaemia		1.4	-	0.6	1.8	1.2	-	0.6	
Not included above									
Basal cell carcinoma of the skin		-	-	-	-	-	-	-	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	

¹ Adjusted for age to the "world standard population".

Age group												All ages ¹
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
10.7	25.2	49.2	112.4	217.0	410.2	609.7	936.0	1470.8	2047.6	2610.2	113.7	
0.6	0.5	4.2	3.1	4.9	11.1	8.3	9.7	10.9	20.8	16.8	1.9	
-	-	-	-	-	-	-	-	-	2.3	-	0.0	
-	0.5	2.1	0.5	2.0	0.6	3.3	4.3	2.7	4.6	-	0.6	
0.6	-	0.5	0.5	0.5	2.5	1.7	4.3	1.4	2.3	12.6	0.4	
-	-	1.1	0.5	-	-	-	1.1	4.1	-	4.2	0.2	
-	-	0.5	1.5	2.5	8.0	3.3	-	2.7	11.5	-	0.7	
1.8	8.9	18.5	44.1	76.9	163.8	191.1	284.6	435.8	574.1	711.5	36.0	
-	2.1	2.1	7.7	7.4	22.2	15.0	28.1	30.0	25.4	29.5	3.4	
-	1.6	4.8	9.2	9.9	22.2	28.2	34.6	66.7	71.5	130.5	5.3	
-	-	0.5	1.5	0.5	3.7	-	2.2	6.8	9.2	12.6	0.6	
1.2	2.1	1.1	4.6	11.8	24.6	31.6	49.8	96.7	143.0	143.1	6.3	
-	1.1	1.1	2.6	12.8	17.9	20.8	40.0	68.1	66.9	96.8	4.4	
-	0.5	1.6	5.1	8.9	19.7	32.4	21.6	44.9	76.1	96.8	4.3	
-	-	0.5	0.5	3.5	9.2	9.1	21.6	23.2	27.7	42.1	1.9	
0.6	1.6	6.9	11.8	19.7	41.3	53.2	77.9	94.0	138.3	126.3	9.0	
-	-	-	1.0	2.5	3.1	0.8	8.7	5.4	16.1	33.7	0.8	
1.8	4.2	9.0	29.2	58.7	117.0	205.2	272.7	400.4	516.5	421.0	29.9	
-	-	0.5	0.5	1.0	0.6	1.7	1.1	2.7	6.9	-	0.3	
-	-	-	2.6	0.5	3.7	5.0	4.3	9.5	9.2	12.6	0.7	
1.8	4.2	8.5	26.2	57.2	112.7	196.9	266.2	384.0	491.1	395.7	28.6	
-	-	-	-	-	-	1.7	1.1	2.7	6.9	12.6	0.2	
0.6	-	-	-	0.5	1.2	-	2.2	1.4	2.3	-	0.2	
0.6	2.6	2.1	2.6	5.4	9.2	12.5	15.1	20.4	34.6	33.7	2.3	
-	-	0.5	-	-	1.2	1.7	3.2	2.7	11.5	21.0	0.4	
-	-	-	0.5	5.4	9.2	10.0	20.6	8.2	9.2	12.6	1.5	
-	-	-	-	-	-	-	-	1.4	-	-	0.0	
0.6	-	-	0.5	-	-	-	-	-	-	-	0.1	
0.6	-	0.5	1.5	3.0	1.2	2.5	4.3	9.5	16.1	4.2	1.0	
-	-	-	-	-	-	0.8	-	-	-	4.2	0.0	
0.6	0.5	0.5	2.1	8.9	17.2	54.8	139.6	257.4	422.0	778.8	14.3	
-	-	-	2.1	7.9	16.0	54.0	137.4	257.4	417.4	778.8	14.0	
0.6	-	0.5	-	-	0.6	-	-	-	4.6	-	0.2	
-	0.5	-	-	1.0	0.6	0.8	2.2	-	-	-	0.2	
0.6	1.6	3.7	8.2	17.8	21.6	27.4	56.3	89.9	136.0	235.8	7.0	
-	1.6	3.2	6.2	15.3	11.7	17.4	34.6	44.9	60.0	75.8	4.0	
0.6	-	0.5	2.1	2.5	9.9	10.0	21.6	44.9	76.1	160.0	3.0	
-	-	0.5	0.5	-	-	2.5	1.1	4.1	4.6	-	0.2	
0.6	3.2	4.2	4.6	11.3	15.4	19.1	11.9	23.2	30.0	21.0	3.9	
-	-	-	1.0	-	1.8	-	1.1	6.8	9.2	12.6	0.3	
-	0.5	0.5	1.0	0.5	0.6	-	-	1.4	2.3	-	0.3	
0.6	0.5	1.1	2.6	8.9	8.6	24.1	37.9	31.3	71.5	92.6	3.6	
1.8	2.6	3.7	10.8	14.8	30.8	49.8	75.7	166.1	186.8	244.2	10.6	
-	-	0.5	-	-	1.2	1.7	-	1.4	-	4.2	0.3	
1.2	2.1	1.1	6.2	7.9	15.4	19.9	28.1	64.0	92.2	75.8	4.3	
0.6	1.1	1.1	2.6	4.9	8.6	6.6	14.1	28.6	39.2	33.7	2.0	
-	-	-	2.1	3.9	6.8	10.8	16.2	40.9	36.9	67.4	2.1	
0.6	0.5	2.1	2.6	3.0	6.8	17.4	30.3	58.6	55.3	88.4	3.8	
0.6	0.5	1.6	2.1	1.0	4.3	6.6	18.4	40.9	20.8	12.6	2.1	
-	-	-	-	-	-	-	-	-	-	4.2	0.0	
-	-	-	-	-	-	-	1.1	-	-	8.4	0.1	
-	-	-	0.5	-	-	-	-	1.4	4.6	-	0.1	

▶ **TABLE 31. Age-specific and age-adjusted mortality rates of cancer in 2007 per 100,000, by primary site, FEMALES.**

Primary site	ICD-10 code								
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	
All sites	C00-96	1.4	2.8	3.8	3.7	4.3	4.3	12.2	
Mouth, pharynx	C00-14	-	-	-	-	-	-	-	
Lip	C00	-	-	-	-	-	-	-	
Tongue	C01-02	-	-	-	-	-	-	-	
Mouth, other	C03-06	-	-	-	-	-	-	-	
Salivary glands	C07-08	-	-	-	-	-	-	-	
Pharynx	C09-14	-	-	-	-	-	-	-	
Digestive organs	C15-26	-	-	-	-	0.6	-	2.6	
Oesophagus	C15	-	-	-	-	-	-	-	
Stomach	C16	-	-	-	-	-	-	0.6	
Small intestine	C17	-	-	-	-	-	-	-	
Colon	C18	-	-	-	-	-	-	0.6	
Rectum, rectosigmoid, anus	C19-21	-	-	-	-	0.6	-	-	
Liver	C22	-	-	-	-	-	-	-	
Gallbladder, bile ducts	C23-24	-	-	-	-	-	-	0.6	
Pancreas	C25	-	-	-	-	-	-	0.6	
Other digestive organs	C26	-	-	-	-	-	-	-	
Respiratory organs	C30-39	0.7	-	-	-	-	-	-	
Nose, sinuses	C30-31	-	-	-	-	-	-	-	
Larynx, epiglottis	C32	-	-	-	-	-	-	-	
Lung, trachea	C33-34	0.7	-	-	-	-	-	-	
Mediastinum, pleura	C38	-	-	-	-	-	-	-	
Bone	C40-41	-	-	-	-	0.6	0.6	-	
Melanoma of the skin	C43	-	-	-	-	-	-	-	
Skin, non-melanoma	C44	-	-	-	-	-	-	-	
Mesothelioma	C45	-	-	-	-	-	-	-	
Kaposi sarcoma	C46	-	-	-	-	-	-	-	
Autonomic nervous system	C47	-	0.7	-	-	-	-	-	
Soft tissues	C48-49	-	-	0.6	-	0.6	-	-	
Breast	C50	-	-	-	-	0.6	0.6	3.2	
Female genital organs	C51-58	-	-	-	-	0.6	1.2	1.9	
Cervix uteri	C53	-	-	-	-	-	0.6	0.6	
Corpus uteri	C54	-	-	-	-	-	-	-	
Uterus, other	C55	-	-	-	-	-	-	-	
Ovary	C56	-	-	-	-	0.6	0.6	1.3	
Other female genital	C51-52,C57	-	-	-	-	-	-	-	
Placenta	C58	-	-	-	-	-	-	-	
Urinary organs	C64-68	0.7	-	-	-	-	-	-	
Kidney	C64-65	0.7	-	-	-	-	-	-	
Bladder, ureter, urethra	C66-68	-	-	-	-	-	-	-	
Eye	C69	-	-	-	-	-	-	-	
Brain, central nervous system	C70-72	-	0.7	1.3	1.2	-	1.2	4.5	
Thyroid gland	C73	-	-	-	-	-	-	-	
Other endocrine glands	C74-75	-	-	0.6	-	-	-	-	
Ill-defined or unknown	C76,C80	-	0.7	-	-	-	-	-	
Lymphoid and haematopoietic tissue	C81-96	-	0.7	1.3	2.5	1.2	0.6	-	
Hodgkin lymphoma	C81	-	-	-	0.6	-	0.6	-	
Non-Hodgkin lymphoma	C82-85,C96	-	-	-	-	-	-	-	
Nodal non-Hodgkin lymphoma		-	-	-	-	-	-	-	
Multiple myeloma	C90	-	-	-	-	-	-	-	
Leukaemia	C91-95	-	0.7	1.3	1.9	1.2	-	-	
Acute leukaemia		-	0.7	1.3	1.9	1.2	-	-	
Not included above									
Carcinoma in situ of the breast	D05	-	-	-	-	-	-	-	
Cervix uteri, non-invasive neoplasms		-	-	-	-	-	-	-	
Borderline tumour of the ovary	D39	-	-	-	-	-	-	-	
Basal cell carcinoma of the skin		-	-	-	-	-	-	-	
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	
Polycythaemia vera		-	-	-	-	-	-	-	


¹ Adjusted for age to the "world standard population".

Age group												All ages ¹
35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-		
14.8	41.7	59.7	112.9	184.2	276.8	394.8	505.8	755.6	1060.5	1411.5	75.5	
0.6	0.5	1.1	1.0	3.4	4.1	5.9	8.7	6.4	10.5	20.8	1.1	
-	-	-	-	-	-	-	-	-	-	1.4	0.0	
0.6	-	0.5	0.5	1.0	2.4	2.2	2.6	1.8	2.3	4.2	0.4	
-	-	-	0.5	-	-	0.7	3.5	4.6	7.0	12.5	0.3	
-	0.5	-	-	-	0.6	0.7	1.7	-	1.2	1.4	0.1	
-	-	0.5	-	2.4	1.2	2.2	0.9	-	-	1.4	0.3	
3.7	10.3	14.0	25.7	48.5	79.2	126.7	161.4	247.9	377.3	563.2	22.5	
-	0.5	-	1.0	2.9	6.5	7.4	8.7	6.4	15.2	23.5	1.1	
1.2	4.3	2.7	2.6	13.7	14.2	11.8	19.1	31.9	39.7	60.9	3.3	
-	-	-	0.5	0.5	-	0.7	0.9	1.8	3.5	6.9	0.2	
0.6	2.7	3.8	5.6	8.3	16.6	25.0	27.8	40.1	94.6	127.3	4.6	
1.2	-	2.7	3.6	4.9	7.1	14.0	14.7	21.0	36.2	77.5	2.4	
-	1.1	1.1	4.1	2.0	5.9	6.6	15.6	26.4	32.7	34.6	1.8	
0.6	0.5	-	2.1	3.4	5.9	11.0	6.9	22.8	24.5	52.6	1.7	
-	1.1	3.8	5.6	10.8	22.5	47.1	63.3	93.0	119.1	142.5	6.9	
-	-	-	0.5	2.0	0.6	2.9	4.3	4.6	11.7	37.4	0.6	
0.6	1.6	7.0	18.5	28.9	46.7	56.0	65.1	89.3	95.8	99.6	9.4	
-	0.5	-	-	-	0.6	2.9	0.9	-	-	5.5	0.2	
-	-	-	0.5	-	-	-	0.9	-	-	1.4	0.0	
0.6	1.1	7.0	18.0	28.4	46.1	52.3	60.7	86.6	93.4	88.6	9.0	
-	-	-	-	0.5	-	-	2.6	2.7	-	4.2	0.1	
-	-	-	-	-	1.2	-	-	0.9	1.2	-	0.2	
0.6	3.8	1.1	2.1	1.5	4.7	5.9	1.7	8.2	11.7	20.8	1.1	
-	0.5	-	-	-	-	0.7	-	2.7	5.8	11.1	0.2	
-	-	1.1	0.5	-	0.6	1.5	2.6	4.6	10.5	4.2	0.3	
-	-	-	-	-	-	-	-	-	-	-	0.0	
-	-	-	-	-	-	-	-	0.9	-	-	0.1	
-	1.1	1.6	1.0	2.4	1.8	0.7	6.1	7.3	8.2	11.1	0.8	
5.6	14.1	21.5	31.8	46.5	55.0	68.5	72.0	110.3	134.3	149.4	14.4	
1.2	3.8	4.8	10.8	22.5	34.9	51.6	68.5	91.2	114.5	123.2	8.7	
0.6	1.1	-	1.0	1.0	3.0	1.5	2.6	8.2	7.0	13.8	0.7	
-	1.1	0.5	1.0	5.4	8.9	13.3	19.1	32.8	40.9	36.0	2.2	
-	-	-	-	-	-	-	-	-	3.5	1.4	0.0	
-	1.6	2.7	5.6	13.7	20.7	28.0	39.9	41.0	44.4	42.9	4.6	
0.6	-	1.6	3.1	2.4	2.4	8.8	6.9	9.1	18.7	29.1	1.2	
-	-	-	-	-	-	-	-	-	-	-	0.0	
-	-	-	2.6	4.4	4.1	14.7	21.7	34.6	53.7	92.7	2.5	
-	-	-	2.6	3.4	3.5	11.8	13.9	25.5	36.2	48.4	1.8	
-	-	-	-	1.0	0.6	2.9	7.8	9.1	17.5	44.3	0.7	
-	-	-	-	-	3.0	-	-	0.9	-	4.2	0.1	
2.5	1.1	1.1	5.6	9.8	15.4	11.8	22.6	21.0	36.2	26.3	3.6	
-	1.1	-	-	1.0	0.6	2.2	0.9	4.6	9.3	16.6	0.4	
-	-	1.6	-	1.5	-	1.5	-	-	1.2	-	0.3	
-	1.1	0.5	6.7	5.9	9.5	16.2	20.8	39.2	64.2	120.4	3.3	
-	2.7	4.3	6.7	7.8	16.0	30.9	53.8	85.7	126.1	148.1	6.5	
-	-	-	-	0.5	0.6	-	1.7	0.9	-	2.8	0.2	
-	0.5	2.2	2.1	4.4	7.1	16.9	31.2	36.5	54.9	59.5	2.8	
-	-	1.6	1.0	2.4	3.0	8.8	14.7	20.1	30.4	18.0	1.4	
-	0.5	0.5	1.0	1.0	4.1	8.8	9.5	21.9	26.9	33.2	1.3	
-	1.6	1.6	3.6	2.0	4.1	5.2	11.3	25.5	42.0	51.2	2.2	
-	1.1	1.6	3.1	1.0	4.1	3.7	6.1	14.6	21.0	24.9	1.6	
-	-	-	-	-	0.6	-	0.9	-	-	2.8	0.1	
-	-	-	-	-	-	-	-	-	-	2.8	0.0	
-	-	1.1	0.5	0.5	0.6	2.2	-	1.8	-	-	0.2	
-	-	-	-	-	-	-	-	0.9	-	1.4	0.0	
-	-	-	-	-	-	-	-	-	-	-	0.0	
-	-	-	-	-	-	0.7	-	1.8	2.3	4.2	0.1	

► **TABLE 32. Mean annual numbers of cancer deaths in 2003-2007, by primary site and health care district. MALES.**

Primary site	ICD-10code											
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	715	536	535	303	197	484	231	232	158	131	75
Mouth, pharynx	C00-14	13	12	10	4	2	8	3	5	3	2	2
Lip	C00	-	-	1	-	-	-	-	0	0	-	-
Tongue	C01-02	3	2	3	1	-	2	1	1	1	1	0
Mouth, other	C03-06	3	4	3	1	0	2	1	2	-	1	0
Salivary glands	C07-08	2	1	0	1	0	1	-	0	1	-	0
Pharynx	C09-14	5	5	3	1	1	4	1	1	1	1	1
Digestive organs	C15-26	213	164	160	84	58	147	71	71	51	36	25
Oesophagus	C15	15	15	12	6	5	13	4	9	4	2	2
Stomach	C16	32	25	28	17	9	28	11	13	6	8	6
Small intestine	C17	3	3	1	1	1	1	1	1	1	-	1
Colon	C18	39	31	31	14	9	27	13	13	10	7	5
Rectum, rectosigmoid, anus	C19-21	30	19	25	13	9	19	10	9	9	7	3
Liver	C22	26	22	16	7	6	16	11	6	4	3	3
Gallbladder, bile ducts	C23-24	9	5	7	4	4	7	4	2	2	1	0
Pancreas	C25	55	41	37	20	15	32	17	17	14	8	5
Other digestive organs	C26	4	3	3	3	0	4	0	1	1	1	1
Respiratory organs	C30-39	189	146	125	79	60	113	63	63	43	38	21
Nose, sinuses	C30-31	1	1	1	0	0	1	0	1	0	-	-
Larynx, epiglottis	C32	4	3	3	3	2	2	1	2	2	2	1
Lung, trachea	C33-34	183	140	121	75	58	108	61	60	40	35	20
Mediastinum, pleura	C38	1	2	1	0	0	1	1	0	0	1	1
Bone	C40-41	1	1	1	0	-	1	0	0	1	0	0
Melanoma of the skin	C43	15	11	12	4	3	10	4	6	5	2	1
Skin, non-melanoma	C44	2	2	1	1	1	2	0	2	1	0	0
Mesothelioma	C45	12	10	11	2	1	3	2	2	2	1	1
Kaposi sarcoma	C46	-	-	-	-	-	-	-	-	-	-	-
Autonomic nervous system	C47	0	0	0	1	0	1	0	0	-	-	-
Soft tissues	C48-49	8	4	4	1	1	3	1	2	1	1	0
Breast	C50	0	0	0	0	-	-	0	0	-	-	-
Male genital organs	C60-63	95	72	77	54	27	74	30	31	17	18	7
Prostate	C61	93	71	77	54	27	73	29	30	17	17	7
Testis	C62	0	1	0	0	-	0	1	0	-	0	-
Other male genital	C60,C63	1	0	0	1	-	1	0	0	-	0	-
Urinary organs	C64-68	47	32	35	21	13	33	17	18	10	10	5
Kidney	C64-65	25	16	18	9	6	19	9	10	6	5	2
Bladder, ureter, urethra	C66-68	21	16	17	11	7	14	7	8	3	4	2
Eye	C69	1	1	1	-	1	1	0	0	0	0	0
Brain, central nervous system	C70-72	22	16	15	12	6	17	9	6	3	4	3
Thyroid gland	C73	2	1	1	1	1	2	1	-	1	0	1
Other endocrine glands	C74-75	2	1	0	0	0	0	1	0	-	0	-
Ill-defined or unknown	C76,C80	22	18	27	13	8	21	8	7	6	7	2
Lymphoid and haematopoietic tissue	C81-96	72	46	55	25	15	48	19	20	15	11	6
Hodgkin lymphoma	C81	2	0	1	0	-	1	0	0	0	0	0
Non-Hodgkin lymphoma	C82-85,C96	34	20	24	10	6	19	9	6	7	4	3
Nodal non-Hodgkin lymphoma		22	13	16	6	5	11	6	3	4	3	2
Multiple myeloma	C90	15	11	11	5	3	14	4	6	4	2	1
Leukaemia	C91-95	20	15	18	9	6	14	6	8	4	4	2
Acute leukaemia		9	8	9	6	3	6	3	3	2	2	1
Not included above												
Basal cell carcinoma of the skin		0	-	-	-	-	0	-	-	-	0	-
PUNLMP and ca in situ of the bladder		-	-	0	-	-	-	0	-	-	-	-
Polycythaemia vera		-	0	1	-	-	1	0	0	-	-	-


	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	196	269	284	260	208	90	326	96	79	144	39	5601
	1	3	5	3	4	1	6	1	1	3	0	93
	-	-	0	0	-	-	0	-	-	0	-	2
	0	1	2	0	1	0	1	0	0	1	-	23
	0	2	2	1	1	0	2	1	0	0	-	25
	0	0	0	1	0	0	1	0	0	1	-	10
	0	1	1	1	2	0	2	-	0	0	0	33
	53	78	89	78	62	29	100	28	21	40	11	1674
	5	7	5	6	4	3	5	2	2	3	1	130
	9	14	21	16	14	5	20	5	3	7	2	299
	0	1	0	1	1	0	2	-	-	0	1	20
	8	14	16	15	11	4	14	5	3	5	2	295
	6	9	12	10	9	6	13	4	2	6	1	229
	7	6	11	6	2	3	11	3	3	6	1	178
	3	5	4	3	2	1	5	2	2	1	1	74
	14	21	18	19	18	7	29	7	6	11	3	416
	0	2	1	2	1	1	1	1	1	1	0	33
	57	73	73	65	50	22	99	30	24	43	8	1488
	0	0	1	0	1	-	1	0	-	-	0	10
	0	2	1	2	1	0	2	0	1	1	1	36
	55	70	71	62	47	21	96	29	23	42	7	1428
	1	1	0	0	0	-	0	-	-	0	-	12
	1	-	1	1	0	0	1	-	-	0	-	10
	3	6	4	5	2	1	6	2	2	1	0	105
	1	0	1	0	2	0	1	0	0	0	-	17
	1	1	2	2	1	1	4	-	1	1	0	59
	-	-	-	-	-	0	-	-	-	-	-	0
	0	0	0	-	0	-	0	-	-	0	-	5
	2	2	3	2	1	0	2	1	-	2	0	40
	-	0	0	0	-	-	-	0	-	-	-	3
	30	37	46	39	38	16	39	12	10	21	8	799
	29	37	45	39	37	15	39	12	10	20	8	787
	1	0	1	0	0	0	-	-	-	0	0	6
	-	0	0	0	0	0	1	0	-	1	-	7
	13	16	13	16	15	7	20	6	7	9	4	366
	7	10	8	8	7	4	11	3	3	5	3	196
	5	6	5	8	8	4	9	3	4	4	1	170
	1	1	1	1	1	-	-	0	0	0	0	11
	5	8	8	8	8	2	12	2	2	4	1	171
	1	2	1	1	1	-	1	-	-	1	0	17
	-	0	0	-	0	-	0	0	0	1	-	7
	9	10	11	12	7	2	8	6	3	4	1	215
	19	29	27	27	17	8	27	8	8	14	5	521
	0	2	2	0	0	0	1	0	-	1	-	12
	8	13	11	14	7	4	9	3	3	5	3	223
	5	9	6	10	4	2	6	2	2	3	2	139
	3	6	5	4	3	2	6	1	2	3	1	112
	7	9	9	7	6	2	11	3	2	4	2	169
	3	5	4	3	2	1	4	2	1	3	1	80
	-	-	-	0	-	-	-	-	-	-	-	1
	0	-	0	0	0	-	-	-	-	-	-	2
	0	1	0	1	0	0	-	0	0	0	-	6



► **TABLE 33. Mean annual numbers of cancer deaths in 2003-2007, by primary site and health care district. FEMALES.**

Primary site	ICD-10 code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	677	588	514	258	183	451	210	205	147	123	58
Mouth, pharynx	C00-14	8	9	5	3	3	6	3	1	1	1	1
Lip	C00	0	0	-	0	-	-	-	-	-	-	-
Tongue	C01-02	3	3	1	1	1	2	1	0	0	0	0
Mouth, other	C03-06	3	3	2	1	1	2	1	0	0	0	0
Salivary glands	C07-08	1	1	0	0	1	2	0	0	-	0	0
Pharynx	C09-14	2	2	1	0	1	0	1	-	0	-	-
Digestive organs	C15-26	196	166	166	85	60	137	77	69	53	46	19
Oesophagus	C15	7	7	7	5	2	8	3	2	3	1	1
Stomach	C16	26	22	25	13	10	21	8	9	8	7	2
Small intestine	C17	2	2	1	0	0	2	0	1	0	1	0
Colon	C18	36	33	43	16	11	28	16	15	10	11	3
Rectum, rectosigmoid, anus	C19-21	26	21	20	10	7	16	11	7	7	5	2
Liver	C22	19	13	10	5	3	7	8	6	3	3	2
Gallbladder, bile ducts	C23-24	13	9	11	8	7	15	8	7	6	4	1
Pancreas	C25	62	54	43	24	18	35	22	21	15	12	7
Other digestive organs	C26	4	4	6	3	2	5	1	1	2	2	1
Respiratory organs	C30-39	92	91	55	24	19	44	17	20	15	12	6
Nose, sinuses	C30-31	1	2	0	0	0	1	1	-	1	0	-
Larynx, epiglottis	C32	1	0	0	0	0	-	-	-	0	0	-
Lung, trachea	C33-34	89	88	53	23	18	42	16	19	13	10	6
Mediastinum, pleura	C38	1	1	1	1	-	1	0	0	1	0	-
Bone	C40-41	1	1	1	0	1	1	0	-	-	-	0
Melanoma of the skin	C43	10	6	7	4	3	5	3	2	4	2	1
Skin, non-melanoma	C44	2	1	2	1	1	3	0	0	1	1	0
Mesothelioma	C45	2	2	3	1	1	1	1	2	1	-	-
Kaposi sarcoma	C46	-	-	0	-	-	-	-	-	-	-	-
Autonomic nervous system	C47	1	-	0	-	0	0	0	-	-	0	-
Soft tissues	C48-49	6	5	4	3	1	5	1	2	1	1	0
Breast	C50	117	113	73	41	27	80	33	38	20	19	11
Female genital organs	C51-58	87	68	51	30	21	59	22	26	17	12	6
Cervix uteri	C53	8	7	5	2	2	4	2	2	2	0	1
Corpus uteri	C54	22	19	13	11	5	15	4	8	4	4	1
Uterus, other	C55	1	1	-	-	0	0	0	-	0	-	-
Ovary	C56	40	29	27	14	12	33	13	13	9	6	4
Other female genital	C51-52,C57	16	12	6	3	1	7	2	3	3	1	1
Placenta	C58	-	-	-	-	-	-	-	-	-	-	-
Urinary organs	C64-68	23	22	26	12	6	20	9	7	6	5	3
Kidney	C64-65	17	13	18	9	3	13	7	6	4	4	2
Bladder, ureter, urethra	C66-68	7	9	8	3	3	7	3	2	2	1	1
Eye	C69	2	0	1	0	0	1	-	0	-	0	0
Brain, central nervous system	C70-72	26	18	19	10	8	14	8	5	5	3	2
Thyroid gland	C73	3	2	3	2	1	2	1	1	1	2	0
Other endocrine glands	C74-75	2	0	1	1	0	1	0	0	0	-	0
Ill-defined or unknown	C76,C80	37	26	34	16	14	28	11	8	12	8	2
Lymphoid and haematopoietic tissue	C81-96	62	55	62	26	19	45	22	25	12	10	6
Hodgkin lymphoma	C81	1	1	1	-	1	1	1	-	-	-	0
Non-Hodgkin lymphoma	C82-85,C96	28	23	29	11	8	18	10	12	6	4	3
Nodal non-Hodgkin lymphoma		18	16	17	6	6	12	7	7	3	2	2
Multiple myeloma	C90	16	15	14	6	5	13	5	7	3	2	1
Leukaemia	C91-95	17	17	18	9	5	13	6	6	4	5	2
Acute leukaemia		9	9	9	5	2	8	3	3	2	3	1
Not included above												
Carcinoma in situ of the breast	D05	1	0	1	1	-	0	-	-	-	0	-
Cervix uteri, non-invasive neoplasms		-	0	-	-	-	-	0	-	-	-	-
Borderline tumour of the ovary	D39	1	0	1	0	0	0	0	-	0	-	0
Basal cell carcinoma of the skin		-	0	0	-	-	0	-	0	-	0	-
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	-	-	-	-
Polycythaemia vera		0	0	1	0	0	0	0	0	-	0	0

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	157	245	249	214	180	75	295	78	66	102	29	5120
	2	2	3	2	1	1	3	0	1	1	0	58
	-	-	0	-	-	-	0	-	-	-	-	2
	0	1	1	1	0	0	0	-	0	0	-	19
	0	1	1	1	-	0	2	0	-	0	-	18
	1	0	0	0	0	-	0	-	0	0	0	9
	1	1	0	0	0	0	0	-	0	0	-	11
	52	82	87	71	66	24	100	24	21	34	10	1651
	2	4	3	2	2	2	5	1	2	2	1	72
	8	12	15	11	11	3	13	4	4	8	1	242
	1	1	1	1	0	1	1	0	-	-	0	16
	6	15	22	14	16	7	18	5	3	5	2	339
	6	10	11	8	8	3	9	2	1	3	1	196
	5	5	6	5	3	1	8	2	1	2	1	118
	7	8	6	6	4	3	9	1	2	2	1	136
	15	22	19	21	18	5	32	8	8	11	3	478
	2	5	2	3	2	1	4	1	1	1	0	54
	13	17	22	15	20	9	33	9	8	16	4	561
	0	0	1	0	1	0	1	0	-	0	-	10
	0	0	0	-	0	0	0	0	-	-	-	4
	13	16	20	14	19	8	32	9	8	15	4	538
	-	-	1	0	0	0	-	-	0	0	-	8
	0	0	0	1	0	-	1	-	-	-	-	7
	2	4	2	2	2	1	3	2	-	1	-	64
	1	2	1	0	1	0	1	0	-	-	0	18
	0	1	0	-	0	-	1	0	0	0	-	17
	-	-	-	0	0	-	-	-	-	-	-	1
	-	0	-	-	-	-	0	-	-	0	-	3
	1	2	2	3	1	1	4	1	1	1	0	46
	27	39	35	37	26	15	41	11	11	13	4	833
	21	29	29	22	20	6	34	9	8	12	3	593
	1	3	3	2	1	1	3	1	1	2	0	55
	5	6	7	7	7	1	9	3	3	2	0	154
	0	0	-	-	1	0	0	-	0	-	-	5
	12	15	14	11	10	3	18	3	3	6	2	298
	3	5	5	3	1	1	4	1	1	2	0	81
	-	-	-	-	-	-	-	-	-	-	-	0
	9	11	12	11	7	3	15	3	3	6	1	222
	7	7	8	7	4	2	9	2	2	4	1	149
	2	4	4	4	3	1	6	1	1	2	1	73
	1	1	1	1	0	-	1	-	0	0	-	11
	6	11	9	11	6	3	12	3	2	4	1	187
	1	2	2	1	0	0	2	1	0	2	-	29
	1	1	1	0	0	-	0	-	0	0	-	9
	8	15	16	13	10	4	15	6	4	4	2	295
	12	26	27	25	19	7	28	9	7	7	2	515
	-	1	0	1	1	0	0	0	0	0	-	9
	5	13	13	11	8	3	12	6	2	3	0	225
	4	6	8	7	5	2	7	3	2	2	-	142
	3	5	5	6	5	2	6	2	2	2	1	127
	5	7	9	7	5	2	9	1	2	2	1	152
	3	4	5	4	2	1	5	1	2	1	1	83
	0	-	-	0	-	0	0	0	-	-	-	4
	-	-	-	-	-	-	0	-	-	-	-	1
	1	1	-	-	0	-	1	0	-	0	-	7
	0	-	-	-	-	-	-	0	-	0	-	2
	-	-	-	-	-	-	-	-	0	-	-	0
	-	1	0	1	0	-	-	-	0	0	-	7




▶ **TABLE 34.** Age-adjusted¹ cancer mortality rates per 100,000 person-years in 2003-2007 by primary site and health care district. **MALES.**

Primary site	ICD-10 code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	117.2	131.5	122.4	126.4	118.8	117.0	116.5	122.1	117.8	107.0	112.9
Mouth, pharynx	C00-14	2.1	3.4	2.4	2.3	1.2	2.2	1.9	2.7	2.1	2.7	2.9
Lip	C00	-	-	0.2	-	-	-	-	0.1	0.1	-	-
Tongue	C01-02	0.4	0.5	0.8	0.9	-	0.7	0.7	0.5	0.8	0.7	0.3
Mouth, other	C03-06	0.5	1.1	0.7	0.3	0.3	0.5	0.6	1.1	-	0.6	0.6
Salivary glands	C07-08	0.3	0.3	0.0	0.4	0.1	0.1	-	0.2	0.5	-	0.6
Pharynx	C09-14	0.8	1.5	0.7	0.7	0.9	1.0	0.7	0.8	0.7	1.3	1.4
Digestive organs	C15-26	34.3	40.5	37.1	35.0	36.0	35.8	35.7	37.7	38.7	29.5	37.8
Oesophagus	C15	2.4	3.9	3.1	2.5	3.3	3.2	2.4	5.0	3.3	2.0	2.5
Stomach	C16	5.0	6.2	6.3	7.3	5.7	6.9	5.8	6.6	4.8	6.7	8.6
Small intestine	C17	0.5	0.6	0.3	0.3	0.6	0.4	0.5	0.5	0.6	-	1.0
Colon	C18	6.3	7.4	6.5	5.4	5.5	6.1	6.1	6.2	7.4	5.2	6.3
Rectum, rectosigmoid, anus	C19-21	4.8	4.5	6.2	5.3	6.1	4.6	4.6	4.9	6.8	5.4	5.0
Liver	C22	4.2	5.7	3.7	2.9	3.4	3.8	5.4	3.5	3.2	2.4	4.6
Gallbladder, bile ducts	C23-24	1.5	1.2	1.5	1.7	2.0	1.9	1.7	1.2	1.1	0.9	1.0
Pancreas	C25	8.8	10.2	8.8	8.6	9.2	8.0	9.0	9.4	10.6	6.2	7.8
Other digestive organs	C26	0.7	0.8	0.7	1.0	0.2	0.9	0.1	0.4	0.9	0.7	0.9
Respiratory organs	C30-39	30.4	35.6	28.5	33.7	35.7	26.7	31.1	32.6	31.3	31.3	32.1
Nose, sinuses	C30-31	0.2	0.2	0.3	0.2	0.1	0.2	0.1	0.3	0.1	-	-
Larynx, epiglottis	C32	0.5	0.8	0.6	1.4	0.9	0.6	0.6	1.2	1.8	2.3	1.4
Lung, trachea	C33-34	29.5	34.1	27.4	32.1	34.4	25.5	30.1	31.0	29.2	28.4	30.1
Mediastinum, pleura	C38	0.1	0.4	0.1	0.1	0.3	0.3	0.3	0.2	0.3	0.6	0.7
Bone	C40-41	0.2	0.3	0.4	0.1	-	0.3	0.2	0.5	0.9	0.2	1.1
Melanoma of the skin	C43	2.5	2.9	3.1	1.6	1.7	2.5	2.4	3.3	3.5	1.4	2.0
Skin, non-melanoma	C44	0.3	0.4	0.1	0.4	0.6	0.4	0.1	0.9	0.4	0.2	0.2
Mesothelioma	C45	2.0	2.4	2.8	0.8	0.7	0.9	0.8	1.1	1.7	0.7	0.7
Kaposi sarcoma	C46	-	-	-	-	-	-	-	-	-	-	-
Autonomic nervous system	C47	0.1	0.1	0.1	0.7	0.2	0.2	0.6	0.4	-	-	-
Soft tissues	C48-49	1.4	0.9	1.0	0.7	0.7	0.6	0.6	0.9	1.4	0.7	0.4
Breast	C50	0.1	0.1	0.1	0.1	-	-	0.1	0.2	-	-	-
Male genital organs	C60-63	15.8	16.3	15.8	19.5	14.5	16.4	13.9	14.8	11.6	13.1	9.8
Prostate	C61	15.6	16.1	15.6	19.3	14.5	15.9	13.1	14.4	11.6	12.8	9.8
Testis	C62	0.1	0.2	0.1	0.1	-	0.2	0.6	0.1	-	0.2	-
Other male genital	C60,C63	0.2	0.1	0.1	0.1	-	0.3	0.2	0.3	-	0.2	-
Urinary organs	C64-68	7.7	7.7	7.6	9.0	7.9	8.0	8.1	9.0	7.0	7.9	6.6
Kidney	C64-65	4.2	4.0	4.0	4.5	3.5	4.7	4.7	5.2	4.5	4.7	3.4
Bladder, ureter, urethra	C66-68	3.5	3.7	3.6	4.5	4.4	3.3	3.4	3.7	2.4	3.2	3.3
Eye	C69	0.1	0.2	0.1	-	0.5	0.3	0.2	0.1	0.2	0.4	0.3
Brain, central nervous system	C70-72	4.0	4.2	4.4	6.5	4.6	5.0	5.8	3.5	2.4	4.6	5.2
Thyroid gland	C73	0.3	0.2	0.2	0.4	0.5	0.4	0.5	-	0.4	0.4	1.1
Other endocrine glands	C74-75	0.2	0.4	0.1	0.2	0.2	0.1	0.4	0.1	-	0.3	-
Ill-defined or unknown	C76,C80	3.7	4.4	5.7	4.8	4.8	5.2	4.4	3.7	4.8	5.3	3.2
Lymphoid and haematopoietic tissue	C81-96	12.1	11.5	12.9	10.8	9.2	11.9	9.8	10.7	11.4	8.4	9.5
Hodgkin lymphoma	C81	0.3	0.0	0.4	0.3	-	0.2	0.3	0.3	0.2	0.2	1.0
Non-Hodgkin lymphoma	C82-85,C96	5.7	5.0	5.8	4.1	3.4	4.7	4.4	2.6	5.3	3.4	3.8
Nodal non-Hodgkin lymphoma		3.7	2.9	4.1	2.4	2.7	2.5	3.2	1.3	2.9	2.2	2.8
Multiple myeloma	C90	2.4	2.7	2.4	2.2	2.0	3.1	1.8	3.1	2.4	1.8	1.6
Leukaemia	C91-95	3.5	3.9	4.2	4.2	3.8	3.8	3.1	4.7	3.5	3.0	2.8
Acute leukaemia		1.6	2.2	2.3	2.8	2.6	1.6	1.5	2.2	1.7	1.7	2.2
Not included above												
Basal cell carcinoma of the skin		0.0	-	-	-	-	0.0	-	-	-	0.2	-
PUNLMP and ca in situ of the bladder		-	-	0.1	-	-	-	0.1	-	-	-	-
Polycythaemia vera		-	0.1	0.1	-	-	0.2	0.1	0.1	-	-	-

¹ Adjusted for age to the "world standard population".

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	110.6	109.4	112.0	127.7	118.2	115.7	106.8	108.6	114.9	125.1	139.8	118.5
	0.7	1.5	2.1	2.0	2.6	1.2	2.1	1.1	2.0	2.3	1.9	2.2
	-	-	0.0	0.1	-	-	0.1	-	-	0.2	-	0.0
	0.1	0.3	0.7	0.2	0.7	0.3	0.3	0.5	0.4	0.8	-	0.5
	0.2	0.8	0.7	0.8	0.6	0.4	0.7	0.4	0.5	0.4	-	0.6
	0.3	0.1	0.1	0.6	0.3	0.2	0.3	0.2	0.4	0.5	-	0.2
	0.1	0.3	0.5	0.3	1.0	0.3	0.7	-	0.7	0.4	1.9	0.8
	30.4	33.2	35.4	39.5	36.0	37.2	33.2	33.2	31.0	35.1	41.2	35.7
	3.1	3.2	2.2	3.2	2.2	3.7	1.6	2.6	3.0	3.2	2.3	2.9
	5.5	5.4	8.1	8.2	8.2	6.1	6.9	6.2	3.7	5.8	7.4	6.4
	0.1	0.5	0.1	0.9	0.6	0.1	0.7	-	-	0.3	2.7	0.4
	4.4	6.1	6.5	7.5	6.0	4.1	4.4	6.2	3.8	4.7	7.3	6.0
	3.2	3.6	4.4	4.6	5.3	7.3	4.1	4.2	3.0	5.1	3.8	4.9
	4.3	2.5	4.4	3.3	1.2	3.6	3.7	3.2	4.9	4.9	2.5	3.8
	1.7	1.9	1.6	1.7	1.3	1.1	1.6	2.0	2.3	0.9	2.3	1.5
	8.0	9.1	7.4	9.1	10.7	10.4	9.7	7.7	9.5	9.6	12.1	9.0
	0.2	0.9	0.6	1.1	0.4	0.7	0.5	1.0	0.7	0.7	0.8	0.7
	30.5	29.6	27.5	31.7	28.5	28.9	31.6	32.5	33.1	36.0	27.6	31.0
	0.2	0.1	0.3	0.2	0.7	-	0.2	0.2	-	-	0.9	0.2
	0.3	1.0	0.3	1.1	0.7	0.3	0.5	0.3	1.0	0.6	1.3	0.8
	29.6	27.9	26.8	30.2	26.3	28.6	30.7	32.0	31.8	35.2	25.4	29.7
	0.4	0.6	0.2	0.2	0.2	-	0.1	-	-	0.2	-	0.2
	0.7	-	0.3	0.3	0.3	0.3	0.3	-	-	0.4	-	0.3
	2.2	2.6	1.9	2.4	1.8	2.3	2.1	1.8	2.8	1.8	1.0	2.4
	0.5	0.1	0.4	0.1	0.8	0.5	0.3	0.7	0.4	0.5	-	0.3
	0.7	0.5	0.8	0.9	0.5	1.8	1.3	-	1.2	0.8	1.6	1.3
	-	-	-	-	-	0.2	-	-	-	-	-	0.0
	0.2	0.0	0.5	-	0.3	-	0.2	-	-	0.4	-	0.2
	1.8	1.0	1.1	1.7	0.4	0.3	0.5	1.5	-	1.6	0.5	1.0
	-	0.1	0.1	0.2	-	-	-	0.4	-	-	-	0.1
	15.6	13.2	16.8	16.3	17.6	18.5	11.6	12.4	14.6	17.4	23.8	15.5
	14.7	12.9	16.2	15.9	17.3	17.8	11.4	12.0	14.6	16.6	22.5	15.1
	0.9	0.2	0.5	0.3	0.2	0.5	-	-	-	0.2	1.2	0.2
	-	0.1	0.2	0.1	0.2	0.3	0.2	0.3	-	0.6	-	0.2
	7.4	6.5	4.8	7.8	8.0	9.2	6.5	7.4	10.0	7.2	15.3	7.7
	4.8	4.2	3.3	3.7	3.8	4.8	3.7	4.4	4.5	3.7	10.6	4.2
	2.6	2.3	1.6	4.1	4.2	4.4	2.9	3.0	5.6	3.5	4.7	3.4
	0.3	0.3	0.3	0.5	0.6	-	-	0.4	0.7	0.2	0.8	0.2
	2.9	4.0	3.9	5.0	6.4	2.9	4.5	2.4	2.9	3.5	5.2	4.4
	0.3	0.7	0.3	0.5	0.5	-	0.4	-	-	0.6	0.5	0.3
	-	0.2	0.3	-	0.1	-	0.1	0.3	0.3	0.4	-	0.2
	5.1	3.9	4.3	5.8	4.2	2.2	2.8	7.0	4.6	3.4	3.4	4.5
	11.3	11.9	11.1	13.0	9.7	10.3	9.2	7.5	11.5	13.5	17.0	11.3
	0.2	1.0	0.9	0.2	0.1	0.3	0.4	0.5	-	1.1	-	0.3
	4.6	5.2	4.4	7.3	4.5	4.7	3.0	2.8	5.8	4.6	8.8	4.8
	2.5	3.8	2.2	5.1	2.6	2.9	1.9	1.4	3.5	3.1	5.7	3.0
	1.9	2.1	1.9	1.9	1.5	2.4	1.6	1.1	2.4	3.1	2.6	2.3
	4.5	3.5	3.9	3.4	3.4	2.9	4.0	3.2	3.3	4.5	5.5	3.8
	2.7	2.0	2.0	1.6	1.4	0.8	1.6	2.1	2.2	3.3	1.9	2.0
	-	-	-	0.1	-	-	-	-	-	-	-	0.0
	0.2	-	0.0	0.1	0.1	-	-	-	-	-	-	0.0
	0.1	0.2	0.0	0.3	0.1	0.4	-	0.3	0.6	0.2	-	0.1




► **TABLE 35. Age-adjusted¹ cancer mortality rates per 100,000 person-years in 2003-2007 by primary site and health care district. FEMALES.**

Primary site	ICD-10 code	Health care district										
		Uusimaa 1	Helsinki 2	Varsinais-Suomi 3	Satakunta 4	Kanta-Häme 5	Pirkanmaa 6	Päijät-Häme 7	Kymenlaakso 8	Etelä-Karjala 9	Etelä-Savo 10	Itä-Savo 11
All sites	C00-96	81.0	84.3	80.5	76.6	78.9	78.0	71.5	79.6	83.7	73.1	66.7
Mouth, pharynx	C00-14	0.9	1.3	0.9	0.8	1.2	1.1	1.3	0.2	0.7	0.8	0.8
Lip	C00	0.0	0.0	-	0.0	-	-	-	-	-	-	-
Tongue	C01-02	0.3	0.3	0.2	0.3	0.5	0.3	0.6	0.0	0.4	0.3	0.6
Mouth, other	C03-06	0.3	0.4	0.3	0.2	0.2	0.4	0.3	0.1	0.2	0.2	0.1
Salivary glands	C07-08	0.1	0.1	0.1	0.2	0.1	0.3	0.1	0.0	-	0.4	0.1
Pharynx	C09-14	0.3	0.4	0.3	0.1	0.4	0.1	0.3	-	0.2	-	-
Digestive organs	C15-26	22.0	22.4	24.6	23.1	24.0	21.6	24.6	23.6	25.9	24.3	17.4
Oesophagus	C15	0.7	0.9	1.0	1.2	1.1	1.3	0.9	0.7	1.1	0.3	0.5
Stomach	C16	3.0	3.4	3.8	3.7	4.3	3.8	2.4	3.3	3.3	3.7	3.1
Small intestine	C17	0.2	0.2	0.2	0.1	0.1	0.3	0.1	0.2	0.2	0.2	0.5
Colon	C18	4.0	4.3	6.1	4.4	5.3	3.9	5.2	5.2	4.9	5.4	3.5
Rectum, rectosigmoid, anus	C19-21	2.7	2.8	2.8	2.7	2.5	2.6	3.5	2.2	3.1	3.1	1.4
Liver	C22	2.2	2.0	1.5	1.6	1.3	1.3	2.8	2.2	1.3	1.7	1.2
Gallbladder, bile ducts	C23-24	1.5	1.1	1.6	2.1	2.4	2.3	2.5	2.3	3.3	1.8	0.8
Pancreas	C25	7.2	7.2	7.0	6.6	6.6	5.4	6.9	7.2	7.8	7.0	5.2
Other digestive organs	C26	0.4	0.6	0.7	0.8	0.4	0.5	0.2	0.3	0.8	1.0	1.1
Respiratory organs	C30-39	11.2	12.9	8.8	7.7	8.6	8.2	6.6	7.1	8.6	7.4	6.7
Nose, sinuses	C30-31	0.1	0.2	0.0	0.1	0.1	0.2	0.3	-	0.5	0.2	-
Larynx, epiglottis	C32	0.1	0.0	0.1	0.1	0.2	-	-	-	0.1	0.2	-
Lung, trachea	C33-34	10.9	12.5	8.5	7.4	8.3	7.9	6.3	7.0	7.8	6.8	6.7
Mediastinum, pleura	C38	0.1	0.1	0.1	0.1	-	0.1	0.1	0.1	0.2	0.1	-
Bone	C40-41	0.1	0.2	0.1	0.0	0.3	0.1	0.2	-	-	-	0.5
Melanoma of the skin	C43	1.2	1.3	1.1	1.4	1.0	0.8	0.8	0.7	2.3	1.3	1.1
Skin, non-melanoma	C44	0.2	0.1	0.2	0.4	0.1	0.3	0.0	0.0	0.2	0.5	0.3
Mesothelioma	C45	0.3	0.3	0.4	0.1	0.2	0.1	0.4	0.5	0.3	-	-
Kaposi sarcoma	C46	-	-	0.0	-	-	-	-	-	-	-	-
Autonomic nervous system	C47	0.3	-	0.3	-	0.2	0.0	0.0	-	-	0.4	-
Soft tissues	C48-49	0.8	0.9	0.6	1.0	0.4	1.1	0.3	0.7	0.6	0.9	0.6
Breast	C50	15.2	18.3	13.8	15.3	14.1	15.8	13.0	18.0	14.5	14.5	16.9
Female genital organs	C51-58	10.7	9.7	8.6	8.6	8.5	11.2	7.4	10.8	11.5	6.4	6.3
Cervix uteri	C53	1.1	1.1	0.8	0.4	0.9	0.8	0.7	0.9	1.7	0.1	0.4
Corpus uteri	C54	2.5	2.4	2.0	2.9	2.0	2.8	1.1	2.9	2.0	2.4	0.9
Uterus, other	C55	0.1	0.0	-	-	0.1	0.0	0.0	-	0.1	-	-
Ovary	C56	5.0	4.6	4.8	4.3	4.8	6.6	5.0	6.2	6.7	3.3	4.1
Other female genital	C51-52,C57	1.9	1.7	1.1	0.9	0.6	0.9	0.6	0.8	1.1	0.6	1.0
Placenta	C58	-	-	-	-	-	-	-	-	-	-	-
Urinary organs	C64-68	2.4	2.5	3.1	3.1	2.3	3.0	3.1	2.5	2.7	2.4	2.9
Kidney	C64-65	1.8	1.7	2.4	2.5	1.5	2.1	2.4	2.0	2.2	2.0	2.2
Bladder, ureter, urethra	C66-68	0.6	0.9	0.8	0.7	0.8	0.9	0.7	0.5	0.6	0.5	0.7
Eye	C69	0.3	0.0	0.1	0.0	0.1	0.3	-	0.1	-	0.1	0.3
Brain, central nervous system	C70-72	3.7	3.5	3.8	3.7	6.4	2.8	3.1	2.2	3.6	2.8	3.7
Thyroid gland	C73	0.4	0.3	0.3	0.3	0.3	0.3	0.4	0.2	0.3	1.1	0.2
Other endocrine glands	C74-75	0.2	0.0	0.1	0.5	0.1	0.1	0.2	0.0	0.2	-	1.4
Ill-defined or unknown	C76,C80	3.9	3.1	4.5	4.1	4.9	4.3	3.4	2.7	6.0	3.4	1.7
Lymphoid and haematopoietic tissue	C81-96	7.2	7.5	9.1	6.7	6.3	7.0	6.6	10.4	6.3	7.0	5.9
Hodgkin lymphoma	C81	0.1	0.1	0.1	-	0.3	0.2	0.1	-	-	-	1.5
Non-Hodgkin lymphoma	C82-85,C96	3.1	2.8	4.0	3.0	2.6	2.6	3.0	4.2	2.7	1.8	2.0
Nodal non-Hodgkin lymphoma		2.0	2.0	2.5	1.8	1.9	1.9	2.3	2.4	1.4	0.8	1.0
Multiple myeloma	C90	1.8	2.0	1.9	1.3	1.9	1.8	1.5	2.5	1.3	1.0	1.4
Leukaemia	C91-95	2.1	2.5	3.0	2.4	1.6	2.4	2.0	3.7	2.3	4.2	0.9
Acute leukaemia		1.4	1.8	2.0	1.5	0.7	1.7	1.1	2.5	1.9	3.3	0.5
Not included above												
Carcinoma in situ of the breast	D05	0.1	0.1	0.1	0.3	-	0.1	-	-	-	0.1	-
Cervix uteri, non-invasive neoplasms		-	0.0	-	-	-	-	0.1	-	-	-	-
Borderline tumour of the ovary	D39	0.1	0.0	0.2	0.1	0.2	0.1	0.2	-	0.1	-	0.1
Basal cell carcinoma of the skin		-	0.0	0.0	-	-	0.0	-	0.0	-	0.1	-
PUNLMP and ca in situ of the bladder		-	-	-	-	-	-	-	-	-	-	-
Polycythaemia vera		0.0	0.1	0.1	0.1	0.3	0.0	0.0	0.0	-	0.1	0.1

¹ Adjusted for age to the "world standard population".

	Pohjois-Karjala 12	Pohjois-Savo 13	Kesk-Suomi 14	Etelä-Pohjanmaa 15	Vaasa 16	Keski-Pohjanmaa 17	Pohjois-Pohjanmaa 18	Kainuu 19	Länsi-Pohja 20	Lappi 21	Åland 22	Whole country
	67.9	71.5	71.2	76.7	80.3	76.4	73.6	71.0	77.6	68.6	80.7	77.3
	0.9	0.6	0.8	0.6	0.5	0.4	0.6	0.2	1.7	0.8	1.0	0.9
	-	-	0.1	-	-	-	0.1	-	-	-	-	0.0
	0.2	0.1	0.3	0.4	0.3	0.1	0.0	-	0.8	0.2	-	0.3
	0.1	0.1	0.2	0.1	-	0.1	0.3	0.2	-	0.2	-	0.2
	0.3	0.1	0.1	0.0	0.0	-	0.1	-	0.3	0.3	1.0	0.1
	0.3	0.3	0.1	0.0	0.1	0.2	0.1	-	0.7	0.1	-	0.2
	19.3	20.7	23.4	20.4	27.0	21.7	23.0	18.5	22.7	21.5	25.3	22.7
	0.5	1.5	0.8	0.3	0.9	1.1	1.3	0.7	1.4	0.8	1.7	0.9
	3.3	3.0	4.4	3.1	5.3	3.1	2.9	3.6	4.6	4.9	2.9	3.5
	0.4	0.3	0.3	0.4	0.1	0.8	0.3	0.2	-	-	0.6	0.2
	2.3	3.9	6.1	4.2	6.0	6.5	4.4	2.9	3.7	3.2	5.9	4.6
	2.5	2.6	3.0	3.0	2.9	2.5	2.1	1.9	0.8	1.8	2.8	2.6
	1.7	1.4	1.8	1.0	1.5	0.7	1.6	1.4	1.3	1.2	3.4	1.7
	2.6	1.8	1.4	1.9	1.9	2.6	2.0	0.9	1.7	0.9	2.1	1.8
	5.5	5.4	5.1	5.9	7.8	4.1	7.7	6.5	8.6	8.2	5.6	6.7
	0.6	0.7	0.5	0.7	0.6	0.3	0.6	0.3	0.7	0.5	0.2	0.6
	5.4	5.3	6.7	5.8	9.9	10.3	8.6	9.1	9.8	10.3	12.8	8.8
	0.1	0.1	0.2	0.0	0.4	0.1	0.3	0.1	-	0.1	-	0.2
	0.0	0.1	0.2	-	0.0	0.3	0.1	0.1	-	-	-	0.1
	5.3	5.0	6.1	5.2	9.5	9.7	8.3	8.9	9.4	10.0	12.8	8.5
	-	-	0.1	0.5	0.0	0.2	-	-	0.1	0.2	-	0.1
	0.0	0.1	0.2	0.5	0.2	-	0.2	-	-	-	-	0.1
	1.0	1.5	0.6	0.6	0.7	0.8	0.6	2.0	-	0.9	-	1.0
	0.6	0.2	0.1	0.1	0.2	0.1	0.3	0.2	-	-	1.0	0.2
	0.0	0.4	0.1	-	0.1	-	0.2	0.3	0.3	0.4	-	0.2
	-	-	-	0.0	0.0	-	-	-	-	-	-	0.0
	-	0.4	-	-	-	-	0.1	-	-	0.6	-	0.1
	0.5	0.4	0.6	1.6	0.4	1.0	0.9	0.9	1.4	1.0	2.6	0.8
	14.5	14.2	11.6	14.7	14.5	17.2	12.3	11.9	14.6	10.1	9.3	14.7
	9.3	8.3	8.9	9.6	9.5	6.6	9.0	8.1	8.7	7.6	10.1	9.3
	0.6	0.7	1.0	0.7	0.7	1.2	1.0	1.2	1.4	1.1	0.9	0.9
	1.9	1.6	2.0	2.4	2.2	1.3	2.0	2.7	2.5	1.6	0.6	2.2
	0.0	0.0	-	-	0.2	0.2	0.0	-	0.1	-	-	0.0
	5.9	5.1	4.5	5.6	5.9	3.6	5.2	3.3	3.4	3.9	8.3	5.0
	0.9	0.9	1.4	0.9	0.5	0.4	0.8	1.0	1.2	1.0	0.2	1.1
	-	-	-	-	-	-	-	-	-	-	-	0.0
	3.3	2.4	2.9	3.5	2.2	2.9	3.1	2.3	3.5	3.7	2.3	2.8
	2.9	1.5	2.0	2.7	1.5	2.3	1.9	1.4	2.8	2.6	0.9	2.0
	0.4	0.9	0.9	0.8	0.7	0.6	1.2	0.9	0.7	1.1	1.5	0.8
	0.4	0.6	0.2	0.2	0.3	-	0.2	-	0.1	0.1	-	0.2
	3.8	4.3	3.5	5.6	3.1	3.2	3.8	4.7	2.7	3.5	5.1	3.7
	0.4	0.6	0.3	0.2	0.1	0.3	0.4	0.2	0.3	0.6	-	0.3
	0.7	0.3	0.3	0.1	0.2	-	0.2	-	0.5	0.2	-	0.2
	3.0	3.4	3.5	3.9	3.6	3.6	3.1	4.0	3.0	2.7	4.8	3.7
	4.6	7.7	7.6	9.1	7.8	8.1	6.9	8.6	8.2	4.6	6.3	7.4
	-	0.4	0.2	0.5	0.2	0.4	0.3	1.0	0.8	0.5	-	0.2
	1.7	2.9	3.3	3.8	3.3	2.1	2.9	4.1	2.4	1.8	0.8	3.0
	1.2	1.5	2.3	2.6	2.2	1.0	1.6	2.7	1.6	1.3	-	1.9
	1.1	1.4	1.3	2.2	1.5	2.9	1.6	1.8	1.4	1.4	2.4	1.7
	1.7	3.0	2.7	2.6	2.7	2.6	2.2	1.6	3.5	1.0	3.1	2.4
	1.2	2.1	1.8	1.8	1.6	2.0	1.5	1.5	2.9	0.4	2.7	1.6
	0.2	-	-	0.0	-	0.1	0.1	0.3	-	-	-	0.1
	-	-	-	-	-	-	0.0	-	-	-	-	0.0
	0.6	0.2	-	-	0.3	-	0.3	0.8	-	0.1	-	0.1
	0.0	-	-	-	-	-	-	0.1	-	0.1	-	0.0
	-	-	-	-	-	-	-	-	0.3	-	-	0.0
	-	0.2	0.1	0.3	0.0	-	-	-	0.4	0.1	-	0.1



In 2020, almost 300 000 people will have had cancer some time earlier in their life

Cancer patients remain in the health care system for several years. The primary and secondary treatments take place mainly during the first five years. Thus, it is customary to count the numbers of cancer patients alive, i.e., the prevalence, stratified by time since diagnosis. We report here predictions for the number of patients alive during their first five-year period after diagnosis.

The prevalence is very much affected by cancer incidence. The more new cases are diagnosed, the higher is the prevalence. On the other hand, prevalence tends to be low for fatal cancers and cancers that are mainly diagnosed at very high ages, where mortality due to other causes of death is high.

Here, prevalence has been predicted in the same way as the incidence (see page 10). A model of constant age-specific prevalence has been applied to prostate cancer. This is vulnerable to error, as it is currently unknown what the future developments will be concerning the prevalence of PSA diagnostics and practices of potential PSA-based mass-screening.

The predictions (see Table on the right) show that prostate cancer will constitute almost one-half of cancer cases diagnosed within the five year period (2016-2020) among persons alive in the end of 2020. Lung cancer, due to its fatality, has a much lower position in prevalence statistics than in the incidence and mortality statistics.

In females, breast cancer now is and will be responsible for more than 40% of the prevalent cases.

With both sexes together, there are currently about 85,000 prevalent cancer patients with a diagnosis made during the previous five year period. This number will increase to about 110,000 by the year 2020. Currently, there are more than 205,000 persons alive with cancer diagnosed at any time in their life. This number will increase to almost 300,000 by the year 2020.

These figures reflect different aspects of the cancer burden that the society has to be able to cope with in the years to come.

➤ **Number of persons alive on 31 December 2007 with cancer diagnosed in the previous five years, and the respective predicted number on 31 December 2020, by sex and site.**

Site	2007		2020	
	N	%	N	%
Males				
Prostate	20205	47.9	28881	49.8
Bladder	2255	5.3	2392	4.1
Colon	2242	5.3	3629	6.3
Skin, non-melanoma	1964	4.7	3419	5.9
Rectum	1741	4.1	2549	4.4
Skin, melanoma	1770	4.2	2938	5.1
Non-Hodgkin lymphoma	1690	4.0	2574	4.4
Lung	1482	3.5	1399	2.4
Kidney	1275	3.0	1296	2.2
Brain, central nervous system	1141	2.7	1511	2.6
Other sites	6390	15.2	7391	12.8
All sites	42155	100	57979	100
Females				
Breast	17942	41.9	22815	41.6
Corpus uteri	3276	7.6	4369	8.0
Colon	2543	5.9	3513	6.4
Skin, non-melanoma	1938	4.5	2330	4.3
Brain, central nervous system	1858	4.3	2747	5.0
Skin, melanoma	1777	4.1	2686	4.9
Non-Hodgkin lymphoma	1613	3.8	2380	4.3
Ovary	1413	3.3	1796	3.3
Rectum	1460	3.4	1902	3.5
Thyroid	1201	2.8	1077	2.0
Kidney	1068	2.5	1240	2.3
Lung	814	1.9	1119	2.0
Other sites	5965	13.9	6804	12.4
All sites	42868	100	54778	100

◆ **TABLE 36. Numbers of prevalent cancers on 1 January 2008, by primary site and time after diagnosis, MALES.**

Primary site	ICD-10 code	Time after diagnosis			
		< 1 year	< 5 years	10 years	Any
All sites	C00-96	10263	42155	63243	85129
Mouth, pharynx	C00-14	253	964	1553	2609
Lip	C00	47	239	459	1080
Tongue	C01-02	58	190	300	416
Mouth, other	C03-06	52	206	307	403
Salivary glands	C07-08	31	112	164	298
Pharynx	C09-14	65	217	323	412
Digestive organs	C15-26	1744	5533	7948	11099
Oesophagus	C15	86	193	225	261
Stomach	C16	229	628	947	1544
Small intestine	C17	42	145	221	306
Colon	C18	598	2242	3313	4700
Rectum, rectosigmoid, anus	C19-21	475	1741	2573	3522
Liver	C22	97	208	235	265
Gallbladder, bile ducts	C23-24	53	103	133	165
Pancreas	C25	159	262	289	321
Other digestive organs	C26	5	11	12	15
Respiratory organs	C30-39	826	1930	2557	3467
Nose, sinuses	C30-31	26	70	102	151
Larynx, epiglottis	C32	102	354	588	914
Lung, trachea	C33-34	687	1482	1833	2339
Mediastinum, pleura	C38	7	12	16	33
Bone	C40-41	18	60	119	385
Melanoma of the skin	C43	433	1770	2789	4630
Skin, non-melanoma	C44	523	1964	2927	3993
Mesothelioma	C45	51	87	97	102
Kaposi sarcoma	C46	8	28	44	82
Autonomic nervous system	C47	2	26	49	156
Soft tissues	C48-49	75	279	450	834
Breast	C50	16	76	120	165
Male genital organs	C60-63	4163	20867	30934	35513
Prostate	C61	4003	20205	29787	33253
Testis	C62	127	560	985	2002
Other male genital	C60,C63	33	102	162	258
Urinary organs	C64-68	810	3530	5638	8509
Kidney	C64-65	292	1275	2047	3167
Bladder, ureter, urethra	C66-68	518	2255	3591	5342
Eye	C69	20	75	174	416
Brain, central nervous system	C70-72	293	1141	1890	3605
Thyroid gland	C73	82	361	616	1263
Other endocrine glands	C74-75	13	23	49	104
Ill-defined or unknown	C76,C80	137	277	339	424
Lymphoid and haematopoietic tissue	C81-96	796	3164	4950	7773
Hodgkin lymphoma	C81	65	318	616	1381
Non-Hodgkin lymphoma	C82-85,C96	428	1690	2595	3862
Nodal non-Hodgkin lymphoma		204	969	1550	2355
Multiple myeloma	C90	85	325	446	543
Leukaemia	C91-95	212	810	1258	1941
Acute leukaemia		74	251	435	894
Not included above					
Basal cell carcinoma of the skin		3090	12926	20834	31779
PUNLMP and ca in situ of the bladder		129	271	304	328
Polycythaemia vera		10	61	88	140

▶ **TABLE 37. Numbers of prevalent cancers on 1 January 2008, by primary site and time after diagnosis, FEMALES.**

Primary site	ICD-10 code	Time after diagnosis			
		< 1 year	< 5 years	10 years	Any
All sites	C00-96	10650	42868	71519	120736
Mouth, pharynx	C00-14	174	729	1134	1811
Lip	C00	24	130	232	382
Tongue	C01-02	50	203	294	426
Mouth, other	C03-06	43	175	268	409
Salivary glands	C07-08	35	134	202	398
Pharynx	C09-14	22	87	138	196
Digestive organs	C15-26	1594	5284	8153	12734
Oesophagus	C15	33	80	115	171
Stomach	C16	186	522	833	1576
Small intestine	C17	39	136	203	308
Colon	C18	663	2543	4071	6335
Rectum, rectosigmoid, anus	C19-21	382	1460	2289	3528
Liver	C22	50	100	115	140
Gallbladder, bile ducts	C23-24	62	134	186	276
Pancreas	C25	176	303	334	388
Other digestive organs	C26	3	6	7	12
Respiratory organs	C30-39	413	922	1237	1659
Nose, sinuses	C30-31	12	47	75	110
Larynx, epiglottis	C32	14	47	72	131
Lung, trachea	C33-34	382	814	1065	1369
Mediastinum, pleura	C38	5	7	10	17
Bone	C40-41	10	54	102	328
Melanoma of the skin	C43	437	1777	2946	5539
Skin, non-melanoma	C44	503	1938	3009	4227
Mesothelioma	C45	9	27	31	38
Kaposi sarcoma	C46	6	20	32	58
Autonomic nervous system	C47	2	20	44	158
Soft tissues	C48-49	68	305	448	899
Breast	C50	4024	17942	30942	50083
Female genital organs	C51-58	1368	5719	9699	18527
Cervix uteri	C53	131	557	1042	2776
Corpus uteri	C54	739	3276	5679	10399
Uterus, other	C55	4	9	46	153
Ovary	C56	348	1413	2203	4053
Other female genital	C51-52,C57	146	457	714	1056
Placenta	C58	-	7	15	90
Urinary organs	C64-68	429	1713	2886	4628
Kidney	C64-65	274	1068	1770	2849
Bladder, ureter, urethra	C66-68	155	645	1116	1779
Eye	C69	22	109	192	462
Brain, central nervous system	C70-72	428	1858	3251	6060
Thyroid gland	C73	264	1201	2270	5440
Other endocrine glands	C74-75	9	28	67	125
Ill-defined or unknown	C76,C80	185	425	540	682
Lymphoid and haematopoietic tissue	C81-96	705	2797	4535	7277
Hodgkin lymphoma	C81	56	256	503	1160
Non-Hodgkin lymphoma	C82-85,C96	419	1613	2588	3851
Nodal non-Hodgkin lymphoma		189	935	1583	2386
Multiple myeloma	C90	83	302	406	502
Leukaemia	C91-95	141	603	1007	1724
Acute leukaemia		57	242	426	934
Not included above					
Carcinoma in situ of the breast	D05	330	1479	2402	3272
Cervix uteri, non-invasive neoplasms		854	3938	7983	15451
Borderline tumour of the ovary	D39	136	591	1093	2281
Basal cell carcinoma of the skin		3591	15918	26027	42247
PUNLMP and ca in situ of the bladder		35	64	73	76
Polycythaemia vera		13	59	94	190

Two-thirds of female cancer patients to be diagnosed in 2011–2013 will survive for five years

The relative survival ratio gives the prospects of patient survival when the effect of the competing risks of death have been eliminated. The actual (crude) 5-year probability of dying from cancer¹ in the period 2005–2007 was 37% in males and 34% in females (Table 38). The 5-year probabilities of dying from the other causes of death were 14% in males and 8% in females. Prostate cancer and non-melanoma skin cancer are typically diagnosed at high ages, and therefore the probability of dying from the other causes of death among patients with these was 20% or more.

For estimation of the actual (crude) probabilities and making predictions, the excess mortality attributed to the cancer of the patients was modelled, accounting for sex, age, follow-up time intervals (first and second three month periods, second six month period, and annual intervals from the second to fifth year after the date of diagnosis) and numerical calendar time using a Poisson model². Period analysis³ was used. The prediction base included four three-year periods: 1996–1998, 1999–2001, 2002–2004 and 2005–2007. Predictions were made by extrapolation for the

period 2011–2013. The results were standardised for age by using the age distribution of patients in each sex-site combination in 2000–2007 as the standard. The results for all sites were further standardised for site distribution by using the distributions in 2000–2007 as the sex-specific standards.

Steady increase in relative survival is predicted for all cancer patients combined (Table 38). For prostate cancer patients, the predicted 5-year relative survival is 97%. This influences the relative survival for all sites combined among males. The trend-based optimistic prediction may not be appropriate for prostate cancer, as the activity in early (PSA) diagnostics may change in the future. For some sites, such as lung cancer and stomach cancer, no increase at all is predicted.

The method adopted here has been validated using historical data. However, for the contemporary predictions, past developments do not necessarily guarantee the future. Thus, the predictions must be viewed with some caution.

¹Chiang, C.L.: *Introduction to Stochastic Processes in Biostatistics*. Wiley, New York 1968.

²Dickman, P.W., Sloggett, A., Hills, M. and Hakulinen, T.: *Regression models for relative survival*. *Stat. Med.* 2004;23:51–64.

³Brenner, H. and Hakulinen, T.: *Up-to-date long-term survival curves of patients with cancer by period analysis*. *J. Clin. Oncol.* 2002;20:826–832.

► **Table 38. Age-standardised 1-year and 5-year estimated cause-specific probabilities of death (%) and relative survival ratios (RSR) for patients followed up in 2005-2007; and predicted age-standardised relative survival ratios (%) for patients to be followed up in 2011-2013, by sex and site.**

Cancer site	One year								Five years							
	Males				Females				Males				Females			
	2005-2007		2011-2013		2005-2007		2011-2013		2005-2007		2011-2013		2005-2007		2011-2013	
	Cause of death %		RSR (%)	RSR (%)	Cause of death %		RSR (%)	RSR (%)	Cause of death %		RSR (%)	RSR (%)	Cause of death %		RSR (%)	RSR (%)
	Cancer	Other			Cancer	Other			Cancer	Other			Cancer	Other		
All sites	24	3	76	77	20	2	80	81	37	14	61	63	34	8	65	67
Oesophagus	64	2	35	38	57	2	42	46	87	4	10	12	83	4	15	18
Stomach	52	3	47	47	50	2	50	49	72	8	25	25	70	6	28	28
Colon	21	4	78	81	20	3	80	82	37	16	60	64	36	12	63	67
Rectum, rectosigmoid, anus	18	4	81	83	16	3	83	85	40	14	57	61	37	10	61	65
Liver	68	2	31	34	73	2	26	29	88	5	9	11	92	3	6	8
Gallbladder, bile ducts	66	2	33	34	67	2	32	33	86	5	11	11	87	4	10	11
Pancreas	79	2	19	22	76	1	23	25	95	3	3	3	95	2	4	5
Larynx	15	3	85	85	16	1	84	85	37	11	61	62	39	5	60	61
Lung, trachea	64	2	35	34	59	2	40	40	89	4	8	8	86	3	12	12
Melanoma of the skin	5	3	95	95	3	2	97	97	19	13	80	82	11	10	88	89
Skin, non-melanoma	3	8	97	96	3	7	97	96	10	32	88	87	10	29	89	87
Soft tissues	22	2	78	81	20	2	80	82	43	9	55	60	40	7	58	62
Breast					2	2	98	98					11	8	89	92
Cervix uteri					12	1	87	88					32	5	67	68
Corpus uteri					6	2	93	94					15	9	84	87
Ovary					22	1	78	82					49	5	49	56
Prostate	1	4	99	99					7	20	92	97				
Testis	3	1	97	98					5	3	94	97				
Kidney	25	3	75	76	22	2	78	80	41	11	57	60	37	8	62	65
Bladder, ureter, urethra	13	5	87	87	17	3	83	83	26	19	72	72	33	14	65	65
Central nervous system	31	1	68	71	21	1	78	81	44	5	55	59	31	4	68	71
Thyroid	8	1	92	93	6	1	94	94	11	6	89	90	9	4	91	92
Hodgkin lymphoma	6	1	94	95	6	0	94	95	13	4	87	88	12	2	88	89
Non-Hodgkin lymphoma	23	3	77	82	21	2	79	84	38	11	60	68	35	7	63	71
Multiple myeloma	32	3	67	65	31	2	68	67	68	9	26	24	69	6	27	25
Leukaemia	32	2	67	68	33	2	67	67	51	7	46	47	53	5	45	46
Acute leukaemia	46	1	53	54	45	1	55	56	65	2	33	34	64	2	35	36

Prospects of cancer screening programmes

Population-based screening programmes for cancer aim to reduce cause-specific mortality from the disease and minimise potential harms. There are nowadays three screening programmes in action: for cervical cancer, breast cancer and colorectal cancer – the latter of which is not yet compulsory for the municipalities.

The current predictions on the cancer burden of breast, cervical, and colorectal cancer up to the year 2020 (see separate sections) are based on the development observed or foreseen during 2009. In addition, decisions on potential new programmes in the future and variation in screening organisation as well as in target age groups, coverage and screening technologies may also affect these figures.

Cervical cancer

In consequence of the screening programme for cervical cancer, which started in the 1960s, the incidence and mortality rates of cervical cancer have decreased by approximately 80%. Currently, the national screening programme covers age groups from 30 (or 25) years up to 60 years every 5th year. The low burden of cancer is predicted

to continue in the future years. Due to the aging of the Finnish female population, there will be a need to assess whether women older than 60 years also should be screened.

The number of high-grade cervical pre-cancerous lesions diagnosed annually in the organised programme is currently about 250 cases, whereas approximately 600 cases are diagnosed outside the programme, largely with spontaneous or opportunistic testing. Half of these pre-cancer cases in opportunistic/spontaneous testing are diagnosed at an age below 30 years. Pre-cancer cases at this age are not likely to develop into an invasive disease and may even regress. The entire burden of pre-cancers can be effectively decreased by reducing spontaneous testing, which has been shown to be less effective and to cause more adverse effects than organised screening.¹

The use of Human Papillomavirus (HPV) based screening and vaccination against oncogenic HPV viruses may also affect the burden of cervical cancer and pre-cancers in the future. A prospective randomised study on HPV screening has been on-going in the Finnish screening programme since 2003. According to preliminary results up to 2007, the detection of high-grade

cervical lesions is high in HPV-screening (see Table 40). Treatment of severe pre-cancerous lesions in screening ages may decrease the future incidence of and mortality from invasive cervical cancer. However, detection of pre-cancers with a low grade and low malignant potential also appears high in HPV based screening introducing over-diagnosis and overtreatment.

It is likely that HPV vaccination will not reduce the burden of cervical cancer or of pre-cancers during the period up to 2020. One cannot rule out an impact on pre-cancers among the youngest age groups if a vaccination programme will be started. However, in these age groups the burden of pre-cancers is largely related to opportunistic screening.

Breast cancer

The national biannual breast cancer mammography screening programme started in 1987. The Finnish government has decided to increase the national target group of women aged 50-59 years gradually up to age 69 during a ten year period from 2007 onwards. Coverage of breast cancer screening already started to increase among

women aged 60-69 years in 2007 and it will further increase gaining full coverage by 2017. This is expected to decrease breast cancer mortality, particularly at a rather old age, 70 years or more.

Another consequence of the extended screening age range is that an increasing proportion of breast cancers will be diagnosed and treated within the programme. In 2007, almost 1200 invasive or in situ carcinomas of the breast were diagnosed by the programme, comprising more than a quarter out of the total number in the whole population. When the extended programme will be fully implemented, this proportion could increase to about 40%.

Since 2006 the screening centres have started to use digital mammography instead of the film mammography. This has the potential to increase the detection rates of malignant findings in the programme.

Colorectal cancer

Organised screening for colorectal cancer among Finnish men and women aged 60-69 years has been on-going since 2004. The target population has been randomised

1:1 into screening and control arms during the first years of the program. The screening test is a biannual guaiac-based faecal occult blood (FOB) test with three test cards for six consecutive samples. Test positives are referred for a full colonoscopy. The program was launched in September 2004 among 22 municipalities, and it has expanded widely over regions and age-cohorts. By 2007, the program covered approximately 35% of the target population in Finland, and a further increase in coverage is expected. The coverage will reach 50% within a few years, which was the original target made in order to evaluate the effectiveness of screening in terms of mortality reduction. Based on the experience of the implementation phase, the programme may gain the same legal position as breast and cervical cancer screening within the next 5 years (by 2015).

Prostate cancer

The large scale European prostate cancer screening study (ERSPC) with 162,000 men was completed in 2008 for the first mortality analysis.² The study aimed to evaluate the potential of a new population-based screening programme for prostate

cancer. The Finnish component in ERSPC was the largest one with 80,000 men, of whom 32,000 were randomly sampled to the screening arm.

During the first 9 years of follow-up the ERSPC showed about 20% reduction in prostate cancer mortality in those invited for screening. In those who were actually screened, the reduction was about 30%. About 1400 men would need to be screened, and 48 additional cases of prostate cancer would need to be diagnosed to prevent one death from prostate cancer. The over-diagnosis and lead time were substantial, reducing the quality of life. There are no systematic data available for Finland on the use of the PSA testing, and therefore it is not yet possible to assess the size of over-diagnosis and adverse effects in the whole population approach, nor to predict future trends in frequency of PSA testing.

¹International Agency for Research on Cancer. IARC/WHO *Handbooks of cancer prevention, Vol 10: Cervix cancer screening*. IARC Press, Lyon 2005.

²Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Berenguer, A., Määttä, L., Bangma, C.H., Aus, G., Villers, A., Rebillard, X., van der Kwast, T., Blijenberg, B.G., Moss, S.M., de Koning, H.J. and Auvinen, A., for the ERSPC Investigators: *Screening and prostate-cancer mortality in a randomised European study*. N. Engl. J. Med. 2009;360:1320-1328.

► **Table 39. Organised cervical cancer screening programme in Finland in the invitation years 2006 and 2007. Numbers of women in the target population, and invited and screened.**

	Target population (1 January)	Invited		Screened		
		n	% of population	n	% of population	% of invited
2006 Information registered from 427 municipalities (out of 431).						
5-yearly screening ¹						
20	28822	257	0.9	71	0.2	27.6
25	30015	8253	27.5	4356	14.5	52.8
30 ²	30942	28749	92.9	16445	53.1	57.2
35 ²	29082	28447	97.8	18003	61.9	63.3
40 ²	34590	34157	98.7	23435	67.8	68.6
45 ²	35703	35227	98.7	25232	70.7	71.6
50 ²	37411	37011	98.9	27973	74.8	75.6
55 ²	37177	35596	95.7	27023	72.7	75.9
60 ²	39835	37560	94.3	29318	73.6	78.1
65	32076	4773	14.9	3650	11.4	76.5
Other ages		1432		882		61.6
30-60 ²	244740	236747	96.7	167429	68.4	70.7
All ages		251462		176388		70.1
Risk group screening		19452		14411		74.1
Total		270914		190799		70.4
2007 Information registered from 400 municipalities (out of 416).						
5-yearly screening ¹						
20	27767	274	1.0	81	0.3	29.6
25	30278	8862	29.3	4554	15.0	51.4
30 ²	30126	28508	94.6	16021	53.2	56.2
35 ²	26848	26678	99.4	16405	61.1	61.5
40 ²	33275	33160	99.7	22347	67.2	67.4
45 ²	34655	34535	99.7	24507	70.7	71.0
50 ²	35246	35208	99.9	26070	74.0	74.0
55 ²	37237	36634	98.4	27637	74.2	75.4
60 ²	39296	38286	97.4	29603	75.3	77.3
65	21265	3441	16.2	2548	12.0	74.0
Other ages		1597		658		41.2
30-60 ²	236683	233009	98.4	162590	68.7	69.8
All ages		247183		170431		68.9
Risk group screening		16234		11788		72.6
Total		263417		182219		69.2

¹ Age groups are defined on the basis of the invitation year and the birth year.

² Age groups targeted in the governmental decree on screening (2006).

▶ **TABLE 40. Organised cervical cancer screening programme in Finland in the invitation years 2006 and 2007. Numbers and percentage distribution of primary screening test results, referrals for further investigations, and histological diagnosis of the cervix uteri.**

Screening test	Screened	Referral		Histological diagnosis													
				Invasive carcinoma		Microinvasive carcinoma		Carcinoma in situ		Dysplasia gravis		Dysplasia moderata		Dysplasia levis		Other and normal	
				n	%	n	%	n	%	n	%	n	%	n	%	n	%
2006																	
Information registered from 427 municipalities (out of 431).																	
Pap test ¹	174028	1502	0.86	7	0.00	6	0.00	46	0.03	167	0.10	199	0.11	177	0.10	900	0.52
I	163229	5	0.00	-	-	-	-	-	-	-	-	1	0.00	-	-	4	0.00
II	9376	196	0.11	-	-	-	-	-	-	3	0.00	9	0.01	24	0.01	160	0.09
III	1177	1175	0.68	3	0.00	4	0.00	21	0.01	109	0.06	169	0.10	148	0.09	721	0.41
IV	122	122	0.07	4	0.00	1	0.00	22	0.01	55	0.03	20	0.01	5	0.00	15	0.01
V	4	4	0.00	-	-	1	0.00	3	0.00	-	-	-	-	-	-	-	-
Inadequate	120	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
HPV test	16771	302	1.80	4	0.02	1	0.01	10	0.06	26	0.16	53	0.32	43	0.26	165	0.98
Negative ¹	14971	6	0.04	-	-	-	-	-	-	-	-	-	-	1	0.01	5	0.03
Positive ²	1800	296	1.76	4	0.02	1	0.01	10	0.06	26	0.16	53	0.32	42	0.25	160	0.95
Total	190799	1804	0.95	11	0.01	7	0.00	56	0.03	193	0.10	252	0.13	220	0.12	1065	0.56
2007																	
Information registered from 400 municipalities (out of 416).																	
Pap test ¹	165420	1499	0.91	18	0.01	2	0.00	49	0.03	172	0.10	205	0.12	169	0.10	884	0.53
I	155254	5	0.00	-	-	-	-	-	-	-	-	-	-	1	0.00	4	0.00
II	8899	240	0.15	1	0.00	-	-	-	-	8	0.00	10	0.01	16	0.01	205	0.12
III	1127	1121	0.68	6	0.00	1	0.00	26	0.02	119	0.07	166	0.10	148	0.09	655	0.40
IV	129	129	0.08	8	0.00	1	0.00	22	0.01	45	0.03	29	0.02	4	0.00	20	0.01
V	5	4	0.00	3	0.00	-	-	1	0.00	-	-	-	-	-	-	-	-
Inadequate	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
HPV test	16799	434	2.58	1	0.01	2	0.01	1	0.01	30	0.18	91	0.54	55	0.33	254	1.51
Negative ¹	15021	10	0.06	1	0.01	-	-	-	-	-	-	-	-	-	-	9	0.05
Positive ²	1778	424	2.52	-	-	2	0.01	1	0.01	30	0.18	91	0.54	55	0.33	245	1.46
Total	182219	1933	1.06	19	0.01	4	0.00	50	0.03	202	0.11	296	0.16	224	0.12	1138	0.62

¹ Women with Papanicolaou class I or II or negative HPV test are not referred for further examinations unless repeated cytology or other results are suggestive of cancer.

² Women whose HPV test is positive are referred for further examinations on the basis of cytology or a repeatedly positive result.

▶ **TABLE 41. Organised breast cancer screening programme in Finland in the invitation years 2006 and 2007. Numbers of women in the target population, and invited and screened, and estimated coverage of the biannual programme by age groups.**

2006							Information registered from 431 municipalities (out of 431).	
Age group ¹	Target population (1 January)	Invited		Screened		Biannual programme		
		n	%	n	% of invited	Invited in 2005 or 2006	Coverage % of population	
50-54 ²	196 315	118 455		101 842	86.0	195 025	99.3	
55-59 ²	206 256	85 084		73 743	86.7	205 956	99.9	
60-64	160 643	29 480		25 516	86.6	56 697	35.3	
65-69	138 500	11 791		10 099	85.7	26 008	18.8	
Total	701 714	244 810		211 200	86.3	483 686	68.9	

2007							Information registered from 405 municipalities (out of 416).	
Age group ¹	Target population (1 January)	Invited		Screened		Biannual programme		
		n	%	n	% of invited	Invited in 2006 or 2007	Coverage % of population	
50-54	188 989	111 043		93 989	84.6	188 645	99.8	
55-59	198 101	80 411		68 562	85.3	198 587	100.2	
60-64	174 784	64 987		54 680	84.1	91 220	52.2	
65-69	131 844	21 184		17 202	81.2	35 359	26.8	
Total	693 718	277 625		234 433	84.4	513 811	74.1	

¹ Age groups are defined on the basis of the invitation and the birth year.

² Age groups targeted in the Decree on Public Health (1992).

▶ **TABLE 42. Organised breast cancer screening programme in Finland in the invitation years 2006 and 2007. Numbers and percentage distribution of screened women, referrals to further examinations and to surgery, and histologically confirmed diagnoses by age groups.**

Age group ¹	Screened		Referral		Additional mammogram		Ultra-sonography		Fine-needle biopsy		Surgery		Histological diagnosis										
	n	%	n	%	n	%	n	%	n	%	n	%	Benign		Malignant		Unknown						
2006																		Information registered from 431 municipalities (out of 431).					
50-54 ²	101842	2761	2.71	2096	2.06	2459	2.41	311	0.31	569	0.56	133	0.13	430	0.42	6	0.01						
55-59 ²	73743	1448	1.96	1213	1.64	1241	1.68	177	0.24	391	0.53	54	0.07	334	0.45	3	0.00						
60-64	25516	566	2.22	491	1.92	468	1.83	45	0.18	185	0.73	20	0.08	162	0.63	3	0.01						
65-69	10099	214	2.12	207	2.05	193	1.91	35	0.35	83	0.82	6	0.06	77	0.76	-	-						
Total	211200	4989	2.36	4007	1.90	4361	2.06	568	0.27	1228	0.58	213	0.10	1003	0.47	12	0.01						
2007																		Information registered from 405 municipalities (out of 416).					
50-54	93989	2616	2.78	1851	1.97	2354	2.5	278	0.30	505	0.54	135	0.14	363	0.39	7	0.01						
55-59	68562	1397	2.04	1015	1.48	1234	1.80	130	0.19	366	0.53	50	0.07	314	0.46	2	0.00						
60-64	54680	1079	1.97	858	1.57	976	1.78	91	0.17	363	0.66	42	0.08	318	0.58	3	0.01						
65-69	17202	450	2.62	397	2.31	416	2.42	64	0.37	203	1.18	13	0.08	190	1.10	-	-						
Total	234433	5542	2.36	4121	1.76	4980	2.12	563	0.24	1437	0.61	240	0.10	1185	0.51	12	0.01						

¹ Age groups are defined on the basis of the invitation and the birth year.

² Age groups targeted in the Decree of Public Health (1992).

▶ **TABLE 43. Implementation of colorectal cancer screening using the faecal occult blood test in 2007. MALES.**

Birth year	Target population (31 December)	Invited	Coverage (%)	Attended	Attendance (%)	Positive	Positive out of attenders (%)	Cancers	Cancers out of positives (%)	Adenomas	Adenomas out of positives (%)
2007 The programme covered 175 municipalities (out of 416).											
1941	30156	3727	12	2632	71	113	4.3	7	6.2	50	44.2
1943	26545	4587	17	3081	67	144	4.7	9	6.3	66	45.8
1945	35640	6230	18	3829	61	132	3.4	6	4.5	57	43.2
1947	41286	7236	18	4285	59	141	3.3	4	2.8	66	46.8
Total	133627	21780	16	13827	63	530	3.8	26	4.9	239	45.1

▶ **TABLE 44. Implementation of colorectal cancer screening using the faecal occult blood test in 2007. FEMALES.**

Birth year	Target population (31 December)	Invited	Coverage (%)	Attended	Attendance (%)	Positive	Positive out of attenders (%)	Cancers	Cancers out of positives (%)	Adenomas	Adenomas out of positives (%)
2007 The programme covered 175 municipalities (out of 416).											
1941	33084	3998	12	3188	80	98	3.1	3	3.1	31	31.6
1943	28250	4822	17	3839	80	83	2.2	6	7.2	23	27.7
1945	36714	6201	17	4728	76	99	2.1	3	3.0	29	29.3
1947	42255	7242	17	5478	76	109	2	2	1.8	26	23.9
Total	140303	22263	16	17233	77	389	2.3	14	3.6	109	28.0

Publications

An up-to-date list of publications authored by staff members of the Finnish Cancer Registry or in which data from the Finnish Cancer Registry constitute an essential part can always be found at www.cancerregistry.fi/publications.html. In this booklet we have listed publications from 2007-2009 according to the publication register on November 5, 2009.

2007

van der Aa, M.: Variation in evidence and outcome of cervical cancer in the Netherlands. Studies based on cancer registry data. Doctor's Thesis. Erasmus University Rotterdam. Rotterdam 2007.

Anttila, A.: Cervical cancer screening is effective – the Finnish experience. *Entre Nous*, WHO Regional Office, Copenhagen 2007; No. 64: 26-28.

Anttila, A.: Rintasyöpäseulonnan vaikutus varmistuu. *Savon Sanomat* 7.11.2007 (in Finnish).

Anttila, A. and Nieminen, P.: Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. *Coll. Antropol.* 2007; 31 Suppl. 2: 17-22.

Arbyn, M., Autier, P. and Ferlay, J.: Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. *Ann. Oncol.* 2007; 18: 1423-1425.

Arbyn, M., Raifu, A.O., Autier, P. and Ferlay, J.: Burden of cervical cancer in Europe: estimates for 2004. *Ann. Oncol.* 2007; 18: 1708-1715.

Arndt, V., Kaatsch, P., Steliarova-Foucher, E., Peris-Bonet, R. and Brenner, H.: Up-to-date monitoring of childhood cancer long-term survival in Europe: central nervous system tumours. *Ann. Oncol.* 2007; 18: 1734-1742.

Arndt, V., Lacour, B., Steliarova-Foucher, E., Spix, C., Znaor, A., Pastore, G., Stiller, C. and Brenner, H.: Up-to-date monitoring of childhood cancer long-term survival in Europe: tumours of the sympathetic nervous

system, retinoblastoma, renal and bone tumours, and soft tissue sarcomas. *Ann. Oncol.* 2007; 18: 1722-1733.

Becker, N., Hakama, M. and Nyström, L.: Evaluation of effectiveness of quality-assured mammography screening in Germany: sample size considerations and design options. *Eur. J. Cancer Prev.* 2007; 16: 225-231.

Berrino, F., De Angelis, R., Sant, M., Rosso, S., Lasota, M.B., Coebergh, J.W., Santaquilani, M. and the EUROCARE Working Group: Survival for eight major cancers and all cancers combined for European adults diagnosed 1995-99: results of the EUROCARE-4 study. *Lancet Oncol.* 2007; 8: 773-783.

Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R. and the EUROCARE Working Group: Trends in cervical cancer survival in Europe, 1983-1994: A population-based study. *Gynecol. Oncol.* 2007; 105: 609-619.

Brenner, H., Coebergh, J.W., Parkin, D.M., Izarzugaza, I., Clavel, J., Arndt, V. and Steliarova-Foucher, E.: Up-to-date monitoring of childhood cancer long-term survival in Europe: leukaemias and lymphomas. *Ann. Oncol.* 2007; 18: 1569-1577.

Brenner, H. and Hakulinen, T.: Maximizing the benefits of model-based period analysis of cancer patient survival. *Cancer Epidemiol. Biomarkers Prev.* 2007; 16: 1675-1681.

Brenner, H. and Hakulinen, T.: Model based hybrid analysis of cancer patient survival. *Eur. J. Cancer* 2007; 43: 921-927.

Brenner, H. and Hakulinen, T.: Patients with previous cancer should not be excluded in international comparative cancer survival studies. *Int. J. Cancer* 2007; 121: 2274-2278.

Brenner, H., Steliarova-Foucher, E. and Arndt, V.: Up-to-date monitoring of childhood cancer long-term survival in Europe: methodology and application to all forms of cancer combined. *Ann. Oncol.* 2007; 18: 1561-1568.

Brewster, D.H., Horner, M.-J.D., Rowan, S., Jelfs, P., de Vries, E. and Pukkala, E.: Left-sided excess of invasive cutaneous melanoma in six countries. *Eur. J. Cancer* 2007; 43: 2634-2637.

Brown, L.M., Chen, B.E., Pfeiffer, R.M., Schairer, C., Hall, P., Storm, H., Pukkala, E., Langmark, F., Kajiser, M., Andersson, M., Joensuu, H., Fosså, S.D. and Travis, L.B.: Risk of second non-hematological malignancies among 376,825 breast cancer survivors. *Breast Cancer Res. Treat.* 2007; 106: 439-451.

Cardis, E., Vrijheid, M., Blettner, M., Gilbert, E., Hakama, M., Hill, C., Howe, G., Kaldor, J., Muirhead, C.R., Schubauer-Berigan, M., Yoshimura, T., Bermann, F., Cowper, G., Fix, J., Hacker, C., Heinmiller, B., Marshall, M., Thierry-Chef, I., Utterback, D., Ahn, Y.-O., Amoros, E., Ashmore, P., Auvinen, A., Bae, J.-M., Bernar, J., Biau, A., Combalot, E., Deboodt, P., Diez Sacristan, A., Eklöf, M., Engels, H., Engholm, G., Gulis, G., Habib, R.R., Holan, K., Hyvönen, H., Kerekes, A., Kurtinaitis, J., Malker, H., Martuzzi, M., Mastauskas, A., Monnet, A., Moser, M., Pearce, M.S., Richardson, D.B., Rodriguez-Artalejo, F., Rogel, A., Tardy, H., Telle-Lamberton, M., Turai, I. and Veress, K.: The 15-country collaborative study of cancer risk among radiation workers in the nuclear industry: Estimates of radiation-related cancer risks. *Radiat. Res.* 2007; 167: 396-416.

Castro, F.A., Haimila, K., Pasanen, K., Kaasila, M., Patama, T., Partanen, J., Surcel, H.-M., Pukkala, E. and Lehtinen, M.: Geographic distribution of cervical cancer-associated human leucocyte antigens and

- cervical cancer incidence in Finland. *Int. J. STD AIDS* 2007; 18: 672-679.
- Chaturvedi, A.K., Engels, E.A., Gilbert, E.S., Chen, B.E., Storm, H., Lynch, C.F., Hall, P., Langmark, F., Pukkala, E., Kajiser, M., Andersson, M., Fosså, S.D., Joensuu, H., Boice, J.D., Kleinerman, R.A. and Travis, L.B.: Second cancers among 104 776 survivors of cervical cancer: evaluation of long-term risk. *J. Natl Cancer Inst.* 2007; 99: 1634-1643.
- Engholm, G., Kejs, A.M.T., Gaard, M., Holmberg, L., Hartley, R., Iddenden, R., Møller, H., Sankila, R., Thomson, C.S. and Storm, H.H.: Colorectal cancer survival in the Nordic countries and the United Kingdom: Excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. *Int. J. Cancer* 2007; 121: 1115-1122.
- Engholm, G., Storm, H.H., Ferlay, J., Christensen, N., Bray, E., Ólafsdóttir, E., Pukkala, E. and Talbäck, M.: *NORDCAN: Cancer incidence and mortality in the Nordic countries, Version 3.0.* Association of the Nordic Cancer Registries. Danish Cancer Society, 2007. Electronic publication <http://www.ancre.nu>.
- Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M. and Boyle, P.: Estimates of the cancer incidence and mortality in Europe 2006. *Ann. Oncol.* 2007; 18: 581-592.
- Finnish Cancer Registry – Institute for Statistical and Epidemiological Cancer Research: *Cancer in Finland 2004 and 2005.* Cancer Statistics of the National Research and Development Centre for Welfare and Health. Cancer Society of Finland Publication No. 72. Helsinki 2007. Fosså, S.D., Gilbert, E., Dores, C.M., Chen, J., McGlynn, K.A., Schonfeld, S., Storm, H., Hall, P., Holowaty, E., Andersen, A., Joensuu, H., Andersson, M., Kajiser, M., Gospodarowicz, M., Cohen, R., Pukkala, E. and Travis, L.B.: Noncancer causes of death in survivors of testicular cancer. *J. Natl Cancer Inst.* 2007; 99: 533-544.
- French, K.M., Barnabas, R.V., Lehtinen, M., Kontula, O., Pukkala, E., Dillner, J. and Garnett, G.P.: Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. *Br. J. Cancer* 2007; 96: 514-518.
- Hakama, M.: Pahanlaatuisten kasvainten seulonta väestöstä. *Duodecim* 2007; 123: 157-158 (in Finnish).
- Hakama, M.: Syöpäseulonnat. In: *Syöpätaudit.* Eds. H. Joensuu, P. Roberts, L. Teppo and M. Tenhunen. Kustannus Oy Duodecim, Helsinki 2007, pp. 50-58 (in Finnish).
- Hakama, M., Auvinen, A., Day, N.E. and Miller, A.B.: Sensitivity in cancer screening. *J. Med. Screen.* 2007; 14: 174-177.
- Hakulinen, T.: Munuaisen ja virtsarakon syövän epidemiologia. *Focus Oncol.* 2007; No. 8: 8-13 (in Finnish).
- Hakulinen, T. and Dyba, T.: Hoidon tulosten mittaaminen ja ennusteelliset tekijät. In: *Syöpätaudit.* Eds. H. Joensuu, P. Roberts, L. Teppo and M. Tenhunen. Kustannus Oy Duodecim, Helsinki 2007, pp. 227-240 (in Finnish).
- Hakulinen, T.R. and Dyba, T.A.: Recent developments in relative survival analysis. In: *Outcome Prediction in Cancer.* Eds. A.F.G. Taktak and A.C. Fisher. Elsevier B.V., Amsterdam 2007, pp. 43-64.
- Hakulinen, T., Ovaska, I., Pukkala, E. and Sankila, R.: Finland. In: *Cancer Incidence in Five Continents Vol. IX.* Eds. M.P. Curado, B. Edwards, H.R. Shin, H. Storm, J. Ferlay, M. Heanue and P. Boyle. IARC Scientific Publications No. 160. International Agency for Research on Cancer. Lyon 2007; p. 292.
- Harila-Saari, A.H., Lähteenmäki, P.M., Pukkala, E., Kyyrönen, P., Lanning, M. and Sankila, R.: Scholastic achievements of childhood leukemia patients: A nationwide, register-based study. *J. Clin. Oncol.* 2007; 25: 3518-3524.
- Hinkula, M., Kauppila, A. and Pukkala, E.: Edellisen johdosta. (Sjöberg-Tuominen, L. and Winter, T.: Monilapsisuus ja uskonto. *Duodecim* 2007; 123: 2355). *Duodecim* 2007; 123: 2355 (in Finnish).
- Hinkula, M., Pukkala, E. and Kauppila, A.: Vähintään viisi lasta synnyttäneiden terveys. *Duodecim* 2007; 123: 1057-1064 (in Finnish).
- Hodgson, D.C., Gilbert, E.S., Dores, G.M., Schonfeld, S.J., Lynch, C.F., Storm, H., Hall, P., Langmark, F., Pukkala, E., Andersson, M., Kajiser, M., Joensuu, H., Fosså, S.D. and Travis, L.B.: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. *J. Clin. Oncol.* 2007; 25: 1489-1497.
- Howard, R.A., Gilbert, E.S., Chen, B.E., Hall, P., Storm, H., Pukkala, E., Langmark, F., Kajiser, M., Andersson, M., Joensuu, H., Fosså, S.D. and Travis, L.B.: Leukemia following breast cancer: an international population-based study of 376,825 women. *Breast Cancer Res. Treat.* 2007; 105: 359-368.
- Kalliala, I., Nieminen, P., Dyba, T., Pukkala, E. and Anttila, A.: Cancer free survival after CIN treatment: Comparisons of treatment methods and histology. *Gynecol. Oncol.* 2007; 105: 228-233.
- Karma, A., von Willebrand, E.O., Tommila, P.V., Paetau, A.E., Oskala, P.S. and Immonen, I.J.: Primary intraocular lymphoma: Improving the diagnostic procedure. *Ophthalmology* 2007; 114: 1372-1377.
- Kauppinen, T., Saalo, A., Pukkala, E., Virtanen, S., Karjalainen, A. and Vuorela, R.: Evaluation of a national register on occupational exposure to carcinogens: Effectiveness in the prevention of occupational cancer, and cancer risks among the exposed workers. *Ann. Occup. Hyg.* 2007; 51: 463-470.
- Koskinen, W.J., Brøndbo, K., Mellin Dahlstrand, H., Luostarinen, T., Hakulinen, T., Leivo, I., Moliin, A., Quint, W.G., Røysland, T., Munck-Wikland, E., Mäkitie, A.A., Pyykkö, I., Dillner, J., Vaheri, A. and Aaltonen, L.-M.: Alcohol, smoking and human papillomavirus in laryngeal carcinoma: a Nordic prospective multicenter study. *J. Cancer Res. Clin. Oncol.* 2007; 133: 673-678.
- Kotaniemi-Talonen, L., Nieminen, P., Hakama, M., Seppänen, J., Ikkala, J., Martikainen, J., Tarkkanen, J., Toivonen, T. and Anttila, A.: Significant variation in performance does not reflect the effectiveness of the cervical cancer screening programme in Finland. *Eur. J. Cancer* 2007; 43: 169-174.
- Kumpulainen, S.: Operative treatment of ovarian cancer and borderline tumors in different hospital categories in Finland. Doctor's Thesis. University of Turku. *Ann. Univ. Turkuensis D 776.* Turku 2007.
- Kumpulainen, S., Kuoppala, T., Leminen, A., Komulainen, M., Puistola, U., Sankila, R., Mäkinen, J. and Grénman, S.: Surgical staging, treatment, and follow-up of borderline tumors in different hospital categories: a prospective nationwide survey in Finland. *Acta Obstet. Gynecol. Scand.* 2007; 86: 610-614.
- Kvåle, R., Auvinen, A., Adami, H.-O., Klint, Å., Hernes, E., Møller, B., Pukkala, E., Storm, H.H., Tryggvadóttir, L., Tretli, S., Wahlqvist, R., Weiderpass, E. and Bray, F.: Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. *J. Natl Cancer Inst.* 2007; 99: 1881-1887.
- Lahkola, A., Auvinen, A., Raitanen, J., Schoemaker, M.J., Christensen, H.C., Feychting, M., Johansen, C., Klæboe, L., Lönn, S., Swerdlow, A.J., Tynes, T. and Salminen, T.: Mobile phone use and risk of glioma in 5 North European countries. *Int. J. Cancer* 2007; 120: 1769-1775.
- Lähteenmäki, P.M., Harila-Saari, A., Pukkala, E.I., Kyyrönen, P., Salmi, T.T. and Sankila, R.: Scholastic achievements of children with brain tumors at the end of comprehensive education: A nationwide, register-based study. *Neurology* 2007; 69: 296-305.
- Lambert, P.C., Dickman, P.W., Österlund, P., Andersson, T., Sankila R. and Glimelius, B.: Temporal trends in the proportion cured for cancer of the colon and rectum: A population-based study using data from the Finnish Cancer Registry. *Int. J. Cancer* 2007; 121: 2052-2059.

Publications

- Lehecka, M., Niemelä, M., Seppänen, J., Lehto, H., Koivisto, T., Ronkainen, A., Rinne, J., Sankila, R., Jääskeläinen, J. and Hernesniemi, J.: No long-term excess mortality in 280 patients with ruptured distal anterior cerebral artery aneurysms. *Neurosurgery* 2007; 60: 235-240.
- Lehto, U.-S., Ojanen, M., Dyba, T., Aromaa, A. and Kellokumpu-Lehtinen, P.: Baseline psychosocial predictors of survival in localized melanoma. *J. Psychosom. Res.* 2007; 63: 9-15.
- Lindgren, A., Pukkala, E., Tuomilehto, J. and Nissinen, A.: Incidence of breast cancer among postmenopausal, hypertensive women. *Int. J. Cancer* 2007; 121: 641-644.
- Lundqvist, E., Kaprio, J., Verkasalo, P.K., Pukkala, E., Koskenvuo, M., Söderberg, K.C. and Feychting, M.: Co-twin control and cohort analyses of body mass index and height in relation to breast, prostate, ovarian, corpus uteri, colon and rectal cancer among Swedish and Finnish twins. *Int. J. Cancer* 2007; 121: 810-818.
- Määttänen, L.: Performance of the Finnish prostate cancer screening trial based on process indicators. Doctor's Thesis. University of Tampere. Acta Universitatis Tamperensis No. 1247. Tampere 2007.
- Määttänen, L., Hakama, M., Tammela, T.L.J., Ruutu, M., Ala-Opas, M., Juusela, H., Martikainen, P., Stenman, U.-H. and Auvinen, A.: Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. *Br. J. Cancer* 2007; 96: 56-60.
- Madanat, L.-M.S., Lähtenmäki, P. M., Alin, J. and Salmi, T.T.: The natural history of thyroid function abnormalities after treatment for childhood cancer. *Eur. J. Cancer* 2007; 43: 1161-1170.
- Malila, N., Hakama, M. and Pukkala, E.: A 25-year follow-up of a population screened with faecal occult blood test in Finland. *Acta Oncol.* 2007; 46: 1103-1106.
- Malila, N. and Vertio, H.: Suolistosyövän seulonta soveltuu terveydenhuollon rutiiniohjelmaksi. *Suom. Lääk.-L.* 2007; 62: 3279 (in Finnish).
- Maule, M., Scélo, G., Pastore, G., Brennan, P., Hemminki, K., Tracey, E., Sankila, R., Weiderpass, E., Olsen, J.H., McBride, M.L., Brewster, D. H., Pompe-Kirn, V., Kliewer, E.V., Chia, K.-S., Tonita, J.M., Martos, C., Jonasson, J.G., Merletti, F. and Boffetta, P.: Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. *J. Natl Cancer Inst.* 2007; 99: 790-800.
- Murtola, T.J., Tammela, T.L., Lahtela, J. and Auvinen, A.: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. *Cancer Epidemiol. Biomarkers Prev.* 2007; 16: 2226-2232.
- Murtola, T.J., Tammela, T.L.J., Määttänen, L., Hakama, M. and Auvinen, A.: Prostate cancer risk among users of finasteride and alpha-blockers – A population based case-control study. *Eur. J. Cancer* 2007; 43: 775-781.
- Nagenthiraja, K., Ewertz, M., Engholm, G. and Storm, H.H.: Incidence and mortality of pancreatic cancer in the Nordic countries 1971-2000. *Acta Oncol.* 2007; 46: 1064-1069.
- Nieminen, P. and Anttila, A.: Introducing HPV screening: challenges and fallacies. *Acta Obstet. Gynecol. Scand.* 2007; 86: 1416-1418.
- Nieminen, P., Kotaniemi-Talonen, L., Hakama, M., Tarkkanen, J., Martikainen, J., Toivonen, T., Ikkala, J. and Anttila, A.: Randomized evaluation trial on automation-assisted screening for cervical cancer: Results after 777,000 invitations. *J. Med. Screen.* 2007; 14: 23-28.
- Ojajärvi, A., Partanen, T., Ahlbom, A., Hakulinen, T., Kauppinen, T., Weiderpass, E. and Wesseling, C.: Estimating the relative risk of pancreatic cancer associated with exposure agents in job title data in a hierarchical Bayesian meta-analysis. *Scand. J. Work Environ. Health* 2007; 33: 325-335.
- Pitkäniemi, J., Moltchanova, E., Haapala, L., Harjutsalo, V., Tuomilehto, J. and Hakulinen, T.: Genetic random effects model for family data with long-term survivors: analysis of diabetic nephropathy in type 1 diabetes. *Genet. Epidemiol.* 2007; 31: 697-708.
- Pokhrel, A.: Age-standardization of relative survival ratios for cancer patients. Doctor's Thesis. University of Tampere. Acta Universitatis Tamperensis No. 1278. Tampere 2007.
- Pukkala, E.: Naisten syöpien yleisyysmuutokset. *Kättilölehti* 2007; 112: 172-174 (in Finnish).
- Pukkala, E., Andersen, A., Berglund, G., Gislefoss, R., Gudnason, V., Hallmans, G., Jellum, E., Jousilahti, P., Knekt, P., Koskela, P., Kyörönen, P., Lenner, P., Luostarinen, T., Löve, A., Ögmundsdóttir, H., Stattin, P., Tenkanen, L., Tryggvadóttir, L., Virtamo, J., Wadell, G., Widell, A., Lehtinen, M. and Dillner, J.: Nordic biological specimen banks as basis for studies of cancer causes and control – more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. *Acta Oncol.* 2007; 46: 286-307.
- Pukkala, E. and Härmä, M.: Does shift work cause cancer? *Scand. J. Work Environ. Health* 2007; 33: 321-323.
- Pukkala, E., Patama, T., Engholm, G., Ólafsdóttir, G.H., Bray, F.L., Talbäck, M. and Pasanen, K.: Small-area based map animations of cancer incidence in the Nordic countries, 1971-2003. *Nordic Cancer Union* 2007: <http://astra.cancer.fi/cancermaps/Nordic> .
- Quaglia, A., Capocaccia, R., Micheli, A., Carrani, E., Vercelli, M. and the EUROCARE-3 Working Group: A wide difference in cancer survival between middle aged and elderly patients in Europe. *Int. J. Cancer* 2007; 120: 2196-2201.
- Richiardi, L., Scélo, G., Boffetta, P., Hemminki, K., Pukkala, E., Olsen, J.H., Weiderpass, E., Tracey, E., Brewster, D.H., McBride, M.L., Kliewer, E.V., Tonita, J.M., Pompe-Kirn, V., Chia, K.-S., Jonasson, J.G., Martos, C. and Brennan, P.: Second malignancies among survivors of germ-cell testicular cancer: A pooled analysis between 13 cancer registries. *Int. J. Cancer* 2007; 120: 623-631.
- Riska, A.: Primary fallopian tube carcinoma: Occurrence, risk and prognostic factors. Doctor's Thesis. University of Helsinki. Helsinki 2007.
- Riska, A., Pukkala, E., Scélo, G., Mellemkjær, L., Hemminki, K., Weiderpass, E., McBride, M.L., Pompe-Kirn, V., Tracey, E., Brewster, D.H., Kliewer, E.V., Tonita, J.M., Chia, K.-S., Jonasson, J.G., Martos, C., Boffetta, P. and Brennan, P.: Second primary malignancies in females with primary fallopian tube cancer. *Int. J. Cancer* 2007; 120: 2047-2051.
- Riska, A., Sund, R., Pukkala, E., Gissler, M. and Leminen, A.: Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. *Int. J. Cancer* 2007; 120: 1351-1354.
- Robinson, D., Sankila, R., Hakulinen, T. and Møller, H.: Interpreting international comparisons of cancer survival: The effects of incomplete registration and the presence of death certificate only cases on survival estimates. *Eur. J. Cancer* 2007; 43: 909-913.
- Roobol, M.J., Zappa, M., Määttänen, L. and Ciatto, S.: The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). *Prostate* 2007; 67: 439-446.
- Sankila, R.: Syövän esiintyminen Pohjois-Suomessa. In: *Elämän puolesta 50 vuotta*. Ed. K. Kiviniitty. Pohjois-Suomen Syöpäyhdistys r.y. Oulu 2007; pp. 192-199. (in Finnish).
- Sankila, R., Pukkala, E., Dyba, T. and Hakulinen, T.: Cancer som sjukdom. Cancerincidens, prognoser för cancerpatienter, och cancerdödlighet. *Finska Läkaresällsk. Handl.* 2007; 167: No. 2: 6-16 (in Swedish).
- Sankila, R., Teppo, L. and Vainio, H.: Syövän yleisyys, syyt ja ehkäisy. In: *Syöpätaudit*. Eds. H. Joensuu, P. Roberts, L. Teppo and M. Tenhunen. Kustannus Oy Duodecim, Helsinki 2007, pp. 34-49 (in Finnish).

- Scélo, G., Boffetta, P., Autier, P., Hemminki, K., Pukkala, E., Olsen, J.H., Weiderpass, E., Tracey, E., Brewster, D.H., McBride, M.L., Kliewer, E.V., Tonita, J.M., Pompe-Kirn, V., Chia, K.-S., Jonasson, J.G., Martos, C., Giblin, M. and Brennan, P.: Associations between ocular melanoma and other primary cancers: An international population-based study. *Int. J. Cancer* 2007; 120: 152-159.
- Scélo, G., Boffetta, P., Corbex, M., Chia, K.-S., Hemminki, K., Friis, S., Pukkala, E., Weiderpass, E., McBride, M.L., Tracey, E., Brewster, D.H., Pompe-Kirn, V., Kliewer, E.V., Tonita, J.M., Martos, C., Jonasson, J.G. and Brennan, P.: Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. *Cancer Causes Control* 2007; 18: 269-278.
- Soerjomataram, I., de Vries, E., Pukkala, E. and Coebergh, J.W.: Excess of cancers in Europe: A study of eleven major cancers amenable to lifestyle change. *Int. J. Cancer* 2007; 120: 1336-1343.
- Steliarova-Foucher, E., Arndt, V., Parkin, D.M., Berrino, F. and Brenner, H.: Timely disclosure of progress in childhood cancer survival by 'period' analysis in the Automated Childhood Cancer Information System. *Ann. Oncol.* 2007; 18: 1554-1560.
- Straif, K., Baan, R., Grosse, Y., Secretan, B., El Ghissassi, F., Bouvard, V., Altieri, A., Benbrahim-Tallaa, L., Cagliano, V. on behalf of the WHO International Agency for Research on Cancer Monograph Working Group: Carcinogenicity of shift-work, painting and fire-fighting. *Lancet Oncology* 2007; 8: 1065-1066.
- Svendsen, A.L., Feychting, M., Klæboe, L., Langmark, F. and Schüz, J.: Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study. *J. Pediatr.* 2007; 151: 548-550.
- Taskila, T.: Cancer survivors at work: Work-related problems and factors associated with their employment, work ability and social support from the work community. Doctor's Thesis. University of Helsinki. Finnish Institute of Occupational Health, People and Work Research Reports 80, Tampere 2007.
- Tedeschi, R., Bloigu, A., Ögmundsdóttir, H.M., Marus, A., Dillner, J., Depaoli, P., Gudnadóttir, M., Koskela, P., Pukkala, E., Lehtinen, T. and Lehtinen, M.: Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. *Am. J. Epidemiol.* 2007; 165: 134-137.
- Timonen, T., Näyhä, S., Koskela, T. and Pukkala, E.: Are sunlight deprivation and influenza epidemics associated with the onset of acute leukemia? *Haematologica* 2007; 92: 1553-1556.
- Tuohimaa, P., Pukkala, E., Scélo, G., Olsen, J.H., Brewster, D.H., Hemminki, K., Tracey, E., Weiderpass, E., Kliewer, E.V., Pompe-Kirn, V., McBride, M.L., Martos, C., Chia, K.-S., Tonita, J.M., Jonasson, J.G., Boffetta, P. and Brennan, P.: Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation. *Eur. J. Cancer* 2007; 43: 1701-1712.
- Tuohimaa, P., Tenkanen, L., Syväla, H., Lumme, S., Hakulinen, T., Dillner, J. and Hakama, M.: Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. *Cancer Epidemiol. Biomarkers Prev.* 2007; 16: 302-307.
- Verdecchia, A., Francisci, S., Brenner, H., Gatta, G., Micheli, A., Mangone, L., Kunkler, I. and the EURO-CARE-4 Working Group: Recent cancer survival in Europe: a 2000-02 period analysis of EURO-CARE-4 data. *Lancet Oncol.* 2007; 8: 784-796.
- Virtanen, A., Pukkala, E. and Auvinen, A.: Angiosarcoma after radiotherapy: a cohort study of 332 163 Finnish cancer patients. *Br. J. Cancer* 2007; 97: 115-117.
- Vrijheid, M., Cardis, E., Blettner, M., Gilbert, E., Hakama, M., Hill, C., Howe, G., Kaldor, J., Muirhead, C.R., Schubauer-Berigan, M., Yoshimura, T., Ahn, Y.-O., Ashmore, P., Auvinen, A., Bae, J.-M., Engels, H., Gulis, G., Habib, R.R., Hosoda, Y., Kurtinaitis, J., Malke, H., Moser, M., Rodriguez-Artalejo, F., Rogel, A., Tardy, H., Telle-Lamberton, M., Turai, I., Usel, M. and Veress, K.: The 15-country collaborative study of cancer risk among radiation workers in the nuclear industry: Design, epidemiological methods and descriptive results. *Radiat. Res.* 2007; 167: 361-379.
- van der Aa, M.A., Pukkala, E., Coebergh, J.W.W., Anttila, A. and Siesling, S.: Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. *Int. J. Cancer* 2008; 122: 1854-1858.
- van der Aa, M.A., Siesling, S., Louwman, W.J., Visser, O., Pukkala, E. and Coebergh, J.W.W.: Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989-2003. *Eur. J. Cancer Prev.* 2008; 17: 453-459.
- Åberg, F., Pukkala, E., Sankila, R., Höckerstedt, K. and Isoniemi, H.: Risk of malignant neoplasms after liver transplantation: A population-based study. *Liver Transpl.* 2008; 14: 1428-1436.
- Adolfsson, J., Hellborg, H., Patama, T. and Pukkala, E.: Small-area based map animations of cancer incidence in the Stockholm-Gotland health care region in Sweden, 1971-2006. *Oncologic Centre Stockholm-Gotland and Finnish Cancer Registry* 2008: <http://astra.cancer.fi/cancermaps/stoc/>.
- Ahonen, H. and Pukkala, E.: Finland. In: *Atlas of Cancer Mortality in the European Union and the European Economic Area 1993-1997*. Eds. P. Boyle and M. Smans. IARC Scientific Publications No. 159. International Agency for Research on Cancer. Lyon 2008, pp. 33-34.
- Anttila, A.: Monitoring and evaluating the impact of HPV vaccination. In: *Guidance for the introduction of HPV vaccines in EU countries*. European Centre for Disease Prevention and Control. Stockholm 2008, pp. 44-49.
- Anttila, A., Ronco, G., Lynge, E., Fender, M., Arbyn, M., Baldauf, J.-J., Patnick, J., McGoogan, E., Hakama, M. and Miller, A.B.: Epidemiological guidelines for quality assurance in cervical screening. In: *European guidelines for quality assurance in cervical cancer screening*. Eds. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan, H.G. Wiener, A. Herbert, J. Daniel and L. von Karsa. European Commission. European Communities, Brussels 2008, pp. 11-68.
- Anttila, A. and Sarkeala, T. Kaksi vuosikymmentä rintasyövän seulontaa Suomessa. Suomen Rintasyöpäryhmä, News 1/2008 (in Finnish).
- Anttila, A., Sarkeala, T., Hakulinen, T. and Heinävaara, S.: Impacts of the Finnish service screening programme on breast cancer rates. *BMC Public Health* 2008; 8: 38 doi:10.1186/1471-2458-8-38, <http://www.biomedcentral.com/1471-2458/8/38>.
- Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., Wiener, H.G., Herbert, A., Daniel, J. and von Karsa, L. (Eds): *European guidelines for quality assurance in cervical cancer screening*. European Commission. European Communities, Brussels 2008.
- Baili, P., Micheli, A., De Angelis, R., Weir, H.K., Francisci, S., Santaquilani, M., Hakulinen, T., Quaresma, M., Coleman, M.P. and the CONCORD Working Group: Life tables for world-wide comparison of relative survival for cancer (CONCORD study). *Tumori* 2008; 94: 658-668.
- Bosetti, C., Levi, F., Ferlay, J., Caravello, W., Lucchini, F., Bertuccio, P., Negri, E. and La Vecchia, C.: Trends in oesophageal cancer incidence and mortality in Europe. *Int. J. Cancer* 2008; 122: 1118-1129.
- Brenner, H. and Hakulinen, T.: Period versus cohort modeling of up-to-date cancer survival. *Int. J. Cancer* 2008; 122: 898-904.

2008

- Chuang, S.-C., Hashibe, M., Scélo, G., Brewster, D.H., Pukkala, E., Friis, S., Tracey, E., Weiderpass, E., Hemminki, K., Tamaro, S., Chia, K.-S., Pompe-Kirn, V., Kliewer, E.V., Tonita, J.M., Martos, C., Jonasson, J.G., Dresler, C.M., Boffetta, P. and Brennan, P.: Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. *Cancer Epidemiol. Biomarker Prev.* 2008; 17: 1543-1549.
- Chuang, S.-C., Scélo, G., Tonita, J.M., Tamaro, S., Jonasson, J.G., Kliewer, E.V., Hemminki, K., Weiderpass, E., Pukkala, E., Tracey, E., Friis, S., Pompe-Kirn, V., Brewster, D.H., Martos, C., Chia, K.-S., Boffetta, P., Brennan, P. and Hashibe, M.: Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. *Int. J. Cancer* 2008; 123: 2390-2396.
- Coleman, M.P., Quaresma, M., Berrino, F., Lutz, J.-M., De Angelis, R., Capocaccia, R., Baili, P., Rachet, B., Gatta, G., Hakulinen, T., Micheli, A., Sant, M., Weir, H.K., Elwood, J.M., Tsukuma, H., Koifman, S., Azevedo e Silva, G., Francisci, S., Santaquilani, M., Verdecchia, A., Storm, H.H., Young, J.L. and the CONCORD Working Group: Cancer Survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol.* 2008; 9: 730-756.
- Dillner, L., Pagliusi, S., Bray, F., Lorincz, A., Kjær, S.K., Anttila, A., Iversen, O.E., Dillner, J., Lehtinen, M. and Paavonen, J.: Strengthening prevention programs to eliminate cervical cancer in the Nordic countries. *Acta Obstet. Gynecol. Scand.* 2008; 87: 489-498.
- Dyba, T. and Hakulinen, T.: Do cancer predictions work? *Eur. J. Cancer* 2008; 44: 448-453.
- Endogenous Hormones and Prostate Cancer Collaborative Group: Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. *J. Natl Cancer Inst.* 2008; 100: 170-183.
- Engholm, G., Ferlay, J., Christensen, N., Bray, F., Gjerstorff, M.L., Klint, Å., Kjørtlum, J.E., Ólafsdóttir, E., Pukkala, E. and Storm, H.H.: NORDCAN: Cancer incidence, mortality and prevalence in the Nordic countries, Version 3.3. Association of Nordic Cancer Registries. Danish Cancer Society 2008: <http://www.ancre.nu> <<http://www.ancre.nu/>> .
- Engholm, G., Storm, H.H., Ferlay, J., Christensen, N., Bray, F., Ólafsdóttir, E., Pukkala, E. and Klint, Å.: NORDCAN: Cancer incidence, mortality and prevalence in the Nordic countries, Version 3.1. Association of Nordic Cancer Registries. Danish Cancer Society 2008: www.ancre.nu.
- Finne, P., Auvinen, A., Määttä, L., Tammela, T. L., Ruutu, M., Juusela, H., Martikainen, P., Hakama, M. and Stenman, U.-H.: Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <math><3.0\ \mu\text{g per liter}</math>. *Eur. Urol.* 2008; 54: 362-370.
- Gondos, A., Bray, F., Brewster, D.H., Coebergh, J.W.W., Hakulinen, T., Janssen-Heijnen, M.L.G., Kurtinaitis, J., Brenner, H. and the EUNICE Survival Working Group: Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries. *Eur. J. Cancer* 2008; 44: 1463-1475.
- Gouveia, J., Coleman, M.P., Haward, R., Zanetti, R., Hakama, M., Borrás, J.M., Primic-Žakelj, M., de Koning, H.J. and Travado, L.: Improving cancer control in the European Union: Conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. *Eur. J. Cancer* 2008; 44: 1457-1462.
- Grce, M., Davies, P., Arbyn, M., Anttila, A., Grubičić, G., Kardum-Skelin, I., Herbert, A., Jordan, J. and von Karsa, L.: Report on the 2007 International Workshop on Human Papillomaviruses and consensus recommendations for cervical cancer prevention. *Cent. Eur. J. Public Health* 2008; 16: 38-40.
- Hakama, M. and Auvinen, A.: Cancer screening. In: *International Encyclopedia of Public Health*. Eds. K. Heggenhougen and S. Quah. San Diego, Academic Press 2008; pp. 464-480.
- Hakama, M., Coleman, M.P., Alexe, D.-M. and Auvinen, A.: Cancer screening: Evidence and practice in Europe 2008. *Eur. J. Cancer* 2008; 44: 1404-1413.
- Hakama, M., Coleman, M.P., Alexe, D.-M. and Auvinen, A.: Cancer screening. In: *Responding to the challenge of cancer in Europe*. Eds. M.P. Coleman, D.-M. Alexe, T. Albrecht and M. McKee, Institute of Public Health of the Republic of Slovenia. Ljubljana 2008, pp. 69-92 (<http://www.euro.who.int/Document/E91137.pdf>).
- Hakama, M. and Malila, N.: Millainen on hyvä seulonta? *Duodecim* 2008; 124: 2193-2199 (in Finnish).
- Hakulinen, T.: Rintasyövän epidemiologia. *Focus Oncol.* 2008; No. 9: 8-12 (in Finnish).
- Hakulinen, T. and Dyba, T.: Cancer survival. In: *International Encyclopedia of Public Health*. Eds. K. Heggenhougen and S. Quah. San Diego, Academic Press 2008; pp. 480-493.
- Hassler, S., Soininen, L., Sjölander, P. and Pukkala, E.: Cancer among the Sami – A review on the Norwegian, Swedish and Finnish Sami populations. *Int. J. Circumpolar Health* 2008; 67: 421-432.
- Hemminki, E., Kyyrönen, P. and Pukkala, E.: Postmenopausal hormone drugs and breast and colon cancer: Nordic countries 1995-2005. *Maturitas* 2008; 61: 299-304.
- Héry, C., Ferlay, J., Boniol, M. and Autier, P.: Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. *Ann. Oncol.* 2008; 19: 1009-1018.
- Héry, C., Ferlay, J., Boniol, M. and Autier, P.: Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. *Ann. Oncol.* 2008; 19: 1187-1194.
- Holl, K., Lundin, E., Kaasila, M., Grankvist, K., Afanasyeva, Y., Hallmans, G., Lehtinen, M., Pukkala, E., Surcel, H.M., Toniolo, P., Zeleniuch-Jacquotte, A., Koskela, P. and Lukanova, A.: Effect of long-term storage on hormone measurements in samples from pregnant women: The experience of the Finnish Maternity Cohort. *Acta Oncol.* 2008; 47: 406-412.
- Holl, K., Surcel, H.M., Koskela, P., Dillner, J., Hallmans, G., Wadell, G., Kaasila, M., Ólafsdóttir, G.H., Ögmundsdóttir, H.M., Pukkala, E., Stattin, P. and Lehtinen, M.: Maternal Epstein-Barr virus and cytomegalovirus infections and risk of testicular cancer in the offspring: a nested case-control study. *APMIS.* 2008; 116: 816-822.
- Howard, R., Gilbert, E., Lynch, C.F., Hall, P., Storm, H., Holowaty, E., Pukkala, E., Langmark, F., Kaijser, M., Andersson, M., Joensuu, H., Fosså, S.D., Allan, J.M. and Travis, L.B.: Risk of leukemia among survivors of testicular cancer: A population-based study of 42,722 patients. *Ann. Epidemiol.* 2008; 18: 416-421.
- Hu, G., Tuomilehto, J., Pukkala, E., Hakulinen, T., Antikainen, R., Vartiainen, E. and Jousilahti, P.: Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. *Hepatology* 2008; 48: 129-136.
- Hu, G., Tuomilehto, J., Pukkala, E., Hakulinen, T., Antikainen, R., Vartiainen, E. and Jousilahti, P.: Kahvi saattaa suojata maksasyövältä. *Duodecim* 2008; 124: 1339. (Published in *Hepatology* 2008; 48: 129-136. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer.)
- Jordan J., Arbyn M., Martin-Hirsch P., Schenck U., Baldauf J.J., Da Silva D., Anttila A., Nieminen P. and Prendiville W.: European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. *Cytopathology* 2008; 19: 342-354.

- Jordan, J., Martin-Hirsch, P., Arbyn, M., Schenck, U., Baldauf, J.-J., Da Silva, D., Anttila, A., Nieminen, P. and Prendiville, W.: Management of abnormal cervical cytology. In: European guidelines for quality assurance in cervical cancer screening. Eds. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan, H.G. Wiener, A. Herbert, J. Daniel and L. von Karsa. European Commission. European Communities, Brussels 2008, pp. 191-230.
- Karim-Kos, H.E., de Vries, E., Soerjomataram, I., Lemmens, V., Siesling, S. and Coebergh, J.W.W.: Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. *Eur. J. Cancer* 2008; 44: 1345-1389.
- von Karsa, L., Anttila, A., Ronco, G., Ponti, A., Malila, N., Arbyn, M., Segnan, N., Castillo-Beltran, M., Boniol, M., Ferlay, J., Hery, C., Sauvaget, C., Voti, L. and Autier, P.: Cancer screening in the European Union. Report on the implementation of the Council Recommendation on cancer screening. First report. International Agency for Research on Cancer. Directorate-General for Health & Consumers. European Communities, Luxembourg 2008.
- Kilkkinen, A., Knekt, P., Heliövaara, M., Rissanen, H., Marniemi, J., Hakulinen, T. and Aromaa, A.: Vitamin D status and the risk of lung cancer: A cohort study in Finland. *Cancer Epidemiol. Biomarkers Prev.* 2008; 17: 3274-3278.
- Kilkkinen, A., Rissanen, H., Klaukka, T., Pukkala, E., Heliövaara, M., Huovinen, P., Männistö, S., Aromaa, A. and Knekt, P.: Antibiotic use predicts an increased risk of cancer. *Int. J. Cancer* 2008; 123: 2152-2155.
- Kotaniemi-Talonen, L., Anttila, A., Malila, N., Tarkkanen, J., Laurila, P., Hakama, M. and Nieminen, P.: Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. *Eur. J. Cancer* 2008; 44: 565-571.
- Kotaniemi-Talonen, L., Malila, N., Nieminen, P., Anttila, A., Tarkkanen, J., Laurila, P. and Hakama, M.: Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening. *Int. J. Cancer* 2008; 123: 2902-2906.
- Kuoppala, J., Lamminpää, A. and Pukkala, E.: Statins and cancer: A systematic review and meta-analysis. *Eur. J. Cancer* 2008; 44: 2122-2132.
- Laakkonen, A.: Occupational exposure to organic dusts and cancer among Finnish workers: special emphasis on the food industry and agriculture. Doctor's Thesis. University of Tampere. Finnish Institute of Occupational Health, People and Work Research Reports 84. Tampere 2008.
- Laakkonen, A. and Pukkala, E.: Cancer incidence among Finnish farmers, 1995-2005. *Scand. J. Work Environ. Health* 2008; 34: 73-79.
- Laakkonen, A., Verkasalo, P.K., Nevalainen, A., Kauppinen, T., Kyyrönen, P. and Pukkala, E.I.: Moulds, bacteria and cancer among Finns: an occupational cohort study. *Occup. Environ. Med.* 2008; 65: 489-493.
- Laakso, A., Dashti, R., Seppänen, J., Juvela, S., Väärt, K., Niemelä, M., Sankila, R. and Hernesniemi, J.A.: Long-term excess mortality in 623 patients with brain arteriovenous malformations. *Neurosurgery* 2008; 63: 244-255.
- Läärä, E., Luostarinen, T., Hakulinen, T., Lyytikäinen, O., Sarna, S., Virtala, A.-M., Riihimäki, H. and Hakama, M. (Eds): Epidemiologian englanti-suomi-englanti-sanasto. Suomen Epidemiologian Seura ja Duodecim 2008; <http://www.finepi.org/files/englantisuomi.pdf>, <http://www.finepi.org/files/suomienglanti.pdf>.
- Lahkola, A., Salminen, T., Raitanen, J., Heinävaara, S., Schoemaker, M.J., Collatz Christensen, H., Feychting, M., Johansen, C., Klæboe, L., Lönn, S., Swerdlow, A.J., Tynes, T. and Auvinen, A.: Meningioma and mobile phone use – a collaborative case-control study in five North European countries. *Int. J. Epidemiol.* 2008; 37: 1304-1313.
- Lähteenmäki, P.M., Sankila, R., Pukkala, E., Kyyrönen, P. and Harila-Saari, A.: Scholastic achievement of children with lymphoma or Wilms tumor at the end of comprehensive education – A nationwide, register-based study. *Int. J. Cancer* 2008; 123: 2401-2405.
- Lahti, T.A., Partonen, T., Kyyrönen, P., Kauppinen, T. and Pukkala, E.: Night-time work predisposes to non-Hodgkin lymphoma. *Int. J. Cancer* 2008; 123: 2148-2151.
- Lampi, P., Tuomisto, J., Hakulinen, T. and Pukkala, E.: Follow-up study of cancer incidence after chlorophenol exposure in a community in southern Finland. *Scand. J. Work Environ. Health* 2008; 34: 230-233.
- Larjavaara, S., Haapasalo, H., Sankila, R., Helén, P. and Auvinen, A.: Is the incidence of meningiomas underestimated? A regional survey. *Br. J. Cancer* 2008; 99: 182-184.
- Laudico, A.V., Lumague, M.R.M., Mapua, C.A., Redaniel, M.T.M., Patama, T. and Pukkala E.: Small-area based map animations of cancer incidence in Metro Manila and Rizal Province in the Philippines, 1980-2002. Philippine Cancer Society – Manila Cancer Registry; Department of Health – Rizal Cancer Registry, Philippines; and Finnish Cancer Registry, Helsinki, Finland, 2008: <http://astra.cancer.fi/cancermaps/philippines>.
- Leinonen, M., Kotaniemi-Talonen, L., Anttila, A., Dyba, T., Tarkkanen, J. and Nieminen, P.: Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. *Int. J. Cancer* 2008; 123: 1344-1349.
- Lohi, J., Kyyrönen, P., Kauppinen, T., Kujala, V. and Pukkala, E.: Occupational exposure to solvents and gasoline and risk of cancers in the urinary tract among Finnish workers. *Am. J. Ind. Med.* 2008; 51: 668-672.
- Lyytikäinen, E., Kaasila, M., Koskela, P., Lehtinen, M., Patama, T., Pukkala, E., Tasanen, K., Surcel, H.-M. and Paavonen, J.: Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. *Sex Transm. Infect.* 2008; 84: 19-22.
- Madanat, L.-M.S., Lähteenmäki, P.M., Hurme, S., Dyba, T., Salmi, T.T. and Sankila, R.: Hypothyroidism among pediatric cancer patients: A nationwide, registry-based study. *Int. J. Cancer* 2008; 122: 1868-1872.
- Madanat, L.-M.S., Malila, N., Dyba, T., Hakulinen, T., Sankila, R., Boice, J.D., Jr. and Lähteenmäki, P. M.: Probability of parenthood after early onset cancer: A population-based study. *Int. J. Cancer* 2008; 123: 2891-2898.
- Mäkinen, T.: The Finnish population-based prostate cancer screening trial. Doctor's Thesis. University of Tampere. Acta Universitatis Tamperensis 1352. Tampere 2008.
- Mäkinen, T., Karhunen, P., Aro, J., Lahtela, J., Määttä, L. and Auvinen, A.: Assessment of causes of death in a prostate cancer screening trial. *Int. J. Cancer* 2008; 122: 413-417.
- Mäkitie, A.A., Lundberg, M., Salmela, K., Kyllönen, L. and Pukkala, E.: Head and neck cancer in renal transplant patients in Finland. *Acta Oto-Laryngol.* 2008; 128: 1255-1258.
- Malila, N. (ed.): Suolistosyövän seulontaohjelman käynnistäminen Suomessa vuosina 2004-2006. Suomen Syöpäyhdistyksen julkaisu nro 73. Syöpäjärjestöt. Helsinki 2008 (in Finnish).
- Malila, N., Oivanen, T. and Hakama, M.: Implementation of colorectal cancer screening in Finland: Experiences from the first three years of a public health programme. *Z. Gastroenterol.* 2008; 46: Suppl. 1: S25-S28.
- Malila, N., Oivanen, T., Malminiemi, O. and Hakama, M.: Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. *Br. Med. J.* 2008; 337:a2261. doi:10.1136/bmj.a2261.

- Maule, M., Scélo, G., Pastore, G., Brennan, P., Hemminki, K., Pukkala, E., Weiderpass, E., Olsen, J.H., Tracey, E., McBride, M.L., Brewster, D.H., Pompe-Kim, V., Tonita, J.M., Kliewer, E.V., Chia, K.S., Jonasson, J.G., Martos, C., Magnani, C. and Boffetta, P.: Risk of second malignant neoplasms after childhood central nervous system malignant tumours: An international study. *Eur. J. Cancer* 2008; 44: 830-839.
- Mursu, J., Nurmi, T., Tuomainen, T.-P., Salonen, J.T., Pukkala, E. and Voutilainen, S.: Intake of flavonoids and risk of cancer in Finnish men: The Kuopio Ischaemic Heart Disease Risk Factor Study. *Int. J. Cancer* 2008; 123: 660-663.
- Murtola, T., Tammela, T.L.J., Lahtela, J. and Auvinen, A.: Antidiabetic medication and prostate cancer risk: A population-based case-control study. *Am. J. Epidemiol.* 2008; 168: 925-931.
- Muwonge, R.: Evaluation of visual screening in prevention of cervical and oral cancer in India. Doctor's Thesis. University of Tampere. *Acta Universitatis Tamperensis* 1345. Tampere 2008.
- Muwonge, R., Ramadas, K., Sankila, R., Thara, S., Thomas, G., Vinoda, J. and Sankaranarayanan, R.: Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: A nested case-control design using incident cancer cases. *Oral Oncol.* 2008; 44: 446-454.
- Patama, T., Engholm, G., Klint, Å., Larønningen, S., Ólafsdóttir, G.H. and Pukkala, E.: Small-area based map animations of cancer mortality in the Nordic countries, 1971-2003. *Nordic Cancer Union* 2008: <http://astra.cancer.fi/cancermaps/Nordic/mort>.
- Patja, K., Sund, R., Kaski, M. and Pukkala, E.: Cancer incidence among persons with Prader-Willi syndrome in Finland. *Int. J. Disabil. Hum. Dev.* 2008; 7: 69-72.
- Pednekar, M.S., Gupta, P.C., Hebert, J.R. and Hakama, M.: Joint effects of tobacco use and body mass on all-cause mortality in Mumbai, India: Results from a population-based cohort study. *Am. J. Epidemiol.* 2008; 167: 330-340.
- Pednekar, M.S., Hakama, M., Hebert, J.R. and Gupta, P.C.: Association of body mass index with all-cause and cause-specific mortality: findings from a prospective cohort study in Mumbai (Bombay), India. *Int. J. Epidemiol.* 2008; 37: 524-535.
- Pokhrel, A., Dyba, T. and Hakulinen, T.: A Greenwood formula for standard error of the age-standardised relative survival ratio. *Eur. J. Cancer* 2008; 44: 441-447.
- Pokhrel, A. and Hakulinen, T.: How to interpret the relative survival ratios of cancer patients. *Eur. J. Cancer* 2008; 44: 2661-2667.
- Pukkala, E. and Patama, T.: Small-area based map animations of cancer incidence in Finland, 1957-2006. *Finnish Cancer Registry* 2008: <http://astra.cancer.fi/cancermaps/suomi19572006/en/index.html>.
- Redaniel, M.T.M., Laudico, A.V., Lumague, M.R.M., Mapua, C.A., Patama, T. and Pukkala, E.: Cancer in the Philippines. Vol. IV Part 1 – Cancer Incidence 1998-2002. *Philippine Cancer Society, Manila* 2008.
- Ronco, G., von Karsa, L. and Anttila, A.: Key performance indicators. In: *European guidelines for quality assurance in cervical cancer screening*. Eds. M. Arbyn, A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan, H.G. Wiener, A. Herbert, J. Daniel and L. von Karsa. *European Commission. European Communities, Brussels* 2008, pp. 231-242.
- Sampo, M.M., Tarkkanen, M., Kivioja, A.H., Taskinen, M.H., Sankila, R. and Böbling, T.O.: Osteosarcoma in Finland from 1971 through 1990. A nationwide study of epidemiology and outcome. *Acta Orthop.* 2008; 79: 861-866.
- Sankila, R., Merikivi, M., Mustonen, S. and Ovaska, I. (Eds.) *Kansainvälinen syöpäsairauksien luokittelu, kolmas laitos, ensimmäinen suomenkielinen laitos. Suomen Syöpäyhdistyksen julkaisu nro 75, Helsinki, 2008.* (A Finnish edition of International classification of diseases for oncology, Third Edition (ICD-O-3). Eds. A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D.M. Parkin and S. Whelan. *WHO, Geneva*, 2000).
- Sarkeala, T.: Performance and effectiveness of organised breast cancer screening in Finland. Doctor's Thesis. University of Tampere. *Acta Universitatis Tamperensis* 1309. Tampere 2008.
- Sarkeala, T. and Anttila, A.: Väestöseulonta vähentää rintasyöpäkuolleisuutta Suomessa. *Suom. Lääk.-L.* 2008; 63: 4305-4309 (in Finnish with English summary).
- Sarkeala, T., Heinävaara, S. and Anttila, A.: Breast cancer mortality with varying invitation policies in organised mammography. *Br. J. Cancer* 2008; 98: 641-645.
- Sarkeala, T., Heinävaara, S. and Anttila, A.: Organised mammography screening reduces breast cancer mortality: A cohort study from Finland. *Int. J. Cancer* 2008; 122: 614-619.
- Seppä, K.: Vuoden Leo Törnqvist –palkittu pro gradu – tutkielma: Suomalaisten paksusuolisyöpäpotilaiden ennusteen analyysi suhteellisen elossäpösymisen ja syykohtaisen kuolleisuuden malleilla käyttäen suurimman uskottavuuden ja Bayesin menetelmiä. *Suomen Tilastoseuran Vuosikirja* 2007. Helsinki 2008, pp. 98-105.
- Seppänen, J.: Mammographic mass-screening and future breast cancer burden in Finland. Doctor's Thesis. University of Helsinki. *Publications of Public Health M* 196:2008. Helsinki 2008.
- Seppänen, J., Heinävaara, S. and Hakulinen, T.: Predicting impacts of mass-screening policy changes on breast cancer mortality. *Stat. Med.* 2008; 27: 5235-5251.
- Seppänen, J., Heinävaara, S., Holli, K. and Hakulinen, T.: Comparison of cancer registry and clinical data as predictors for breast cancer survival. *Cancer Causes Control* 2008; 19: 1299-1304.
- Seppänen, J. and Klaukka, T.: Syöpälääkkeiden myynti on nelinkertaistunut. *Suom. Lääk.-L.* 2008; 63: 3326-3328 (in Finnish).
- Siesling, S., van der Aa, M.A., Coebergh, J.W.W. and Pukkala, E. on behalf of the Working Group of the Netherlands Cancer Registry: Time-space trends in cancer incidence in the Netherlands in 1989-2003. *Int. J. Cancer* 2008; 122: 2106-2114.
- Siew, S.S., Kauppinen, T., Kyyrönen, P., Heikkilä, P. and Pukkala, E.: Exposure to iron and welding fumes and the risk of lung cancer. *Scand. J. Work. Environ. Health* 2008; 34: 444-450.
- Sioris, T., Sihvo, E., Sankila, R. and Salo, J.: Effect of surgical volume and hospital type on outcome in non-small cell lung cancer surgery: A Finnish population-based study. *Lung Cancer* 2008; 59: 119-125.
- Sistonen, S.J., Koivusalo, A., Lindahl, H., Pukkala, E., Rintala, R.J. and Pakarinen, M.P.: Cancer after repair of esophageal atresia: population-based long-term follow-up. *J. Pediatr. Surg.* 2008; 43: 602-605.
- Soerjomataram, I., Pukkala, E., Brenner, H. and Coebergh, J.W.W.: On the avoidability of breast cancer in industrialized societies: older mean age at first birth as an indicator of excess breast cancer risk. *Breast Cancer Res. Treat.* 2008; 111: 297-302.
- Soininen, L. and Pukkala, E.: Mortality of the Sami in Northern Finland 1979-2005. *Int. J. Circumpolar Health* 2008; 67: 45-57.
- Talback, M., Hakulinen, T. and Stenbeck, M.: Cancerförekomst In: *Onkologi*. Eds. U. Ringborg, T. Dalianis and R. Henriksson. *Liber, Stockholm* 2008, pp. 17-25 (in Swedish).
- Tarvainen, L., Kyyrönen, P., Kauppinen, T. and Pukkala, E.: Cancer of the mouth and pharynx, occupation and exposure to chemical agents in Finland [in 1971-95]. *Int. J. Cancer* 2008; 123: 653-659.

Taskinen, M., Ranki, A., Pukkala, E., Jeskanen, L., Kaitila, I. and Mäkitie O.: Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. *Am. J. Med. Genet.* 2008; 146A: 2370-2375.

Turunen, A.W, Verkasalo, P.K., Kiviranta, H., Pukkala, E., Jula, A., Männistö, S., Räsänen, R., Marniemi, J. and Vartiainen, T.: Mortality in a cohort with high fish consumption. *Int. J. Epidemiol.* 2008; 37: 1008-1017.

Väkevä, L., Reitamo, S., Pukkala, E., Sarna, S. and Ranki, A.: Long-term follow-up of cancer risk in patients treated with short-term cyclosporine. *Acta Derm. Venerol.* 2008; 88: 117-120.

Vidarsdóttir, H., Gunnarsdóttir, H.K., Ólafsdóttir, G.H., Pukkala, E. and Tryggvadóttir, L.: Cancer risk by education in Iceland: a census-based cohort study. *Acta Oncol.* 2008; 47: 385-390.

Virgili, G., Gatta, G., Ciccolallo, L., Capocaccia, R., Biggeri, A., Crocetti, E., Lutz, J.-M. and Paci, E. for the EUROCORE Working Group: Survival in patients with uveal melanoma in Europe. *Arch. Ophthalmol.* 2008; 126: 1413-1418.

Worrillow, L.J., Smith, A.G., Scott, K., Andersson, M., Ashcroft, A.J., Dores, G.M., Glimelius, B., Holowaty, E., Jackson, G.H., Jones, G.L., Lynch, C.F., Morgan, G., Pukkala, E., Scott, D., Storm, H.H., Taylor, P.R., Vyberg, M., Willett, E., Travis, L.B. and Allan, J.M.: Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. *J. Med. Genet.* 2008; 45: 142-146.

2009

Adolfsson, J., Hellborg, H., Patama, T. and Pukkala, E.: Stockholm-Gotlandregionens cancerkartor: Cancerutveckling för valda diagnoser i regionen under tidsperioden 1971 till 2006. *Onkologiskt Centrum, Stockholm-Gotlandregionen och Finlands Cancerregister 2009*: http://astra.cancer.fi/cancermaps/stoc/index_se.html (in Swedish).

de Angelis, R., Francisci, S., Baili, P., Marchesi, F., Roazzi, P., Belot, A., Crocetti, E., Pury, P., Knijn, A., Coleman, M., Capocaccia, R. and the EUROCORE Working Group: The EUROCORE-4 database on cancer survival in Europe: Data standardization, quality control and methods of statistical analysis. *Eur. J. Cancer* 2009; 45: 909-930.

Anttila, A., von Karsa, L., Aasmaa, A., Fender, M., Patnick, J., Rebolj, M., Nicula, F., Vass, L., Valerianova, Z., Voti, L., Sauvagat, C. and Ronco, G.: Cervical cancer screening policies and coverage in Europe. *Eur. J. Cancer* 2009; 45: 2649-2658.

Anttila, A., Ronco, G. and Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE): Description of the national situation of cervical cancer screening in the member states of the European Union. *Eur. J. Cancer* 2009; 45: 2685-2708.

Arbyn, M., Raifu, A.O., Weiderpass, E., Bray, F. and Anttila, A.: Trends of cervical cancer mortality in the member states of the European Union. *Eur. J. Cancer* 2009; 45: 2640-2648.

Auvinen, A., Raitanen, J., Moss, S., de Koning, H.J., Hugosson, J., Tammela, T., Roobol, M., Lilja, H. and Hakama, M.: Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. *Cancer Epidemiol. Biomarkers Prev.* 2009; 18: 2000-2005.

Berrino, F., Verdecchia, A., Lutz, J.-M., Lombardo, C., Micheli, A., Capocaccia, R. and the EUROCORE Working Group: Comparative cancer survival information in Europe. *Eur. J. Cancer* 2009; 45: 901-908.

Brenner, H., Francisci, S., de Angelis, R., Marcos-Gragera, R., Verdecchia, A., Gatta, G., Allemani, C., Ciccolallo, L., Coleman, M., Sant, M. and the EUROCORE Working Group: Long-term survival expectations of cancer patients in Europe in 2000-2002. *Eur. J. Cancer* 2009; 45: 1028-1041.

Brenner, H. and Hakulinen, T.: Implications of incomplete registration of deaths on long-term survival estimates from population-based cancer registries. *Int. J. Cancer* 2009; 125: 432-437.

Brenner, H. and Hakulinen, T.: Up-to-date cancer survival: period analysis and beyond. *Int. J. Cancer* 2009; 124: 1384-1390.

Capocaccia, R., Gavin, A., Hakulinen, T., Lutz, J.-M. and Sant, M. (Eds): *Survival of cancer patients in Europe, 1995-2002: The EUROCORE 4 study*. *Eur. J. Cancer* 2009; 24: 901-1094.

Chaturvedi, A.K., Kleinerman, R.A., Hildesheim, A., Gilbert, E.S., Storm, H., Lynch, C.F., Hall, P., Langmark, F., Pukkala, E., Kaijser, M., Andersson, M., Fosså, S.D., Joensuu, H., Travis, L.B. and Engels, E.A.: Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. *J. Clin. Oncol.* 2009; 27: 967-973.

Folkesson, J., Engholm, G., Ehrnrooth, E., Kejs, A.-M., Pählman, L., Harling, H., Wibe, A., Gaard, M., Jónsson, T., Tryggvadóttir, L., Brewster, D.H., Hakulinen, T. and Storm, H.H.: Rectal cancer survival in the Nordic countries and Scotland. *Int. J. Cancer* 2009; 125: 2406-2412.

Francisci, S., Capocaccia, R., Grande, E., Santaquilani, M., Simonetti, A., Allemani, C., Gatta, G., Sant, M., Zigon, G., Bray, F., Janssen-Heijnen, M. and the EUROCORE Working Group: The cure of cancer: A European perspective. *Eur. J. Cancer* 2009; 45: 1067-1079.

Gatta, G., Zigon, G., Capocaccia, R., Coebergh, J.W., Desandes, E., Kaatsch, P., Pastore, G., Peris-Bonet, R., Stiller, C.A. and the EUROCORE Working Group: Survival of European children and young adults with cancer diagnosed 1995-2002. *Eur. J. Cancer* 2009; 45: 992-1005.

Gondos, A., Bray, F., Hakulinen, T., Brenner, H. and the EUNICE Survival Working Group: Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. *Ann. Oncol.* 2009; 20: 564-573.

Gondos, A., Holleczeck, B., Janssen-Heijnen, M., Brewster, D.H., Bray, F., Rosso, S., Hakulinen, T. and Brenner, H.: Model-based projections for deriving up-to-date cancer survival estimates: An international evaluation. *Int. J. Cancer* 2009; 125: 2666-2672.

Hakulinen, T.: Mahan ja ruokatorven syövän epidemiologia. *Focus Oncol.* 2009; No. 10: 6-15 (in Finnish).

Haukka, J., Sankila, R., Klaukka, T., Lönnqvist, J., Niskanen, L., Tanskanen, A., Wahlbeck, K. and Tiihonen, J.: Incidence of cancer and antidepressant medication: record linkage study. *Int. J. Cancer* 2009. doi: 10.1002/ijc.24537.

Haukka, J., Sankila, R., Klaukka, T., Lönnqvist, J., Niskanen, L., Tanskanen, A., Wahlbeck, K. and Tiihonen, J.: Incidence of cancer and statin usage – Record linkage study. *Int. J. Cancer* 2009. doi: 10.1002/ijc.24536.

Holl, K.: Maternal risk factors and testicular cancer in the offspring. A nested case-control study. Doctor's Thesis. University of Tampere. National Institute for Health and Welfare, Research 4. Helsinki 2009.

Holl, K., Lundin, E., Surcel, H.-M., Grankvist, K., Koskela, P., Dillner, J., Hallmans, G., Wadell, G., Olafsdóttir, G.H., Ögmundsdóttir, H.M., Pukkala, E., Lehtinen, M., Stattin, P. and Lukanova, A.: Endogenous steroid hormone levels in early pregnancy and risk of testicular cancer in the offspring: A nested case-referent study. *Int. J. Cancer* 2009; 124: 2923-2928.

Publications

- Holli, K., Hietanen, P., Saaristo, R., Huhtala, H., Hakama, M. and Joensuu, H.: Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial. *J. Clin. Oncol.* 2009; 27: 927-932.
- Jordan, J., Martin-Hirsch, P., Arbyn, M., Schenck, U., Baldauf, J.J., da Silva, D., Anttila, A., Nieminen, P. and Prendiville, W.: European guidelines for clinical management of abnormal cervical cytology, part 2. *Cytopathology* 2009; 20: 5-16.
- Kaasila, M., Koskela, P., Kirnbauer, R., Pukkala, E., Surcel, H.-M. and Lehtinen, M.: Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile-aged Finnish women. *Int. J. Cancer* 2009; 125: 2166-2172.
- Kalliala, I., Dyba, T., Nieminen, P., Hakulinen, T. and Anttila, A.: Mortality in a long-term follow-up after treatment of CIN. *Int. J. Cancer* 2009. doi:10.1002/ijc.24713.
- Karppi, J., Kurl, S., Nurmi, T., Rissanen, T.H., Pukkala, E. and Nyssönen, K.: Serum lycopene and the risk of cancer: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. *Ann. Epidemiol.* 2009; 19: 512-518.
- Kaupilla, A., Kyyrönen, P., Hinkula, M. and Pukkala, E.: Birth intervals and breast cancer risk. *Brit. J. Cancer* 2009; 101: 1213-1217.
- Kauppinen, T., Heikkilä, P., Plato, N., Woldbaek, T., Lenvik, K., Hansen, J., Kristjansson, V. and Pukkala, E.: Construction of job-exposure matrices for the Nordic Occupational Cancer Study (NOCCA). *Acta Oncol.* 2009; 48: 791-800.
- Koljonen, V., Kukko, H., Pukkala, E., Sankila, R., Böhling, T., Tukiainen, E., Sihto, H. and Joensuu, H.: Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. *Brit. J. Cancer* 2009; 101: 1444-1447.
- Koljonen, V., Kukko, H., Tukiainen, E., Böhling, T., Sankila, R., Pukkala, E., Sihto, H., Joensuu, H., Kyllönen, L. and Mäkisalo, H.: Incidence of Merkel cell carcinoma in renal transplant recipients. *Nephrol. Dial. Transplant.* 2009; 24: 3231-3235.
- Kotaniemi-Talonen, L.: Kohdunkaulansyövän seulonta. *Duodecim* 2009; 125: 2168-2170 (in Finnish).
- Kotaniemi-Talonen, L.: Randomised evaluation of new technologies within the population-based cervical cancer screening programme in Finland: Cross-sectional performance and validity. Doctor's Thesis. University of Helsinki. Helsinki 2009.
- Kumpulainen, S., Sankila, R., Leminen, A., Kuoppala, T., Komulainen, M., Puistola, U., Hurme, S., Hiekkänen, H., Mäkinen, J. and Grénman, S.: The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer – A prospective nation-wide study in Finland. *Gyn. Oncol.* 2009; 115: 199-203.
- Laukkanen, J.A., Pukkala, E., Rauramaa, R., Mäkilallio, T.H., Toriola, A.T. and Kurl, S.: Cardiorespiratory fitness, lifestyle factors and cancer risk and mortality in Finnish men. *Eur. J. Cancer.* doi:10.1016/j.ejca.2009.07.013.
- Laukkanen, J.A., Pukkala, E., Rauramaa, R., Mäkilallio, T.H., Toriola, A.T. and Kurl, S.: Hyvä kunto saattaa pienentää miehen syöpäriskiä. *Duodecim* 2009; 125: 2231 (in Finnish).
- Laurila, M., Tammela, T.L.J., Auvinen, A., Isola, J., Visakorpi, T., Luukkaala, T., Määttä, L., Ruutu, M., Ala-Opas, M., Mildh, M. and Martikainen, P.: Biological aggressiveness of prostate cancer in the Finnish screening trial. *Int. J. Cancer* 2009; 124: 547-552.
- Li, Y., Karjalainen, A., Koskinen, H., Vainio, H., Pukkala, E., Hemminki, K. and Brandt-Rauf, P.W.: Serum growth factors in asbestosis patients. *Biomarkers* 2009; 14: 61-66.
- Lindbohm, M.-L., Sallmén, M., Kyyrönen, P., Kauppinen, T. and Pukkala, E.: Risk of liver cancer and exposure to organic solvents and gasoline vapors among Finnish workers. *Int. J. Cancer* 2009; 124: 2954-2959.
- Lohi, S., Mäki, M., Montonen, J., Knekt, P., Pukkala, E., Reunanen, A. and Kaukinen, K.: Malignancies in cases with screening-identified evidence of coeliac disease: a long-term population-based cohort study. *Gut* 2009; 58: 643-647.
- Lynge, E., Anttila, A., Arbyn, M., Segnan, N. and Ronco, G.: What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. *Eur. J. Cancer* 2009; 45: 2714-2721.
- Lyytinen, H.: A nationwide study on breast cancer risk in postmenopausal women using hormone therapy in Finland. Doctor's Thesis. University of Helsinki. Helsinki 2009.
- Lyytinen, H., Dyba, T., Ylikorkala, O. and Pukkala, E.: A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. *Int. J. Cancer* 2009. doi: 10.1002/ijc.24738.
- Lyytinen, H., Pukkala, E. and Ylikorkala, O.: Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. *Obstet. Gynecol.* 2009; 113: 65-73.
- Madanat-Harjuoja, L.-M., Malila, N., Lähteenmäki, P., Pukkala, E., Mulvihill, J.J., Boice, J.D. Jr. and Sankila, R.: Risk of cancer among children of cancer patients - A nationwide study in Finland. *Int. J. Cancer* 2009. doi:10.1002/ijc.24856.
- Madanat-Harjuoja, L.-M., Malila, N., Lähteenmäki, P., Pukkala, E., Mulvihill, J.J., Boice, J.D. Jr. and Sankila, R.: Syövän hoidot eivät lisää jälkeläisten syöpäriskiä. *Duodecim* 2009; 125: 2120 (in Finnish).
- Malila, N. and Oivanen, T.: Hyvät ensikokemukset paksusuolisyövän seulonnasta Suomessa. *Duodecim* 2009; 125: 583-584 (in Finnish).
- Micheli, A., Ciampichini, R., Oberaigner, W., Cicolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R. and the EUROCCARE Working Group: The advantage of women in cancer survival: An analysis of EUROCCARE-4 data. *Eur. J. Cancer* 2009; 45: 1017-1027.
- Murtola, T.J., Tammela, T.L.J., Määttä, L., Ala-Opas, M., Stenman, U.H., and Auvinen, A.: Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. *Brit. J. Cancer* 2009; 101: 843-848.
- Nicula, F.A., Anttila, A., Neamtiu, L., Žakelj, M.P., Tachezy, R., Chil, A., Grce, M. and Kesic, V.: Challenges in starting organised screening programmes for cervical in the new member states of the European Union. *Eur. J. Cancer* 2009; 45: 2679-2684.
- Olsen, J.H., Möller, T., Anderson, H., Langmark, F., Sankila, R., Tryggvadóttir, L., Falck Winther, J., Rechner, C., Jonmundsson, G., Christensen, J. and Garwicz, S.: Lifelong cancer incidence in 47 697 patients treated for childhood cancer in the Nordic Countries. *J. Natl Cancer Inst.* 2009; 101: 806-813.
- Pakkanen, S., Pukkala, E., Kainulainen, H., Matikainen, M.P., Koivisto, P.A., Tammela, T.L.J. and Schleutker, J.: Increased risk of cancer in Finnish families with clinically aggressive prostate cancer. *Cancer Epidemiol. Biomarkers Prev.* 2009. doi:10.1158/1055-9965.
- Pokhrel, A. and Hakulinen, T.: Age-standardisation of relative survival ratios of cancer patients in a comparison between countries, genders and time periods. *Eur. J. Cancer* 2009; 45: 642-647.
- Pukkala, E.: Onko yötyöläisen syöpä ammattitauti. *Suomen Lääkärelehti* 2009; 64: 2748-2749 (in Finnish).
- Pukkala, E., Martinsen, J.I., Lynge, E., Gunnarsdóttir, H.K., Sparén, P., Tryggvadóttir, L., Weiderpass, E. and Kjærheim, K.: Occupation and cancer – follow-up of 15 million people in five Nordic countries. *Acta Oncol.* 2009; 48: 646-790.

- Pukkala, E. and Patama, T.: Syövän ajallinen ja alueellinen vaihtelu kartta-animaatioina Suomessa 1957-2006. Suomen Syöpärekisteri 2009: <http://astra.cancer.fi/cancermaps/suomi19572006/index.html> (in Finnish).
- Quaglia, A., Tavilla, A., Shack, L., Brenner, H., Janssen-Heijnen, M., Allemani, C., Colonna, M., Grande, E., Grosclaude, P., Vercelli, M. and the EUROCORE Working Group: The cancer survival gap between elderly and middle-aged patients in Europe is widening. *Eur. J. Cancer* 2009; 45: 1006-1016.
- Ronco, G. and Anttila, A.: Cervical cancer screening in Europe – Changes over the last 9 years. *Eur. J. Cancer* 2009; 45: 2629-2631.
- Ronco, G., van Ballegooijen, M., Becker, N., Chil, A., Fender, M., Giubilato, P., Kurtinaitis, J., Lancucki, L., Lynge, E., Morais, A., O'Reilly, M., Sørensen, P., Suteu, O., Rebolj, M., Veerus, P., Žakelj, M.P. and Anttila, A.: Process performance of cervical screening programmes in Europe. *Eur. J. Cancer* 2009; 45: 2659-2670.
- Roobol, M.J., Kerkhof, M., Schröder, F.H., Cuzick, J., Sasieni, P., Hakama, M., Stenman, U.H., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L., Recker, F., Berenguer, A., Ruutu, M., Kujala, P., Bangma, C.H., Aus, G., Tammela, T.L., Villers, A., Rebillard, X., Moss, S.M., de Koning, H.J., Hugosson, J. and Auvinen, A.: Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). *Eur. Urol.* 2009; 28: 584-591.
- Rosso, S., De Angelis, R., Ciccolallo, L., Carrani, E., Soerjomataram, I., Grande, E., Zigon, G., Brenner, H. and the EUROCORE Working Group: Multiple tumours in survival estimates. *Eur. J. Cancer* 2009; 45: 1080-1094.
- Sankila, R. and Pukkala, E.: Syöpätaudit In: Sairauksien ehkäisy. Ed. K. Koskenvuo, Kustannus Oy Duodecim, Helsinki 2009 (in Finnish). <http://www.terveyskirjasto.fi>.
- Sankila, R. and Storm, H.: It's a Nordic thing. *Brit. Med. J.* 2009;339:1102.
- Sant, M., Allemani, C., Santaquilani, M., Knijn, A., Marchesi, F., Capocaccia, R. and the EUROCORE Working Group: EUROCORE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. *Eur. J. Cancer* 2009; 45: 931-991.
- Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Berenguer, A., Määttä, L., Bangma, C.H., Aus, G., Villers, A., Rebillard, X., van der Kwast, T., Blijenberg, B.G., Moss, S.M., de Koning, H.J. and Auvinen, A. for the ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. *N. Engl. J. Med.* 2009; 360: 1320-1328.
- Seppä, K. and Hakulinen, T.: Mean and median survival times of cancer patients should be corrected for informative censoring. *J. Clin. Epidemiol.* 2009; 62: 1095-1102.
- Sihto, H., Kukko, H., Koljonen, V., Sankila, R., Böbling, T., and Joensuu, H.: Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. *J. Natl Cancer Inst.* 2009; 101: 938-945.
- Simen-Kapeu, A.: Epidemiological study of tobacco use and human papillomavirus. Implications for public health prevention. Doctor's Thesis. University of Tampere. National Institute for Health and Welfare, Research 20/2009. Helsinki 2009.
- Simen-Kapeu, A., Luostarinen, T., Jellum, E., Dillner, J., Hakama, M., Koskela, P., Lenner, P., Löve, A., Mahlamäki, E., Thoresen, S., Tryggvadóttir, L., Wadell, G., Youngman, L. and Lehtinen, M.: Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. *Am. J. Epidemiol.* 2009; 169: 480-488.
- Söderberg, K.C., Kaprio, J., Verkasalo, P.K., Pukkala, E., Koskenvuo, M., Lundqvist, E. and Peychting, M.: Overweight, obesity and risk of haematological malignancies: A cohort study of Swedish and Finnish twins. *Eur. J. Cancer* 2009; 45: 1232-1238.
- Sund, R., Pukkala, E. and Patja, K.: Cancer incidence among persons with fragile X syndrome in Finland: a population-based study. *J. Intellect. Disabil. Res.* 2009; 53: 85-90.
- Tedeschi, R., Luostarinen, T., Marus, A., Bhalava, D., Ögmundsdóttir, H.M., Dillner, J., De Paoli, P., Gudnadóttir, M., Surcel, H.-M., Pukkala, E., Lehtinen, M. and Lehtinen, T.: No risk of maternal EBV infection for childhood leukemia. *Cancer Epidem. Biomarkers Prev.* 2009; 18: 2790-2792.
- Toriola, A.T., Surcel, H.-M., Agborsangaya, C., Grankvist, K., Tuohimaa, P., Toniolo, P., Lukanova, A., Pukkala, E. and Lehtinen, M.: Serum 25-Hydroxyvitamin D and the risk of ovarian cancer. *Eur. J. Cancer.* doi: 10.1016/j.ejca.2009.08.002.
- Tuomisto, J., Holl, K., Rantakokko, P., Koskela, P., Hallmans, G., Wadell, G., Stattin, P., Dillner, J., Ögmundsdóttir, H.M., Vartiainen, T., Lehtinen, M. and Pukkala, E.: Maternal smoking during pregnancy and testicular cancer in the sons: A nested case-control study and meta-analysis. *Eur. J. Cancer* 2009; 45: 1640-1648.
- Verdecchia, A., Guzzinati, S., Francisci, S., De Angelis, R., Bray, F., Allemani, C., Tavilla, A., Santaquilani, M., Sant, M. and the EUROCORE Working Group: Survival trends in European cancer patients diagnosed from 1988 to 1999. *Eur. J. Cancer* 2009; 45: 1042-1066.
- Wolters, T., Roobol, M.J., Steyerberg, E.W., van den Bergh, R.C., Bangma, C.H., Hugosson, J., Ciatto, S., Kwiatkowski, M., Villers, A., Luján, M., Nelen, V., Tammela, T.L. and Schröder, F.H.: The effect of study arm on prostate cancer treatment in a large screening trial (ERSPC). *Int. J. Cancer* 2009. doi:10.1002/ijc.24870.

► Leading sites of cancer in 2007 and 2010, by sex.

Primary site	2007			2010 (prediction)	
	No. of cases	%	Incidence per 100,000 ¹	No. of cases	95 % prediction interval
MALES					
Prostate	4183	31.9	85.6	4555	4423-4687
Lung, trachea	1511	11.5	30.3	1581	1469-1694
Colon	743	5.7	15.4	852	774-930
Bladder, ureter, urethra	588	4.5	11.6	653	585-720
Skin, non-melanoma ²	557	4.2	10.4	636	569-703
Rectum, rectosigmoid, anus	555	4.2	11.6	615	548-682
Non-Hodgkin lymphoma	535	4.1	12.0	600	534-665
Melanoma of the skin	457	3.5	10.6	541	481-601
Pancreas	455	3.5	9.3	520	459-582
Kidney	399	3.0	8.8	412	360-465
Brain, central nervous system	372	2.8	10.7	420	365-474
Stomach	371	2.8	7.8	366	317-416
Leukaemia	316	2.4	8.4	339	286-391
Liver	255	1.9	5.1	317	272-363
Oesophagus	161	1.2	3.4	178	142-215
Multiple myeloma	130	1.0	2.7	141	110-172
Testis	129	1.0	4.8	131	102-159
All sites²	13121	100.0	281.9	14256	13959-14553
FEMALES					
Breast	4140	31.9	87.5	4369	4066-4671
Colon	824	6.3	12.4	856	777-934
Corpus uteri	787	6.1	14.2	846	769-924
Lung, trachea	675	5.2	11.0	727	656-798
Brain, central nervous system	561	4.3	13.4	613	548-678
Skin, non-melanoma ²	529	4.1	5.7	564	501-627
Non-Hodgkin lymphoma	515	4.0	9.4	550	488-613
Pancreas	495	3.8	6.6	574	510-637
Melanoma of the skin	447	3.4	9.4	490	433-547
Rectum, rectosigmoid, anus	438	3.4	7.1	464	406-522
Ovary	420	3.2	8.4	477	419-534
Kidney	339	2.6	5.4	369	318-420
Stomach	291	2.2	4.6	285	241-329
Thyroid gland	282	2.2	7.5	266	220-312
Leukaemia	246	1.9	5.3	244	203-285
Bladder, ureter, urethra	193	1.5	2.5	206	168-244
Liver	151	1.2	2.0	174	140-208
Gallbladder, bile ducts	148	1.1	2.0	134	104-163
Cervix uteri	144	1.1	3.7	151	119-184
Multiple myeloma	130	1.0	2.0	127	98-156
All sites²	12988	100.0	241.2	13732	13336-14128

¹ Adjusted for age to the "world standard population".

² Excludes basal cell carcinomas of the skin.